



**RUSSIAN
SOCIETY
OF CARDIOLOGY**

**RUSSIAN
NATIONAL CONGRESS
OF CARDIOLOGY**

**CARDIOLOGY-2016:
CHALLENGES AND SOLUTIONS**

SCIENTIFIC PROGRAMME

**September 20–23, 2016
Ekaterinburg**





**RUSSIAN
NATIONAL CONGRESS
OF CARDIOLOGY**

**CARDIOLOGY-2016:
CHALLENGES AND SOLUTIONS**

SCIENTIFIC PROGRAMME

**September 20–23, 2016
Ekaterinburg**



DEAR COLLEAGUES AND FRIENDS!

On behalf of the Ministry of Health of the Russian Federation I am pleased to welcome you at the Russian National Congress of Cardiology 2016 in Ekaterinburg! Today the Russian Society of Cardiology joins together practitioners and scientists, trainers and clinicians working both in Cardiology and other areas for further reduction of cardiovascular morbidity as well as innovative development of the Russian Cardiology.

Today, the wide platform of interdisciplinary interaction allows active participation of the professional community in development and introduction of up-to-date programmes of continuous medical education, organization of socially-oriented and advocacy events, doing research work and implementation of new methods of diagnosis and treatment into the clinical practice.

I am convinced that the efforts against cardiovascular diseases will be multiplied. The Congress will open up new prospects for improving health care system through innovative medical technologies, and will be a step forward to the development of national Cardiology.

I wish all participants of the Russian National Congress of Cardiology successful work, good health, happiness and prosperity!

Minister of Health of the Russian Federation
Veronika Skvortsova





DEAR COLLEAGUES!


I am delighted to welcome the delegates of the Russian National Congress of Cardiology 2016! Every year, the significance of our Event is growing, the increasing number of doctors and researchers, among them those from foreign countries, come to participate; more and more scientific and educational sessions are included into the programme.

This year, the Russian National Congress of Cardiology is held in Ekaterinburg that reflects one of the basic principles of the Russian Society of Cardiology – the increasing importance of the Russian regions. Ekaterinburg is one of the Russian capitals in the field of Cardiology, a city of the remarkable history, of the great scientific and human potential, with its active position in the RSC Board.

Today, the Congress allows us to see the results of the Year of Struggle against Cardiovascular Diseases in Russia, to set new long- and short-term goals in reduction of cardiovascular morbidity and mortality. This year much attention is paid to educational events within the Congress programme. Our society is one of the most active participants of the pilot project on continuous medical education. Each year the role of our Society in specialists advanced training is increasing, which includes future professional accreditation.

I am sure that the success of our Congress, making plans for the future and an active position of all delegates in the discussions will become the success key for our Society and will help to raise its rating among professional associations. I wish interesting communication, exchange of experience, ideas and knowledge to all delegates of the Congress. Ekaterinburg will welcome our guests with warm weather, its beauty and hospitality!

President of the Russian Society of Cardiology
Evgeny Shlyakhto



**PROGRAMME COMMITTEE OF THE RUSSIAN NATIONAL
CONGRESS OF CARDIOLOGY**

Chairman of the Programme Committee —
President of the Russian Society of Cardiology,
Prof. Evgeny Shlyakhto (Saint-Petersburg)

Congress Executive Secretary —
Board Member of the Russian Society of Cardiology,
Prof. Yuri Lopatin (Volgograd)

Chairman of the Local Organizing Committee —
Board Member of the Russian Society of Cardiology,
Prof. Yan Gabinsky (Ekaterinburg)

Co-chairmen of the Program Committee Working Groups

Akchurin R.S. (Moscow)	Lopatin Y.M. (Volgograd)
Alekyan B.G. (Moscow)	Mareev V.Yu. (Moscow)
Baranova E.I. (Saint-Petersburg)	Matskeplishvili S.T. (Moscow)
Belenkov Y.N. (Moscow)	Nedogoda S.V. (Volgograd)
Boitsov S.A. (Moscow)	Oganov R.G. (Moscow)
Bokeria L.A. (Moscow)	Paleev F.N. (Moscow)
Vasyuk Y.A. (Moscow)	Popov S.V. (Tomsk)
Galagudza M.M. (St.Petersburg)	Revishvili A.S. (Moscow)
Golitsyn S.P. (Moscow)	Ruda M.J. (Moscow)
Golukhova E.Z. (Moscow)	Smolensky A.V. (Moscow)
Dzemeshkevich S.L. (Moscow)	Tereshchenko S.N. (Moscow)
Zateischikov D.A. (Moscow)	Ternovoy S.K. (Moscow)
Ezhov M.V. (Moscow)	Tkachuk V.A. (Moscow)
Karaskov A.M. (Novosibirsk)	Chazova I.E. (Moscow)
Karpov R.S. (Tomsk)	Chumakova G.A. (Barnaul)
Karpov Y.A. (Moscow)	Shalnova S.A. (Moscow)
Kuznetsov V.A. (Tyumen)	Yavelov I.S. (Moscow)
Kuharchuk V.V. (Moscow)	

ABSTRACTS COMMITTEE

Chairman – Duplyakov D.V. (Samara)

Abugov S.A. (Moscow)	Mitrofanova L.B. (Saint-Petersburg)
Barbarash O.L. (Kemerovo)	Moiseeva O.M. (Saint-Petersburg)
Gapon L.I. (Tyumen)	Nebieridze D.V. (Moscow)
Gordeev M.L. (Saint-Petersburg)	Podzolkov V.I. (Moscow)
Grinshtein Yu.I. (Krasnoyarsk)	Pokushalov E.A. (Novosibirsk)
Demin A.A. (Novosibirsk)	Puzyrev V.P. (Tomsk)
Zemtsovsky E.V. (Saint-Petersburg)	Rotar O.P. (Saint-Petersburg)
Kapustina A.V. (Moscow)	Ryzhkova D.V. (Saint-Petersburg)
Kozioleva N.A. (Perm)	Skibitsky V.V. (Krasnodar)
Kostareva A.A. (Saint-Petersburg)	Tarlovskaya E.I. (Nizhny Novgorod)
Lebedev D.S. (Saint-Petersburg)	Tsaregorodtsev D.A. (Moscow)
Libis R.A. (Orenburg)	Shlyk S.V. (Rostov-on-Don)
Lishmanov Yu.B. (Tomsk)	Shumakov D.V. (Moscow)
Miller O.N. (Novosibirsk)	Yakovlev A.N. (Saint-Petersburg)
	Yakushin S.S. (Ryazan)

AWARD COMMITTEE OF THE RUSSIAN SOCIETY OF CARDIOLOGY 2016

Shlyakhto E.V. (Saint-Petersburg) – **Chairman**

Boitsov S.A. (Moscow), Galyavich A.S. (Kazan), Dovgalevsky P.Y. (Saratov), Duplyakov D.V. (Samara), Karpov R.S. (Tomsk), Kozioleva N.A. (Perm), Konradi A.O. (St. Petersburg)

YOUNG SCIENTISTS AWARD COMMITTEE

Villevalde S.V. (Moscow), Duplyakov D.V. (Samara), Kontsevaya A.V. (Moscow), Grinshtein Yu.I. (Krasnoyarsk), Osipova I.V. (Barnaul), Shkolnik E.L. (Moscow), Mayanskaya S.D. (Kazan), Sumin A.N. (Kemerovo), Melekhov A.V. (Moscow)

BEST POSTER PRESENTATION AWARD COMMITTEE

Abugov S.A. (Moscow), Akhmedzhanov N.M. (Moscow), Balanova Yu.A. (Moscow), Karpenko M.A. (Saint-Petersburg), Konstantinov V.O. (Saint-Petersburg), Kosmacheva E.D. (Krasnodar), Lifshits G.I. (Novosibirsk), Protasov K.V. (Irkutsk), Ragino Yu.I. (Novosibirsk), Rotar O.P. (Saint-Petersburg), Smolenskaya O.G. (Ekaterinburg), Philippov E.V. (Ryazan), Chernova A.A. (Krasnoyarsk), Chesnikova A.I. (Rostov-on-Don), Shesternya P.A. (Krasnoyarsk).

SECRETARIAT OF THE CONGRESS PROGRAMME COMMITTEE

Konradi A.O. (Saint- Petersburg), Kontsevaya A.V. (Moscow),
Nedoshivin A.O. (Saint-Petersburg), Tanicheva A.A. (Saint-Petersburg),
Chumak I.B. (Saint-Petersburg)

LOCAL ORGANIZING COMMITTEE MEMBERS

Yakovleva S.V. (Ekaterinburg), Golubeva I.V. (Ekaterinburg)

GENERAL INFORMATION

The Organizing Committee invites you to take part in the Russian National Congress of Cardiology which will be held in Ekaterinburg on 20-23 September, 2016.

CONGRESS VENUE

International Exhibition Centre «Ekaterinburg EXPO» (2 EXPO Boulevard, Ekaterinburg).

HOW TO GET THERE

By bus from metro station «Botanicheskaya»

During the Congress a special bus service will be organized from Metro station «Botanicheskaya» to Ekaterinburg-Expo. The bus stop is opposite the intercept parking along Schwartz Street.

The buses will go every 10-15 minutes.

By bus from hotels

Please, check the bus timetable at the hotels.

REGISTRATION

On-line registration of the participants at the official website of the Russian Society of Cardiology **www.scardio.ru** is possible up to September 10, 2016.

Admittance to all sessions and the exhibition is free of charge, admittance by badges that are issued to the registered participants only.

On-site Registration Timetable

20 September — 07.30–17.00
 21 September — 08.00–17.00
 22 September — 08.00–18.00
 23 September — 08.00–13.30

Registration desks can be found at the central entrance, near the 1st Pavilion.

All registered at the RSC website www.scardio.ru and all those who paid for the Congress materials will be able to get a Congress bag and a badge in the registration area (Central entrance, near the 1st Pavilion).

CONGRESS MATERIALS

From September 1, 2016 — 2,500 rubles (for RSC members – 2,000 rubles).

One can pay for the Congress materials (Congress bag, Congress scientific programme, Abstract Book, Exhibition Catalogue, Certificate) in the registration area on any day of the Congress.

Congress materials are free of charge for RSC Board members, all session chairs and Young Scientists Award winners.

Attention! All Congress sessions and the exhibition are free to attend after the registration procedure. Registration is required of all participants. Each participant will receive a name badge, which will serve as a pass to all sessions and the exhibition.

POSTERS

Posters are to be presented on September 20–22 in the 3rd Pavilion of Ekaterinburg-EXPO from 09.00 to 18.00. Moderators of the poster sessions will be selecting the best posters every day during the lunch break on September 20 from 12.30 to 13.00, September 21 and September 22 from 12.30 to 13.30.

Poster presenters place their posters in accordance with the number of presentations specified in the scientific programme on the presentation day from 08:00 to 09:00. The posters must not exceed the following dimensions: 90 cm (width), 120 cm (height).

The posters must be removed after 18:00 on the presentation day.

CONGRESS SESSIONS TIMETABLE

September 20, 09.00–16.30

September 21, 09.00–17.00

September 22, 09.00–19.00

September 23, 09.00–15.00

All lecture halls are located in the 4th Pavilion of Ekaterinburg-EXPO, mini-lecture rooms and poster area are in the 3rd Pavilion.

EXHIBITION

Exhibition of medical, diagnostic and therapeutic equipment, modern information technology, and specialized medical publications will be presented daily in the 3rd Pavilion of Ekaterinburg-EXPO:

September 20, 08.00–18.00

September 21, 08.00–18.00

September 22, 08.00–19.00

September 23, 08.00–15.00

ORGANIZING COMMITTEE ROOM

The Organizing Committee Room is in the 4th Pavilion of Ekaterinburg-EXPO.

THE RUSSIAN NATIONAL CONGRESS OF CARDIOLOGY 2015 IS ACCREDITED IN THE CONTINUOUS MEDICAL EDUCATION SYSTEM

What does it mean?

The Congress is accredited in the new model system of CME by the Co-ordination Council for Development of Continuous Medical and Pharmaceutical Education for cardiologists, internists and general practitioners. For participation in the Congress you will be given educational credits (subject to you visit the Congress within all days of its work) to be counted as academic hours at regular qualification improvement training.

What to do?

You should register on the first Congress day on September 20 before 14:00 and announce your wish to receive a CME Certificate. On the last Congress day on September 23 in the registration area you can get the individually numbered certificate.

If you chose the option of participation in the educational programme during on-line registration, repeated registration is not required.

OFFICIAL CONGRESS EVENTS

- September 20, 16.45 – 18.00
Awarding Ceremonies: Russian Society of Cardiology Awards and Young Scientists Awards
Location: Plenary Session Hall (2 EXPO Boulevard), Ekaterinburg EXPO
- September 20, 19.15 – 21.00
Opening Ceremony
Location: Opera Theatre (46A Lenin ave.)
Admission by invitation only.
- September 21, 17.15 – 18.30
Russian Society of Cardiology Board Meeting
Location: Plenary Session Hall (2 EXPO Boulevard), Ekaterinburg EXPO

INFORMATION FOR SPEAKERS

Presentation requirements:

- File format .ppt or .pptx (MS Office 2003/2007/2010).
- Standard animation
- Standard fonts (Windows)
- Multimedia file (audio and video) must be in the same folder as the presentation file.
- Acceptable video formats: avi, mp4, wmv.
- The maximum size of the video file: 200 Mb (larger files can cause delay at the presentation opening)
- Maximum resolution video: 640x480 px, it is allowed to use the best quality video (up to fullHD) after the prior agreement with the technical personnel.

EQUIPMENT

- All lecture halls are equipped with laptops connected to the projector and/or widescreen panels.
- Using speakers' equipment is not allowed.
- All the laptops are equipped with a presenter (the device to switch slides) which can be replaced by a presenter of the lecturer after the consultation with technical personnel.
- Internet access (for broadcasting, video conferences, etc.) using the presentation equipment is possible only after the consultation the technical personnel.
- Presentations must be downloaded in advance, in any case no later than 20 minutes before the session starts.
- Presentations must be given to the technical personnel in the lecture hall.
- Speakers are strictly forbidden to work independently with the presentation equipment.

SIMULTANEOUS TRANSLATION

The official language of the Congress is Russian. Simultaneous English-Russian translation will be provided during plenary sessions with participation of foreign speakers, Russian-Serbian symposia and international sessions supported by companies.

Please, do not use mobile phones during the Congress sessions!

PRESENTATIONS BY YOUNG SCIENTISTS AWARD WINNERS

will be held on September 20 in the Conference Hall 1A from 09.00 to 10.30.


INTERNET

Free Wi-Fi Internet is provided on the territory of Ekaterinburg-EXPO.


SMOKING

The Russian Society of Cardiology actively promotes healthy lifestyle and considers smoking to be a serious risk factor of cardiovascular diseases. The Organizing Committee strongly recommends to all participants to refrain from smoking at the time of the Congress.


PLAN OF PAVILIONS



PLAN OF HALLS IN PAVILION 4



Time/Hall	PLENARY SESSION HALL	CONFERENCE HALL 1	CONFERENCE HALL 1A	CONFERENCE HALL 2	CONFERENCE HALL 3
07:30–09:00	Registration (Central entrance)				
09:00–10:30	PLENARY SESSION Innovations in cardiology — 2016 Online broadcasting Simultaneous translation	SYMPOSIUM Patients after acute coronary syndrome: effective approaches to prevention of recurrent vascular events	Young scientists awards session	SYMPOSIUM Anticoagulant therapy. Safety first. Open discussion. <i>(supported by Boehringer Ingelheim)</i> Online broadcasting	SYMPOSIUM Challenges and achievements in ACS and pulmonary embolism
10:30–11:00	BREAK				
11:00–12:30	PLENARY SESSION Hot issues in arrhythmology — 2016 Online broadcasting Simultaneous translation	SYMPOSIUM Current technologies of coronary artery disease diagnosis: from anatomy to function or vice versa?	SECTION SESSION Arterial hyperten- sion, metabolic syndrome, diabetes mellitus Part I	BATTLE OF SCHOLARS — 2016 Final competition	SYMPOSIUM Myocardial infarction — 2016
12:30–13:00	BREAK				

CONFERENCE HALL 4	CONFERENCE HALL 4A	CONFERENCE HALL 5	CONFERENCE HALL 5A	CONFERENCE HALL 6	CONFERENCE HALL 7
SYMPOSIUM Early diagnosis of myocardial infarction	SECTION SESSION Coronary artery disease, lipids and atherosclerosis Part I	SYMPOSIUM Controversial issues in cardio-neurology	SYMPOSIUM Rare types of cardiomyopathies	SYMPOSIUM Improvement of continuous professional education of nurses in cardiology departments as an integral constituent of the quality medical care	SCIENTIFIC SESSION Cardiovascular patients with anxiety disorders. Novel approach to prevention
SYMPOSIUM CAD and CHF — 2016: time to change <i>(supported by Servier)</i> Online broadcasting	SECTION SESSION Coronary artery disease, lipids and atherosclerosis Part II 	SYMPOSIUM How to prevent recurrent events or is there life after ACS? <i>(Supported by Dr.Reddis)</i>	SCIENTIFIC SESSION Reduction of cardiovascular risk in rheumatic diseases: finding better solutions	SYMPOSIUM Value-based medicine in cardiology	SYMPOSIUM Therapy evolution in course of cardiovascular continuum: place of sartans <i>(supported by Teva)</i>

Time/Hall	PLENARY SESSION HALL	CONFERENCE HALL 1	CONFERENCE HALL 1A	CONFERENCE HALL 2	CONFERENCE HALL 3
13.00–14.30	SYMPOSIUM International clinical research: how to put results into practice <i>(supported by KRKA)</i> Online broadcasting	SYMPOSIUM Organization of specialized medical care to ACS patients: yesterday, today and tomorrow <i>(supported by AstraZeneca)</i>	SECTION SESSION Arterial hypertension, metabolic syndrome, diabetes mellitus Part II	SYMPOSIUM A way to the patient's heart <i>(supported by Egis)</i>	SYMPOSIUM Gender-specific and personalized approach to high cardiovascular risk patients <i>(supported by Zentiva of Sanofi Group)</i>
14.30–15.00	BREAK				
15.00–16.30	PLENARY SESSION Cardiology 2016: challenges and solutions Online broadcasting Simultaneous translation	SYMPOSIUM Improving prognosis in non-STEMI patients – strategic goal in choosing double antiplatelet therapy <i>(supported by AstraZeneca)</i> Online broadcasting	SECTION SESSION Arterial hypertension, metabolic syndrome, diabetes mellitus Part III	SYMPOSIUM Atherosclerosis and cardiovascular risks. Dialectics of choice in clinical practice. <i>(supported by Pfizer)</i> Online broadcasting Simultaneous translation	SYMPOSIUM Hot issues of antiplatelet therapy in ACS <i>(supported by Sanofi)</i> Online broadcasting

16.45–18.00 **AWARDING CEREMONIES 2016: RUSSIAN SOCIETY OF CARDIOLOGY AWARDS
YOUNG SCIENTISTS AWARDS**

18.15 Bus departure from Ekaterinburg EXPO to the Opening ceremony

18.45–19.15 Welcome of participants in the Opera Theatre

19.15–21.00 **OPENING CEREMONY IN THE OPERA THEATRE**

21.00 Reception

CONFERENCE HALL 4	CONFERENCE HALL 4A	CONFERENCE HALL 5	CONFERENCE HALL 5A	CONFERENCE HALL 6	CONFERENCE HALL 7
SYMPOSIUM Orthotopic cardiac transplantation: current aspects	SECTION SESSION CAD, lipids and atherosclerosis Part III	SYMPOSIUM Noncompaction cardiomyopathy	SYMPOSIUM Hot issues in cardiovascular epidemiology and prevention	SYMPOSIUM Rare but frequent cardiac diseases Simultaneous translation	SYMPOSIUM Pulmonary embolism: from acute event to its consequences <i>(Supported by Bayer AG)</i>
SYMPOSIUM Chronic heart failure: future is near! <i>(supported by Novartis)</i>	SECTION SESSION Hybrid surgery and interventional cardiology	SYMPOSIUM Continuum of epidemiological studies and registries in one of the russian regions with high levels of cardiovascular mortality: implications for public health practice	SYMPOSIUM Antithrombotic therapy of cardiovascular diseases: what is new?	SYMPOSIUM Chronic heart failure – whether and how can we reduce mortality? <i>(in cooperatiuon with European Heart Rythm Associassion)</i> Simultaneous translation	SYMPOSIUM Key stages of cardiovascular continuum development: impact point <i>(supported by Teva)</i>

PLENARY SESSION HALL

09.00–10.30

PLENARY SESSION INNOVATIONS IN CARDIOLOGY – 2016

Online broadcasting / Simultaneous translation

Chairpersons:

Gabinsky Ya.L. (Ekaterinburg), Merkely B. (Hungary)

- **Merkely B. (Hungary).** CRT – State of the art.
- **Popov S.V. (Tomsk).** Translational cardiology at work: from bench to bedside.
- **Kotovskaya Yu.V. (Moscow).** Central pressure and arterial stiffness: new technologies and prospects.
- **Gabinsky Ya.L. (Ekaterinburg).** Coronary passport – innovation in cardiology.

CONFERENCE HALL 1

09.00–10.30

SYMPOSIUM

Patients after acute coronary syndrome: effective approaches to prevention of recurrent vascular events

Chairpersons:

Pogosova N.V. (Moscow), Pozdnyakov Yu.M. (Moscow)

- **Pogosova N. V. (Moscow).** Lipids, pre-diabetes and diabetes in CAD patients after acute coronary syndromes: lessons from European monitoring .
- **Oganov R. G. (Moscow).** Comorbid conditions in CAD patients.
- **Pozdnyakov Y. M. (Moscow).** Challenging issues of decision-making in CAD clinical cases.
- **Osipova I.V. (Barnaul).** Optimal non-pharmacological approaches in stable CAD patients in hospital setting.
- **Poponina T. M. (Tomsk).** Optimal medical therapy of stable CAD patients: difficulties and solutions

CONFERENCE HALL 1A

09.00–10.30

YOUNG SCIENTISTS AWARDS SESSION

Jury members:

**Villevalde S.V. (Moscow), Duplyakov D.V. (Samara),
Kontsevaya A.V. (Moscow), Grintshtein Yu.I. (Krasnoyarsk),
Osipova I.V. (Barnaul), Shkolnik E.L. (Moscow),
Mayanskaya S.D. (Kazan), Sumin A.N. (Kemerovo),
Melekhov A.V. (Moscow)**

- **Alieva I.N. (Moscow).** Multispiral computed tomography as compared to myocardial biopsy in myocarditis diagnosis in patients with dilated cardiomyopathy.
- **Benimetskaya K.S. (Krasnoyarsk).** Association of proprotein convertase subtilisin/kexin type 9 (PCSK9) with lipid metabolism disorders in the Russian population.
- **Gladkikh N.N. (Tomsk).** Assessment of LV deformation in 4D STRAIN mode of dobutamine stress-test in revealing coronary atherosclerosis in patients with intermediate pre-test probability of coronary artery disease.
- **Kyrgisova M.A. (Tomsk).** Association of angiogenic growth factors, anti-inflammatory and pro-inflammatory cytokines with long-term clinical outcomes of autologous mononuclear marrow cells transplantation in STEMI.
- **Semenova E.V. (Omsk).** Optimized approach to delayed aortic root identification in undifferentiated connective tissue dysplasia.
- **Skibitsky A.V. (Krasnodar).** Antihypertensive therapy with antidepressants and their effect on central aortal pressure, vascular wall stiffness and 24-hours BP pattern in patients with uncontrolled AH and depressive disorders.
- **Shapkina M.Yu. (Novosibirsk).** Atrial fibrillation: prevalence and determinants in the Russian population (cross-sectional study, 9,255 subjects).

CONFERENCE HALL 2

09.00–10.30

SYMPOSIUM

Anticoagulant therapy. Safety first. Open discussion
(supported by Boehringer Ingelheim)

Online broadcasting

Chairperson:

Shlyakhto E.V. (Saint-Petersburg)

- **Shlyakhto E.V. (Saint-Petersburg)**. Introduction.
- **Baranova E.I. (Saint-Petersburg)**. Anticoagulants in atrial fibrillation. Risks and benefits ratio?
- **Vinogradov O.I. (Moscow)**. Safety of new oral antocoagulants in stroke prevention.
- **Zotova I.V. (Moscow)**. Safety of new oral antocoagulants in clinical practice.
- Panel discussion. Questions and answers.

CONFERENCE HALL 3

09.00–10.30

SYMPOSIUM

Challenges and achievements in ACS and pulmonary embolism

Chairpersons:

Boldueva S.A. (Saint-Petersburg), Averkov O.V. (Moscow)

- **Tavlujeva T.V. (Kemerovo)**. Results of joint cardiovascular programme of the Kuzbass ambulance service and Regional Vascular Centre in 2015.
- **Kakorin S.V., Erlikh A.D. (Moscow)**. Complications and mortality in patients with acute coronary syndrome and carbohydrate metabolism disorders (Moscow ACS syndrome).
- **Kashtalap V.V. (Kemerovo)**. Clinical case. A STEMI patient with pre-hospital thrombolysis and multivessel stenting.
- **Vasiltseva O.YA., Selivanova I.Kh., Gorlova A.A., Vorozhtsova I.N., Karpov R.S. (Tomsk)** Pulmonary embolism in clinical practice (12-year city hospital registry).
- **Edemsky A.G. (Novosibirsk)**. Estimation of operability of chronic thromboembolic pulmonary hypertension.

CONFERENCE HALL 4

09.00–10.30

SYMPOSIUM

Early diagnosis of myocardial infarction

Chairpersons:

Voevoda M.I. (Novosibirsk), Martynov A.I. (Moscow)

- **Voevoda M.I. (Novosibirsk).** Theoretical aspects of a new myocardial necrosis marker. **Martynov A.I. (Moscow)** Early diagnosis of myocardial infarction (Ispolin trial).
- **Plavunov N.F., Sokolov A.Yu., Zhuk M.Yu (Moscow).** Acute myocardial infarction diagnosis in specialized medical care (trial on early detection of cardiac damage with heart fatty acid-binding protein in the Moscow ambulance service).
- **Shtegman O.A. (Krasnoyarsk).** Acute myocardial infarction diagnosis in the Krasnoyarsk ambulance service.

CONFERENCE HALL 4A

09.00–10.30

SECTION SESSION

Coronary artery disease, lipids and atherosclerosis

Part I

Chairpersons:

Yakushin S.S. (Ryazan), Yakhontov D.A. (Novosibirsk)

- **Gerasimova E.V., Popkova T.V., Novikova D.S., Krugly L.B., Fomicheva O.A. (Moscow).** Atherosclerotic damage of coronary and internal carotid arteries in patients with rheumatoid arthritis.
- **Minushkina L.O., Aseicheva O.Yu., Selezneva N.D., Nikitin A.G., Zateishikov D.A. (Moscow).** Clinical significance of estrogen receptor gene polymorphism in patients with AH and CAD.
- **Feoktistova V.S., Boldueva S.A., Leonova I.A., Sirotkina O.V., Stepanova A.A. (Saint-Petersburg).** Effect of ABCG1 cholesterol transporter gene variants on insulin sensitivity in patients with coronary artery disease.

- **Rudchenko I.V., Tyrenko V.V., Koltsov A.V., Sinopalnikov D.O., Kachnov V.A. (Saint-Petersburg).** Pre-hypertension in military men: incidence and association with risk factors.
- **Shashenkov I.V., Babak S.L. (Moscow).** Enhanced external counterpulsation in treatment of patients with coronary artery disease and sleep apnoea.
- **Tarasov A.V., Khirmanov V.N., Kravtsov V.Yu. (Saint-Petersburg).** Results of intravascular biopsy of coronary artery endothelium.

CONFERENCE HALL 5

09.00–10.30

SYMPOSIUM

Controversial issues in cardioneurology

Chairpersons:

Ostroumova O.D. (Moscow), Volkova L.I. (Ekaterinburg)

- **Ostroumova O.D. (Moscow).** Cardiocerebral continuum.
- **Kislyak O.A. (Moscow).** Stroke prevention in patients with AH and diabetes mellitus.
- **Podzolkov V.I. (Moscow).** Stroke in young women.
- **Shaposhnik I.I. (Chelyabinsk).** Heart rhythm disorders as a cause of cerebro-vascular events.
- **Volkova L.I. (Ekaterinburg).** Current understanding of diagnosis and treatment of discirculatory encephalopathy.

CONFERENCE HALL 5A

09.00–10.30

SYMPOSIUM

Rare types of cardiomyopathies

Chairpersons:

Zaklyazminskaya E.V. (Moscow), Frolova Yu.V. (Moscow)

- **Blagova O.V., Nedostup A.V., Kogan E.A., Sedov V.P. (Moscow).** Cardial and exocardial masks of different types of cardiac amyloidosis.

- **Frolova Yu.V., Dymova O.V., Mershina E.A., Kim S.Yu., Van E.Yu., Zaklyazminskaya E.V., Sinitsin V.E., Dzemeshevich S.L. (Moscow).** Hypertrophic cardiomyopathy with multiple-level obstruction: current diagnosis and treatment.
- **Leontyeva I.V. (Moscow).** Heart damage in Barth syndrome.
- **Malikova M.S., Zaklyazminskaya E.V., Frolova Yu.V., Federov D.N., Tarasov D.G., Dzemeshevich S.L., Sinitsin V.E., (Moscow, Astrakhan).** LV myocardial crypt with Barlow syndrome.
- **Kotlukova N.P. (Moscow).** What is hidden behind cardiomyopathy syndrome in infants?
- **Varionchik N.V., Lutokhina Yu.V., Blagova O.V., Zaklyazminskaya E.V. (Moscow).** Genetically and morphologically verified combination of arrhythmogenic right ventricular dysplasia, non-compact myocardium and myocarditis.

CONFERENCE HALL 6

09.00–10.30

SYMPOSIUM

Improvement of continuous professional education of nurses in cardiology departments as an integral constituent of the quality medical care

Chairperson:

Levina I.A. (Ekaterinburg)

- **Levina I.A. (Ekaterinburg).** Improvement of continuous professional education of nurses in cardiology departments as an integral constituent of the quality medical care.
- **Mirgorodskaya O.P., Mirgorodsky K.A. (Chelyabinsk).** Development of information and educational environment within continuous professional education of nurses in cardiology departments.
- **Espe N.A. (Khanty-Mansiisk).** Continuous professional education of nurses in Khanty-Mansiysk Autonomous District – Ugra within the year of struggle against cardiovascular diseases.

CONFERENCE HALL 7

09.00–10.30

SCIENTIFIC SESSION

Cardiovascular patients with anxiodepressive disorders. Novel approach to prevention

Chairpersons:

**Petrova M.M. (Krasnoyarsk), Garganeeva N.P. (Tomsk),
Poponina T.M. (Tomsk)**

- **Petrova M.M. (Krasnoyarsk).** Current approaches to management of anxiodepressive disorders in cardiological patients.
- **Garganeeva N.P. (Tomsk).** Anxiety and depressive disorders as psychosomatic components of clinical picture in cardiovascular diseases.
- **Poponina T.M. (Tomsk), Poponina Yu.S. (Tomsk), Gunderina K.I. (Tomsk), Markov V.A. (Tomsk).** Improving prognosis in patients with acute coronary syndrome associated with anxiety disorders.
- **Ardashova N.Yu. (Kemerovo), Barbarash O.L. (Kemerovo), Lebedeva N.B. (Kemerovo).** Psychological status and its correction in patients waiting for coronary artery bypass graft surgery.
- **Akimova E. (Tyumen region).** Some factors of emotional stress and coronary artery disease in the open population: prevalence, interrelations.
- **Garganeeva N.P. (Tomsk), Belokrylova M.F. (Tomsk), Tyukalova L.I. (Tomsk).** Psychosocial factors preventing vocational rehabilitation in patients after coronary artery bypass graft surgery.

PLENARY SESSION HALL

11.00–12.30

PLENARY SESSION

HOT ISSUES IN ARRHYTHMOLOGY — 2016

Online broadcasting | Simultaneous translation

Chairpersons:

Revishvili A.Sh. (Moscow), Popov S.V. (Tomsk)

- **Revishvili A.Sh. (Moscow).** Atrial fibrillation: from understanding mechanism to choosing therapy.
- **Hedman A. (Финляндия).** Why catheter ablation of atrial fibrillation does not cure all the atrial fibrillation patients?
- **Popov S.V. (Tomsk).** Cardiac resynchronization therapy: innovation and clinical practice.
- **Lebedev D.S. (Saint-Petersburg).** New findings in ventricular tachyarrhythmias treatment.

CONFERENCE HALL 1

11.00–12.30

SYMPOSIUM

Current technologies of coronary artery disease diagnosis: from anatomy to function or vice versa?

Chairpersons:

Sinitsyn V.E. (Moscow), Boschenko A.A. (Tomsk), Karpov R.S. (Tomsk)

- **Sinitsyn V.E. (Moscow).** Current capabilities and development prospects of spiral CT for coronary angiography in coronary atherosclerosis diagnosis.
- **Boschenko A.A., Vrublevsky A.V. (Tomsk).** Stress-echocardiography in coronary artery disease diagnosis: new opportunities or a tendency to elimination?
- **Pavlukova E.N., Gladkikh H.N., Karpov R.S. (Tomsk).** Clinical significance of LV mechanics assessment in coronary artery disease.
- **Lishmanov Yu.B., Zavadovsky K.V., Saushkin V.V., Saushkina Yu.V.,**

Gulya M.O., Mochulya A.V. (Tomsk). Current tendencies in CAD radionuclide diagnosis.

- **Usov V.Yu. Shelkovnikova T.A., Bukhovets I.L., Aleksandrova E.V., Maksimova A.S., Bobrikova E.E. (Tomsk).** Contrast enhanced methods in radiological pathophysiological assessment of coronary atherosclerosis and myocardial viability.
- **Krylov A.L. (Tomsk).** Endovascular methods of coronary bed investigation in CAD patients.

CONFERENCE HALL 1A

11.00–12.30

SECTION SESSION

Arterial hypertension, metabolic syndrome, diabetes mellitus

Part I

Chairpersons:

Podzolkov V.I. (Moscow), Libis R.A. (Orenburg)

- **Abdulgasanov R.A., Bokeria L.A., Abdulgasanova M.R., Ivanov A.V., Provotorova Yu.R., Gasymov E.G. (Moscow).** Conn syndrome in patients with essential arterial hypertension.
- **Gorlova A.A., Vasil'tseva O.Ya., Vorozhtsova I.N. (Tomsk).** Metabolic disorders in patients with arterial thromboembolism.
- **Blednova A.Yu., Eliseeva L.N. (Krasnodar).** Prevalence and management of cardiovascular diseases in patients with arthropathies.
- **Podsonnaya I.V., Efremushkin G.G. (Barnaul).** Arterial hypertension and mortal ischemic stroke.
- **Gruzdeva O.V., Dyleva Yu.A., Antonova L.V., Matveeva V.G., Karetnikova V.N., Uchasova E.G., Fanaskova E.V., Ivanov S.V., Barbarash O.L. (Kemerovo).** Adipokines from epicardial and subcutaneous fat tissues and cardiovascular risk factors in CAD patients.

CONFERENCE HALL 2

11.00–12.30

BATTLE OF SCHOLARS — 2016. FINAL COMPETITION

Jury:

Andreev D.A. (Moscow), Barbarash O.L. (Kemerovo), Gilyarevsky S.P. (Moscow), Drapkina O.M. (Moscow), Zakirova A.N. (Ufa), Kontsevaya A.V. (Moscow), Menzorov M.V. (Ulyanovsk), Nikulina S.Yu. (Krasnoyarsk), Pavlova T.V. (Samara), Petrova M.M. (Krasnoyarsk), Shaposhnik I.I. (Chelyabinsk), Yakushin S.S. (Ryazan)

Finalists:

**Lege Cordis (Astrakhan)
Heart Team (Saint-Petersburg)
Chelyabinsk meteorite (Chelyabinsk)**

CONFERENCE HALL 3

11.00–12.30

SYMPOSIUM MYOCARDIAL INFARCTION — 2016

Chairpersons:

Ruda M.Ya. (Moscow), Chazov E.I. (Moscow)

- **Barbarash O.L. (Kemerovo).** ECG in non-STEMI — 2016.
- **Yavelov I.S. (Moscow).** Hyperglycemia in ACS: effect on prognosis and treatment.
- **Averkov O.V. (Moscow).** ECG in STEMI — 2016.

CONFERENCE HALL 4

11.00–12.30

SYMPOSIUM

CAD and CHF — 2016: time to change

(supported by Servier)

Online broadcasting

Chairperson: **Glezer M.G. (Moscow)**

- **Mareev V.Yu. (Moscow).** Guideline updates.
- **Glezer M.G. (Moscow).** Novel approaches in CAD treatment.
- **Lopatin Yu.M. (Moscow).** Novel approaches in CHF treatment

CONFERENCE HALL 4A

11.00–12.30

SECTION SESSION

Coronary artery disease, lipids and atherosclerosis

Part II

Chairpersons:

Grinshtein Yu.I. (Krasnoyarsk), Minushkina L.O. (Moscow)

- **Martsevich S.Yu., Kutishenko N.P., Deev A.D., Ginzburg M.L. (Moscow).** Comparative assessment of antianginal effectiveness and acceptability of Nicorandil and placebo in combination with the basic Metoprolol Tartrate therapy in patients with stable effort angina: KVAZAR trial.
- **Gavrilova N.E., Metelskaya V.A., Boitsov S.A. (Moscow).** Intergrated biomarker: coronary risk identification.
- **Kosinova A.A., Grinshtein I.Yu., Grinshtein Yu.I., Kovalev A.V., Sukhovolsky V.G. (Krasnoyarsk).** Fourier transform spectroscopy of blood in identification of acetylsalicylic acid resistnace in coronary artery disease.
- **Teterina M.A. (Moscow).** Effect of early administrated Atorvastatin and Rosuvastatin maximum tolerated doses on lipid metabolism in ACS patients.
- **Yakhontov D.A., Ostanina Yu.O., Autenshlus A.I. (Novosibirsk).** Clinical manifestation of multifocal atherosclerosis in different age groups of CAD patients.
- **Markov V.A., Shikanov V.A., Golovenkin S.E. (Tomsk, Krasnoyarsk).** Early express diagnosis of acute myocardial infarction.

CONFERENCE HALL 5

11.00–12.30

SYMPOSIUM

How to prevent recurrent events or is there life after ACS? (Supported by Dr.Reddis)

Chairpersons:

Ter-Akopyan A.V. (Moscow), Lomakin N.V. (Moscow)

- **Buryachkovskaya L.I. (Moscow).** Platelets: what happens if they are really angry.
- **Lomakin N.V. (Moscow).** From population to individualization, or how to help a specific patients in the era of clinical standards.
- **Ter-Akopyan A.V. (Moscow).** Early, late and very late stent thromboses: how to prevent. An X-ray surgeon's perspective.
- **Staroverov I.I. (Moscow).** ACS without PCI: how to treat such a patient?

CONFERENCE HALL 5A

11.00–12.30

SCIENTIFIC SESSION

Reduction of cardiovascular risk in rheumatic diseases: finding better solutions

Chairpersons:

Popkova T.V. (Moscow), Novikova D.C. (Moscow)

- **Novikova D.C., Popkova T.V. (Moscow).** Topical issues of diagnosis and treatment of cardiovascular diseases in rheumatoid arthritis patients.
- **Rebrov A.P., Gaidukova I.Z. (Saratov).** Are adhesion molecules a common target for a rheumatologist and a cardiologist?
- **Kirillova I.G. (Moscow).** Specific characteristics of CHF in early rheumatoid arthritis patients.
- **Markelova E.I. (Moscow).** Cardiovascular disorders in gout patients.
- **Kondratyeva L.V. (Moscow).** Association of endocrine pathology with cardiovascular risk in rheumatic patients.

CONFERENCE HALL 6

11.00–12.30

SYMPOSIUM

Value-based medicine in cardiology

Chairpersons:

Shlyakhto E.V. (Saint-Petersburg), Omelyanovsky V.V. (Moscow)

- **Shlyakhto E.V. (Saint-Petersburg).** Value-based medicine in cardiology. Paradigm change.
- **Konradi A.O. (Saint-Petersburg).** Effectiveness of medical interventions as seen by a patient.
- **Omelyanovsky V.V. (Moscow).** Health technologies assessment as a current trend of medical care efficiency improvement.
- **Kontsevaya A.V. (Moscow).** Efficiency of medical interventions as seen by an economist.

CONFERENCE HALL 7

11.00–12.30

SYMPOSIUM

Therapy evolution in course of cardiovascular continuum: place of sartans (supported by Teva)

Chairperson:

Kobalava Zh.D. (Moscow)

- **Kobalava Zh.D. (Moscow).** Antihypertensive therapy with sartans.
- **Ageev F.T. (Moscow).** Choosing a sartan for a CHF patient: pros and cons.

PLENARY SESSION HALL

13.00–14.30

SYMPOSIUM

International clinical research: how to put results into practice

(supported by KRKA)

Online broadcasting

Chairperson: **Shlyakhto E.V. (Saint-Petersburg)**

- **Shlyakhto E.V. (Saint-Petersburg)**. How to join efforts in struggle against cardiovascular diseases (ROSU-PATH, Russian arm)
- **Vrablik M. (Czech Republic)**. Impact of statin therapy in reducing CV risk: European experience in the light of ROSU-PATH study.
- **Kobalava Zh.D. (Moscow)**. How to control hypertension and protect future of our patients here and now.
- **Drapkina O.M. (Moscow)**. How to use integrated approach in hypertension treatment: strength in SYNERGY
- **Susekov A.V. (Moscow)**. How to spot unseen danger and prevent complications of Ischemic Heart Disease in the future.
- **Mareev V.Yu. (Moscow)**. How to implement data of international research in clinical practice and retain achieved results.

CONFERENCE HALL 1

13.00–14.30

SYMPOSIUM

Organization of specialized medical care to ACS patients: yesterday, today and tomorrow

(supported by AstraZeneca)

Chairpersons: **Shpektor A.V. (Moscow), Alekryan B.G. (Moscow)**

- **Vasilyeva E.Yu. (Moscow)**. How to improve medical care to ACS patients and make it well-timed in Russia: Moscow experience.
- **Alekryan B.G. (Moscow)**. ACS endovascular therapy 2016: introduction of Stent for Life in Russia appeals to everybody.
- **Barbarash O.L. (Kemerovo)**. New facilities and new challenges in ACS therapy: experience of the Kemerovo region.

CONFERENCE HALL 1A

13.00–14.30

SECTION SESSION

Arterial hypertension, metabolic syndrome, diabetes mellitus

Part II

Chairpersons:

Tarlovskaya E.I. (Nizhny Novgorod), Nebieridze D.V. (Moscow)

- **Abdulgasanov R.A., Bokeria L.A., Abdulgasanova M.R., Ivanov A.V., Provorotova Yu.R., Gasymov E.G. (Moscow).** Symptomatic arterial hypertension in patients with essential arterial hypertension (results of investigation of 1,950 patients).
- **Yakhontov D.A., Khidirova J.D., Zhuravleva I.I., Shulyatyeva O.Yu. (Novosibirsk).** Arterial hypertension and comorbidities in clinical practice.
- **Kachkovsky M.A. (Samara).** Challenges in diagnosis of secondary arterial hypertension.
- **Ripp T.M., Mordovin V.F., Semke G.V., Pekarsky S.E., Falkovskaya A.Yu., Lichikaki V.A., Zubanova I.V., Sitkova E.S., Popov S.V., Karpov R.S. (Tomsk).** Organoprotective effects of invasive AH treatment.
- **Kardashevskaya L.I., Mikhailichenko E.S. (Ukraine).** Arterial hypertension as a key factor of cardiovascular events in war and economic embargo in Donbass.
- **Mangileva T.A. (Simferopol).** Differential diagnosis, patients' adherence and prognosis in AH stage I.
- **Evseyeva M.E., Ivanova L.V., Rostovtseva M.V., Barbarash I.V. (Stavropol).** Professional stress and cardiovascular status: aspects of BP regulation and vascular ageing.

CONFERENCE HALL 2

13.00–14.30

SYMPOSIUM

A way to the patient's heart

(supported by Egis)

Chairperson:

Martynov A.I. (Moscow)

- **Martynov A.I. (Moscow).** How to reduce cardiovascular risk with minimal therapy?
- **Martsevich S.Yu. (Moscow).** Study of beta-blockers administration in clinical practice and its matching clinical guidelines within two out-patient cardiovascular registries.
- **Ezhov M.V. (Moscow).** European guidelines on cardiovascular prevention 2016. Role of statins.

CONFERENCE HALL 3

13.00–14.30

SYMPOSIUM

Gender-specific and personalized approach to high cardiovascular risk patients

(supported by Zentiva of Sanofi Group)

Chairperson:

Karpov Yu.A. (Moscow)

- **Karpov Yu.A. (Moscow).** Optimized approaches to cardiovascular risk reduction in males.
- **Kislyak O.A. (Moscow).** Choosing antihypertensive therapy for females of different age groups.
- **Mikhin V.P. (Kursk).** Personalized approach to lipid-lowering therapy administration.

CONFERENCE HALL 4

13.00–14.30

SYMPOSIUM

Orthotopic cardiac transplantation: current aspects

Chairpersons:

Gabbasova L.A. (Moscow), Karpenko M.A. (Saint-Petersburg), Shevchenko A.O. (Moscow)

- **Gabbasova L.A. (Moscow).** Specificities of Russian legislation governing organ transplantation.
- **Karpenko M.A., Sitnikova M.Yu., Moiseeva O.M., Sukhova I.V., Fedotov P.A., Sazonova Yu.V. (Saint-Petersburg).** Cardiac transplantation waiting list: ways to reduce mortality.
- **Gotye S.V., Shevchenko A.O. (Moscow).** Long-term outcomes of cardiac transplantation (750 follow up studies).
- **Kosmacheva E.D., Barbukhatti K.O., Porkhanov V.A., Stavenchuk T.V. (Krasnodar).** Our 7-year experience of cardiac transplantations and post-operative management of the patients.

CONFERENCE HALL 4A

13.00–14.30

SECTION SESSION

CAD, lipids and atherosclerosis

Part III

Chairpersons:

Abdullaev A.A. (Makhachkala), Oleinikov V.E. (Penza)

- **Khondkaryan E.V., Aparkina A.V., Gaidukova I.Z., Rebrov A.P. (Saratov).** Association between arterial stiffness and renal function markers in ankylosing spondylitis patients.
- **Yaroslavskaya E.I., Kuznetsov V.A., Krinochkin D.V., Teffenberg D.V., Kutrunov V.N., Dyachkov S.M. (Tumen).** New method of non-invasive CAD diagnosis in patients with myocardial perfusion defect.
- **Khokhlov R.A., Tribuntseva L.V., Burlachuk V.T., Filatova O.S., Cherednikova A.S. (Voronezh).** Screening of patients with familial hypercholesterolemia with the help of hospital registry.

- **Bezdeneshnykh A.V., Sumin A.N., Kazachek Ya.V., Osokina A.V., Kondrikova N.V., Bairakova Yu.V., Ivanov S.V., Barbarash O.L. (Kemerovo).** Noncoronary atherosclerosis progressing a year after CABG: comparative assessment of criteria.
- **Galin P.Yu., Gubanov T.G., Isaev M.P. (Orenburg).** Cause-specific effectiveness of Trimetazidine SR in patients with microvascular angina.
- **Tarasov A.V., Khirmanov V.N., Kulyashova L.B. (Saint-Petersburg).** Chlamydia Pneumoniae in patients with acute and chronic coronary atherosclerosis.

CONFERENCE HALL 5

13.00–14.30

SYMPOSIUM

Noncompaction cardiomyopathy

Chairpersons:

Boytsov S.A. (Moscow), Blagova O.V. (Moscow)

- **Kulikova O.V., Myasnikov R.P., Kharlap M.S., Umarova M.K., Koretsky S.N., Basargina E.N., Boitsov S.A. (Moscow).** Clinical picture of familial left ventricular noncompaction.
- **Polyak M.E., Zaklyazminskaya E.V. (Moscow).** Mutation range in left ventricular noncompaction.
- **Blagova O.V., Nedostup A.V., Pavlenko E.V., Kogan E.A., Sedov V.P. (Moscow).** Myocardial infarction (necrosis) as a typical manifestation of noncompaction cardiomyopathy.
- **Merzhina E.A., Zaklyazminskaya E.V., Frolova Yu.V., Sinitsin V.E. (Moscow).** MRI in diagnosis and prognosis assessment in noncompaction cardiomyopathy.
- **Myasnikov R.P., Boytsov S.A. (Moscow).** Noncompaction cardiomyopathy: topical issues of cardiovascular complications prevention.

CONFERENCE HALL 5A

13.00–14.30

SYMPOSIUM

Hot issues in cardiovascular epidemiology and prevention

Chairpersons:

Rotar O.P. (Saint-Petersburg), Oschepkova E.A. (Moscow)

- **Rotar O.P., Konradi A.O., Shlyakhto E.V. (Saint-Petersburg).** On behalf of ESSE-RF study participants. Biomarkers in cardiovascular risk stratification.
- **Oschepkova E.A., Zhernakova Yu.V. (Moscow).** Renal disorders in the Russian population.
- **Shalnova S.A., Balanova Yu.A., Deev A.D., Boytsov S.A. (Moscow).** On behalf of ESSE-RF study participants. First result of prospective analysis.
- **Philippov E.V., Yakushin S.S. (Ryazan).** Endothelial function and its significance for cardiovascular prevention. MERIDIAN-RO study.

CONFERENCE HALL 6

13.00–14.30

SYMPOSIUM

Rare but frequent cardiac diseases

Simultaneous translation

Chairpersons:

Zateyshchikov D.A. (Moscow), Kostareva A.A. (Saint Petersburg), Garca-Giustiniani D. (Spain)

- **Zateyshchikov D.A. (Moscow).** Acute coronary syndrome and familial hyperlipidemia.
- **Chumakova O.S. (Moscow).** Genetics of sudden death in athletes.
- **Kostareva A. A. (Saint Petersburg).** Genetic basis and clinical course of cardiomyopathy combined with neuromuscular symptoms.
- **Garca-Giustiniani D. (Spain).** The practical application of genetics in hereditary cardiomyopathies.

CONFERENCE HALL 7

13.00–14.30

SYMPOSIUM

Pulmonary embolism: from acute event to its consequences

(Supported by Bayer AG)

Chairperson:

Duplyakov D.V. (Samara)

- **Duplyakov D.V. (Samara), Khasanov N.R. (Kazan).** Pulmonary embolism — in-patient management based on risk stratification.
- **Nemirova E.V. (Nizhny Novgorod).** Chronic thromboembolic pulmonary hypertension — current view on patients' management. Surgical and pharmacological methods of treatment.
- Discussion, questions and answers.

PLENARY SESSION HALL

15.00–16.30

PLENARY SESSION

Cardiology 2016: challenges and solutions

Online broadcasting | Simultaneous translation

Chairpersons:

**Shlyakhto E.V. (Saint-Petersburg), Pinto F. (Portugal),
Hendel R. (USA)**

- **Shlyakhto E.V. (Saint-Petersburg).** Revolutions in cardiology of the 21st century: challenges and tendencies.
- **Pinto F. (Portugal).** Implementation of guidelines: the role of scientific societies.
- **Hendel R. (USA).** Appropriate use of cardiovascular technology

CONFERENCE HALL 1

15.00–16.30

SYMPOSIUM

**Improving prognosis in non-STEMI patients –
strategic goal in choosing double antiplatelet therapy**
(supported by AstraZeneca)

Online broadcasting

Chairperson:

Gabinsky Ya.L. (Ekaterinburg)

- **Glezer M.G. (Moscow).** Risk stratification and challenges of non-invasive approach to therapy in non-STEMI patients.
- **Matskeplishvili S.T. (Moscow).** Clinical discussion. A non-STEMI patient after revascularization.
- **Galyavich A.S. (Kazan).** Clinical discussion. A non-STEMI patient undergoing non-invasive treatment.
- **Villevalde S.V. (Moscow).** Role of a doctor in improving prognosis and following consistent antiplatelet therapy in patients after myocardial infarction.

CONFERENCE HALL 1A

15.00–16.30

SECTION SESSION

**Arterial hypertension, metabolic syndrome,
diabetes mellitus**
Part III

Chairpersons:

Ripp T.M. (Tomsk), Gapon L.I. (Tumen)

- **Bezdeneshnykh N.A., Sumin A.N., Federova N.V., Bezdeneshnykh A.V., Indukaeva E.V., Artamonova G.V. (Kemerovo).** Cardio-ankle vascular index increase is associated with diabetes mellitus II and pre-diabetes according to ESSE-RF study in Western Siberia.
- **Topolyanskaya S.V., Vakulenko O.N., Kupina L.M., Strizhova N.V. (Moscow).** Association of hyperuricemia and cardiovascular diseases in elderly patients.

- **Abdulgasanov R.A., Bokeria L.A., Abdulgasanova M.R., Ivanov A.V., Provotorova Yu.R., Gasymov E.G. (Moscow).** Arterial hypertension and renal parenchymal disease (diagnosis and treatment).
- **Kakorin S.V., Erlikh A.D., Kiledinsky A.G. (Moscow).** Carbohydrate metabolism disorder in ACS patients (Moscow ACS registry).
- **Benimetskaya K.S., Timoshenko N.A., Ragino Yu.I., Voevoda M.I. (Novosibirsk).** Electrophysiological evidences of myocardial damage associated with metabolic syndrome and its markers in males with coronary atherosclerosis.
- **Gritsenko O.V., Chumakova G.A. (Kemerovo, Barnaul).** HF risk factors in obese patients.

CONFERENCE HALL 2

15.00–16.30

SYMPOSIUM

Atherosclerosis and cardiovascular risks.

Dialectics of choice in clinical practice

(supported by Pfizer)

Online broadcasting | Simultaneous translation

Chairperson:

Sergienko I.V. (Moscow)

- **Lansberg P. J. (Netherlands).** New developments in dyslipidemia and updated ESC guidelines on primary prevention and dyslipidemia
- **Bubnova M.G. (Moscow).** Correction of atherogenic dyslipidemia as an important component of preventive and rehabilitation strategies.
- **Sergienko I.V. (Moscow).** Stenosis percentage or stability, or what does a statin dose depend on?

CONFERENCE HALL 3

15.00–16.30

SYMPOSIUM

Hot issues of antiplatelet therapy in ACS

(supported by Sanofi)

Online broadcasting

Chairperson:

Ruda M.Ya. (Moscow)

- **Averkov O.V. (Moscow).** Double antiplatelet therapy in ACS guidelines: options and limitations.
- **Yakovlev A.N. (Saint-Petersburg).** A balance between effectiveness and safety of double antiplatelet therapy.
- **Barbarash O.L. (Kemerovo).** Duration of double antiplatelet therapy.
- Questions and answers.

CONFERENCE HALL 4

15.00–16.30

SYMPOSIUM

Chronic heart failure: future is near!

(supported by Novartis)

Chairperson:

Mareev V.Yu. (Moscow)

- **Kobalava Zh.D. (Moscow).** A CHF patient: is there an escape from the risk zone?
- **Lopatin Yu.M. (Volgograd).** Evolution of CHF guidelines in the 21st century.
- **Mareev V.Yu. (Moscow).** Emerging future for CHF patients.

CONFERENCE HALL 4A

15.00–16.30

SECTION SESSION

Hybrid surgery and interventional cardiology

Chaipersons:

Abugov S.A. (Moscow), Zverev D.A. (Saint-Petersburg)

- **Maksimkin D.A., Shugushev Z.Kh. (Moscow).** Bifurcation stenoses of the left main coronary artery: current treatment strategy.
- **Volkova O.A., Shugushev Z.Kh., Maksimkin D.A., Faibushevich A.G., Chepurnoi A.G. (Moscow).** Role of Роль intravascular modeths of investigation in the «expert» CAD diagnosis.
- **Kashtanov M.G., Idov E.M., Chernyshev S.D., Kardapoltsev L.V., Berdnikov S.V. (Ekaterinburg).** Repeated alcohol septal ablation in patients with residual LVOT obstruction.
- **Melkozerov K.V., Terekhin S.A., Kalashnikov V.Yu. (Moscow).** CAD diagnosis and treatment in patients with diabetes mellitus and critical lower limb ischemia.
- **Chernigina T.P., Shugushev Z.Kh., Maksimkin D.A., Goloshapov-Aksenov R.S. (Moscow).** Endovascular therapy for non-STEMI patientsT.
- **Bogdanov Yu.I., Vechersky Yu.Yu., Batalov R.E., Zatulkin V.V., Popov S.V. (Tomsk).** Hybrid approach in atrial fibrillation treatment in patients after CABG.



CONFERENCE HALL 5

15.00–16.30

SYMPOSIUM

Continuum of epidemiological studies and registries in one of the russian regions with high levels of cardiovascular mortality: implications for public health practice

Chairpersons: **Nikulina N.N. (Moscow), Yakushin S.S.(Ryazan), Boytsov S.A. (Moscow)**

- **Smirnova E.A. (Ryazan).** CHF epidemiology study in the Ryazan region: 5-year follow-up results.
- **Boytsov S. A.(Moscow), Nikulina N. N. (Moscow).** REZONANCE epidemiologic study: analysis of incidence, mortality, quality of diagnosis and treatment of CAD acute forms.
- **Shalnova S.A. (Moscow), Filippov E.B. (Ryazan).** All causes mortality in a region of high mortality: focus on risk factors.
- **Lukyanov M.M. (Moscow), Vorobyev A.N. (Ryazan).** RECVAZA registry: risk assessment, treatment and outcomes in patients with concomitant cardiovascular diseases in outpatient clinical practice.
- **Yakushin S.S. (Ryazan).** Previous epidemiological studies and registries: implementation challenges and solutions, introduction into practice.

CONFERENCE HALL 5A

15.00–16.30

SYMPOSIUM

Antithrombotic therapy of cardiovascular diseases: what is new?

Chairpersons:
Yavelov I.S. (Moscow), Panchenko E.P. (Moscow), Dobrovolsky A.B. (Moscow)

- **Yavelov I.S. (Moscow).** Antidotes to new oral anticoagulants – is it the way to improve safety?

- **Komarov A.L. (Moscow).** Anticoagulants in patients with ACS. Do we need to prolong treatment?
- **Panchenko E.P. (Moscow).** Anticoagulant therapy in patients with atrial fibrillation in clinical practice. Results of GARFIELD-AF registry.
- **Dobrovolsky A.B. (Moscow).** Effect of fibrinogen on platelet reactivity measured by the VerifyNow P2Y12 assay.

CONFERENCE HALL 6

15.00–16.30

SYMPOSIUM

Chronic heart failure – whether and how can we reduce mortality?

(in cooperatiuon with European Heart Rythm Associassion)

Simultaneous translation

Chaipersons:

Popov S.V. (Tomsk), Merkely B. (Hungary)

- **Chudzik M. (Poland).** Whether and how can we decrease mortality in heart failure?
- **Duplyakov D.V. (Samara).** ECG and sudden cardiac death – although it is sudden, can we predict it?
- **Popov S.V. (Tomsk).** Cardiac resynchronization therapy: which patinets and why? Clinical cases.
- **Romanov A.B. (Novosibirsk).** Arrhythmia in heart failure patient – pharmacological or invasive treatment? Clinical guidelines.
- **Merkely B. (Hungary).** Do we really understand and follow to recommendation in treatment of heart failure?
- Discussion

CONFERENCE HALL 7

15.00–16.30

SYMPOSIUM

**Key stages of cardiovascular continuum development:
impact point**

(supported by Teva)

Chairperson:

Ageev F.T. (Moscow)

- **Ageev F.T. (Moscow).** New European guidelines on HF: pathophysiology and therapy.
- **Ovchinnikov A.G. (Moscow).** Diastolic dysfunction as a separate nosology.

PLENARY SESSION HALL

16.45–18.00

AWARDING CEREMONIES 2016:

**RUSSIAN SOCIETY OF CARDIOLOGY AWARDS
YOUNG SCIENTISTS AWARDS**

19.15–21.00

OPENING CEREMONY IN THE OPERA THEATRE



Время/Зал	PLENARY SESSION HALL	CONFERENCE HALL 1	CONFERENCE HALL 1A	CONFERENCE HALL 2	CONFERENCE HALL 3
09.00–10.30	PLENARY SESSION Emergency cardiology – 2016 Online broadcasting	SYMPOSIUM Practical aspects of choosing anti-thrombotic therapy in AF patients in different clinical situations (<i>supported by Boehringer Ingelheim</i>) Online broadcasting	SYMPOSIUM Opportunities and prospects for WG «Young Cardiologists» development	SYMPOSIUM A high risk patient – dancing on a volcano (<i>supported by AstraZeneca</i>)	SYMPOSIUM Reperfusion therapy in ACS: trends and innovations. (<i>supported by SupraGene</i>)
10.30–11.00	BREAK				
11.00–12.30	SYMPOSIUM The gold medal of VICTORY or how to achieve BP control in different clinical situations. (<i>supported by KRKA</i>)	SYMPOSIUM A novel view on therapy of a patient at a high cardiovascular risk. (<i>supported by Boehringer Ingelheim</i>)	SYMPOSIUM New work areas for Young Cardiologists: keep the traditions alive – multiply innovations	SYMPOSIUM Optimization of anticoagulants in thrombotic diseases (<i>supported by Pfizer</i>) Online broadcasting	SYMPOSIUM Extending potential of cardiovascular risk managing (<i>supported by Sanofi</i>)
12.40–13.20	PLENARY SESSION HALL	PLENARY LECTURE M.Oliveira (Portugal). Autonomic modulation therapy for the management of cardiovascular diseases Online broadcasting Simultaneous translation			
12.30–13.30		BREAK			

CONFERENCE HALL 4	CONFERENCE HALL 4A	CONFERENCE HALL 5	CONFERENCE HALL 5A	CONFERENCE HALL 6	CONFERENCE HALL 7
SYMPOSIUM Combination therapy: when more does not mean better <i>(supported by Servier)</i>	SECTION SESSION Arterial hypertension, metabolic syndrome, diabetes mellitus Part IV	SYMPOSIUM Heart rate control. Challenges and interpetation in routine clinical practice. <i>(supported by Takeda)</i>	SYMPOSIUM Microvascular angina: not a myth anymore but a type of chronic coronary artery disease.	SYMPOSIUM Practical approaches to diagnosis and treatment of heart failure Simultaneous translation	LUNCH SYMPOISUM A high and very high risk patient: what should a physician do in his routine clinical practice? <i>(supported by Gedeon Richter)</i>
SYMPOSIUM Physician's library: to assist a cardiologist <i>(supported by Actavis)</i>	SECTION SESSION Arrhythmology, stimulation, resynchronization Part I	SYMPOSIUM Current view on management of acute heart failure <i>(supported by Novartis)</i>	MASTER CLASS Diagnosis of coronary artery disease: guidelines for a practical doctor	SYMPOSIUM Secondary prevention of myocardial infarction and acute disorders of cerebral circulation Simultaneous translation	SYMPOSIUM Extrasystolic arrhythmia: risk stratification and management in different clinical situations

Time/Hall	PLENARY SESSION HALL	CONFERENCE HALL 1	CONFERENCE HALL 1A	CONFERENCE HALL 2	CONFERENCE HALL 3
13.30–15.00	PLENARY SESSION Epidemiology, prevention, sport medicine Online broadcasting Simultaneous translation	SYMPOSIUM Combination therapy of hypertension. What to choose and how to treat? <i>(supported by Takeda)</i> Online broadcasting	SYMPOSIUM Multi-faced comorbidity in patients with chronic coronary artery disease	SYMPOSIUM Chronic heart failure: taking initiative in the struggle for outcome <i>(supported by Pfizer)</i>	SYMPOSIUM Long-term (longer than 1 year) dual antiplatelet therapy: possible benefits and risks? <i>(supported by AstraZeneca)</i>
15.00–15.30	BREAK				
15.30–17.00	PLENARY SESSION Noncoronary myocardial diseases Online broadcasting	SYMPOSIUM New era in atherosclerosis treatment: the impossible is possible <i>(supported by Amgen)</i>	MASTER CLASS One's own doctor: myths and self-deceptions of patients	SYMPOSIUM Current approaches in diagnosis and treatment of pulmonary hypertension <i>(supported by Pfizer)</i> Online broadcasting	SYMPOSIUM Time for innovations: what else can we do for a patient?
17.00–17.15	BREAK				
17.15–18.30	ASSEMBLY OF THE RUSSIAN SOCIETY OF CARDIOLOGY BOARD				

CONFERENCE HALL 4	CONFERENCE HALL 4A	CONFERENCE HALL 5	CONFERENCE HALL 5A	CONFERENCE HALL 6	CONFERENCE HALL 7
SYMPOSIUM Three whales of adherence in AH treatment <i>(supported by Servier)</i>	SECTION SESSION Noncoronary diseases, valve pathology, congenital disorders, pediatric cardiology, pulmonary hypertension Part I	SYMPOSIUM Medical assistance to patients with acute vascular conditions (myocardial infarction and stroke) – team approach	SCIENTIFIC SESSION Genetic issues of clinical pharmacology in cardiology practice	SYMPOSIUM Current anticoagulation therapy: from randomized studies and guidelines to clinical practice <i>(supported by Bayer)</i>	SYMPOSIUM Discussion board: adherence. Why do patients not always follow doctor's advice? <i>(supported by Berlin-Chemie)</i>
SCIENTIFIC SESSION Coronary artery disease and depression: a dilemma for practice	SECTION SESSION Noncoronary diseases, valve pathology, congenital disorders, pediatric cardiology, pulmonary hypertension Part II	SYMPOSIUM Current diuretic therapy <i>(supported by Takeda)</i>	SCIENTIFIC SESSION Genetic basis of cardiac diseases	SYMPOSIUM Safe and patient-oriented activities of nurses in cardiology units	DEBATES Biomarkers in acute coronary syndrome

PLENARY SESSION HALL

09.00–10.30

PLENARY SESSION EMERGENCY CARDIOLOGY 2016

Online broadcasting

Chairperson:

Ruda M.Ya. (Moscow)

- **Averkov O.V. (Moscow).** Myocardial infarction 2016.
- **Tereschenko S.N., Zhiron I.V. (Moscow).** Acute heart failure 2016.
- **Golitsyn S.P. (Moscow).** Cardiac arrhythmias 2016.
- **Yavelov I.S. (Moscow).** Pulmonary embolism 2016.

CONFERENCE HALL 1

09.00–10.30

SYMPOSIUM

Practical aspects of choosing antithrombotic therapy in AF patients in different clinical situations
(supported by Boehringer Ingelheim)

Online broadcasting

Chairpersons:

Arkhipov M.V. (Ekaterinburg), Novikova N.A. (Moscow)

- **Arkhipov M.V. (Ekaterinburg).** New oral anticoagulants: from trials to clinical practice.
- **Adasheva T.V. (Moscow).** A patient with atrial fibrillation and renal disease. How to prioritize?
- **Janiszewski S.N. (Moscow).** Developing stroke in a patient with atrial fibrillation. What to do?
- **Novikova N.A. (Moscow).** A patient with atrial fibrillation and ischemic heart disease. Principles of choosing antithrombotic therapy.
- **Questions and answers.**

CONFERENCE HALL 1A

09.00–10.30

SYMPOSIUM

Opportunities and prospects for WG «Young Cardiologists» development

Chairpersons:

**Chernova A.A. (Krasnoyarsk), Garkina S.V. (Saint-Petersburg),
Shepel R.N. (Moscow)**

- **Chernova A.A. (Krasnoyarsk), Garkina S.V. (Saint-Petersburg),
Shepel R.N. (Moscow).** Innovation policy of WG «Young Cardiologists».
- **Shepel R.N. (Moscow).** Distance medical learning — focus on a young specialist.
- **Rubanenko A.O. (Samara), Chernova A.A. (Krasnoyarsk).** «Young cardiologists» rating: development and prospects.
- **Garkina S.V. (Saint-Petersburg).** Clinical practice of a young cardiologist today — prospects and possible obstacles. Innovative technologies in arrhythmology.
- **Starodubtseva I.A. (Voronezh).** International collaboration of young cardiologists of the Russian Society of Cardiology with various European organizations — EULAR.
- **Cherepanova N.A. (Samara)** Initial experience of Pulmonary Hypertension Centre in the Samara region.
- **Kashtalap V.V. (Kemerovo).** Clinical cases as an instrument of qualification improvement for young doctors — focus on radiosurgery (capabilities of WG «Young Cardiologists»).

CONFERENCE HALL 2

09.00–10.30

SYMPOSIUM

A high risk patient – dancing on a volcano

(supported by AstraZeneka)

Chairpersons:

Shlyakhto E.V. (Saint-Petersburg), Kobalava Zh.D. (Moscow)

- **Susekov A.V. (Moscow).** Seismology forecast: dyslipidemia news.
- **Kobalava Zh.D. (Moscow).** How not to wake up a volcano: why we should not interrupt statin treatment?
- **Mareev V.Yu. (Moscow).** Rescuer landing: high intensity treatment with statins.

CONFERENCE HALL 3

09.00–10.30

SYMPOSIUM

Reperfusion therapy in ACS: trends and innnovations

(supported by SupraGene)

Chairpersons:

Boytssov S.A. (Moscow), Karpov R.S. (Tomsk)

- **Markov V.A. (Tomsk).** Pharmacoinvasive strategy in STEMI.
- **Erlikh A.D. (Moscow).** Thrombolytic therapy in the Russian clinical practice.
- **Kostogryz V.B. (Ukraine).** The role of thrombolytic therapy in ACS patients in Donetsk.
- **Khripun A.V. (Rostov-on-Don).** Clinical case discussion.
- **Markin S.S. (Moscow).** Thrombolytic therapy in acute cerebrovascular events and pulmonary embolism.

CONFERENCE HALL 4

09.00–10.30

SYMPOSIUM

Combination therapy: when more does not mean better (supported by Servier)

Chairpersons:

Karpov Yu.A. (Moscow), Gezer M.G. (Moscow)

- **Karpov Yu.A. (Moscow).** Therapy intensification as a way to achieve the main goals in AH treatment.
- **Glezer M.G. (Moscow).** Fixed combinations as an effective tool under current present conditions.
- **Privalova E.V. (Moscow).** Fixed combinations: composition has a significance.
- **Glezer M.G., Karpov Yu.A. (Moscow).** From bench to bedside. New results of Russian studies.

CONFERENCE HALL 4A

09.00–10.30

SECTION SESSION

Arterial hypertension, metabolic syndrome, diabetes mellitus Part IV

Chairpersons:

Evseyeva M.E. (Stavropol), Kakorin S.V. (Moscow)

- **Bokeria L.A., Abdulgasanov R.A., Abdulgasanova M.R., Ivanov A.V., Provotorova Yu.R., Gasyimov E.G. (Moscow).** Secondary arterial hypertension in patients with metabolic syndrome.
- **Nazarova O.A., Nazarova A.B., Pushkina N.V. (Ivanovo).** Vascular and rheologic disorders in AH patients with target organs damage.
- **Obukhova T.Yu, Budkar L.N., Karpova E.A. (Ekaterinburg).** Effect of diabetes mellitus II and cardiovascular comorbidities on professional chronic fluoride poisoning development time.
- **Orlov A.V., Soldatenkova N.A., Rotar O.P., Boyarinova M.A., Alieva A.S., Solntsev V.N., Rogoza A.N., Konradi A.O. (Saint-Petersburg).** Prevalence of early vascular ageing in the Russian population: can we accurately assess it in epidemiologic studies?

- **Bagry A.E., Mikhailichenko E.S., Schukina E.V., Efremenko V.A., Malovichko I.S., Yarovaya N.F., Rakitskaya I.V. (Ukraine).** Combination of Valsartan and Spironolacton in patients with essential AH.
- **Abdulgasanov R.A., Bokeria L.A., Abdulgasanova M.R., Ivanov A.V., Provotorova Yu.R., Gasymov E.G. (Moscow).** Adrenal phaeochromocytoma in patients with essential AH.

CONFERENCE HALL 5

09.00–10.30

SYMPOSIUM

Heart rate control. Challenges and interpretation in routine clinical practice

(supported by Takeda)

Chairperson:

Arytyunov G.P. (Moscow)

- **Kozioleva N.A. (Perm).** Differential diagnosis of sinus tachycardias.
- **Arytyunov G.P. (Moscow).** Beta-blockers and heart rate reduction therapy. A physician's perspective.
- **Tarlovskaya E.I. (Nizhny Novgorod).** The original brand and generics. How to make a right choice.

CONFERENCE HALL 5A

09.00–10.30

SYMPOSIUM

Microvascular angina: not a myth anymore but a type of chronic coronary artery disease

Chairpersons:

Soboleva G.N. (Moscow), Boldueva S.A. (Saint Petersburg)

- **Soboleva G.N., Karpov YU.A. (Moscow).** Microvascular angina: current understanding of pathogenesis and diagnosis.
- **Karpov YU.A., Soboleva G.N. (Moscow).** Nociceptive afferent innervation in vascular tone regulation in patients with microvascular angina.

- **Petrova V.B., Boldueva S.A. (Saint-Petersburg).** Specific character of pain syndrome and detection of nociceptive disorders in patients with microvascular angina.
- **Boldueva S.A., Zakharova O.V. (Saint-Petersburg).** Novels in medical therapy of microvascular angina.

CONFERENCE HALL 6

09.00–10.30

SYMPOSIUM

Practical approaches to diagnosis and treatment of heart failure

Simultaneous translation

Chairpersons:

Maisel A. (San-Diego, USA), Matskeplishvili S.T. (Moscow)

- **Cleland J. (Great Britain).** Treating patients with heart failure who have atrial fibrillation – what do we really know?
- **Maisel A. (USA).** Biomarkers in heart failure treatment – from bench to bedside.
- **Matskeplishvili S.T. (Moscow).** Choosing an inotropic support strategy in treatment of cardiogenic shock and severe heart failure.
- **Yakovlev A. N. (Saint Petersburg).** Treating post-ICU patients with acute heart failure.
- **Erlikh A.D. (Moscow).** Treating patients with ACS and acute HF in Russian in-patient hospitals (on RECORD-3 registry data).

CONFERENCE HALL 7

09.00–10.30

LUNCH SYMPOISUM

A high and very high risk patient: what should a physician do in his routine clinical practice?

(supported by Gedeon Richter)

Chairperson: **Lopatin Y. M. (Volgograd)**

- **Ostroumova O. D. (Moscow)**. Fixed combination of amlodipine and lisinopril ACE inhibitor in clinical practice: GEOGRAPHY study findings.
- **Perepech N.B. (Saint-Petersburg)**. Ekvamer is the first and the only fixed combination for high-risk patients.
- **Nedogoda S. V. (Volgograd)**. How to help a patient with AH and arterial hypertension and increased heart rate.
- **Lopatin Y. M. (Volgograd)**. Prevention of heart failure in patients with hypertension: new European guidelines.
- **Lopatin Y. M. (Volgograd)**. Questions and answers: what do we want to know in daily clinical practice.

PLENARY SESSION HALL

11.00–12.30

SYMPOSIUM

The gold medal of VICTORY or how to achieve BP control in different clinical situations

(supported by KRKA)

Chairperson: **Galyavich A.S. (Kazan), Ostroumova O.D. (Moscow)**

Moderator: **Chukaeva I.I. (Moscow)**

- **Galyavich A.S. (Kazan)**. Team performance: multi-target organ protection in addition to AH effect.
- **Ostroumova O.D. (Moscow)**. Single skating performance: the final results of VICTORY international study.
- **Kislyak O.A. (Moscow)**. Pair skating performance: fixed-dose therapy for BP lowering of each AH patient.
- **Chukaeva I.I. (Moscow)**. Synchronized skating performance: how to achieve high adherence in an AH patient.

CONFERENCE HALL 1

11.00–12.30

SYMPOSIUM

A novel view on therapy of a patient at a high cardiovascular risk

(supported by Boehringer Ingelheim)

Chairperson: **Arutyunov G.P. (Moscow)**

- **Arutyunov G.P. (Moscow).** Introduction.
- **Arutyunov G.P. (Moscow).** Treating a patient at high risk of cardiovascular complications in clinical practice: choosing criteria.
- **Kareva E.N. (Moscow).** Are all sartans the same? Pharmacologist's perspective.
- **Drapkina O.M. (Moscow).** Current antihypertensive therapy of a patient at high risk of cardiovascular complications.
- **Demidova T.Yu. (Moscow).** A patient with diabetes mellitus: ways to reduce cardiovascular risk.

CONFERENCE HALL 1A

11.00–12.30

SYMPOSIUM

New work areas for Young Cardiologists: keep the traditions alive – multiply innovations

Chairpersons:

**Chernova A.A. (Krasnoyarsk), Chulkov V.S. (Chelyabinsk),
Gudkova S.V. (Samara)**

- **Chernova A.A. (Krasnoyarsk).** New opportunities for Young Cardiologists: promising directions of development for regional RSC branches.
- **Shepel R.N. (Moscow).** Opportunities and prospects for a young cardiologist as a scientist.
- **Posnenkova O.M. (Saratov), Kiselev A.R. (Saratov).** RSC Young Cardiologists WG in the Saratov region: history, achievements and prospects.
- **Dzhioeva O.N. (Moscow).** Cardiac risks of exocardiac surgical interventions. Diagnostic and therapeutic strategies.

- **Dolginina S.I. (Samara).** A patient with atrial fibrillation: current problem state.
- **Chulkov V.S. (Chelyabinsk).** Chelyabinsk regional society of young cardiologists: past, present and future.
- **Gudkova S.V. (Samara).** Development prospects for young cardiologists of the Samara region.
- **Kozhokar K.S. (Surgut).** Main directions of development of the Surgut regional RSC branch.

CONFERENCE HALL 2

11.00–12.30

SYMPOSIUM

Optimization of anticoagulants in thrombotic diseases

(supported by Pfizer)

Online broadcasting

Chairpersons: **Mareev V.Yu. (Moscow), Kobalava Zh.D. (Moscow)**

- **Mareev V.Yu. (Moscow).** How to keep a balance between efficacy and safety in patients with atrial fibrillation and of different clinical subgroups.
- **Kobalava Zh.D. (Moscow).** Adherence and clinical outcomes of anticoagulation therapy in patients with thrombosis associated diseases.
- **Andreev D.A. (Moscow).** How to protect a patient at all stages of treatment for venous thromboembolism.

CONFERENCE HALL 3

11.00–12.30

SYMPOSIUM

Extending potential of cardiovascular risk managing

(supported by Sanofi)

Chairpersons: **Karpov Yu.A. (Moscow), Vasilieva E.Yu. (Moscow)**

- **Averkov O.V. (Moscow).** What stands behind cardiovascular risk?
- **Akhmedzhanov N.M. (Moscow).** Current opportunities and unmet medical issues.
- **Karpov Yu.A. (Moscow).** New paradigm in lowering cardiovascular risk.

CONFERENCE HALL 4

11.00–12.30

SYMPOSIUM

Physician's library: to assist a cardiologist (supported by Actavis)

Chairperson: **Arkhipov M.V. (Ekaterinburg)**

- **Arkhipov M.V. (Ekaterinburg).** Global and regional epidemiology of chronic kidney disease.
- **Chesnikova A.I. (Rostov-on-Don).** RAAS blockers: renoprotection in renal dysfunction.
- **Tarlovskaya E.I. (Nizhny Novgorod).** Statins and chronic renal disease: benefits and risks.
- **Kozioleva N.A. (Perm).** Choice of antiplatelet therapy in renal dysfunction: balance between efficiency and safety.

CONFERENCE HALL 4A

11.00–12.30

SECTION SESSION

Arrhythmology, stimulation, resynchronization Part I

Chairpersons:

Davtyan K.V. (Moscow), Romanov A.B. (Novosibirsk)

- **Shulman V.A., Nikulina S.Yu., Aksyutina N.V., Poplavskaya E.E., Maksimov V.N. (Krasnoyarsk).** 4Q25 chromosome RS2200733 polymorphism in patients with atrial fibrillation.
- **Okisheva E.A., Tsaregorodtsev D.A., Sulimov V.A. (Moscow).** Degree of heart rate increasing and decreasing in survival prognosis in patients with postinfarction cardiosclerosis within 5 years.
- **Mikhailichenko S.I., Lyubkina E.V., Revishvili A.Sh. (Moscow).** Efficacy of interventional treatment of atrial fibrillation and atrial tachycardia with trigger localization in superior vena cava.
- **Lebedev D.I., Smorgon A.V., Usenkov S.Yu., Archakov E.A., Batalov R.E., Popov S.V. (Tomsk).** SPECKLE-TRACKING intracardiac echocardiography in assessment of pulmonary veins isolation in patients with atrial fibrillation.

- **Tsaregorodtsev D.A., Okisheva E.A., Sulimov V.A. (Moscow).** Complex risk stratification of sudden cardiac death in patients with myocardial infarction.
- **Ionin V.A., Zaslavskaya E.L., Soboleva A.V., Polyakova E.A., Bazhenova E.A., Belyaeva O.D., Baranova E.I., Shlyakhto E.V. (Saint-Petersburg).** Galectin-3 and aldosterone – circulating atrial fibrillation risk markers in blood of patients with metabolic syndrome.

CONFERENCE HALL 5

11.00–12.30

SYMPOSIUM

Current view on management of acute heart failure (supported by Novartis)

Chairpersons:

Shlyakhto E.V. (Saint-Petersburg), Fomin I.V. (Nizhny Novgorod)

- **Nedoshivin A.O. (Saint-Petersburg).** Heart failure in the Russian Federation: burden on health care system.
- **Lopatin Yu.M. (Volgograd).** Drawbacks of the current approaches to treatment of patients with heart failure and ways of their correction. Creation of specialized service for heart failure patients.
- **Fomin I.V. (Nizhny Novgorod).** Heart failure in ICU unit: focus on patients with renal dysfunction.
- Discussion.

CONFERENCE HALL 5A

11.00–12.30

MASTER CLASS

Diagnosis of coronary artery disease: guidelines for a practical doctor

Chairpersons: **Nikulina N.N. (Ryazan), Yakushin S.S. (Ryazan)**

- **Nikulina N.N., Yakushin S.S. (Ryazan).** Current terminology, classification and diagnosis for chronic types of coronary artery disease.
- **Nikulina N.N. (Ryazan).** Diagnosis of acute types of coronary artery disease from the standpoint of current clinical guidelines and requirements of morbidity and mortality statistics.

CONFERENCE HALL 6

11.00–12.30

SYMPOSIUM

Secondary prevention of myocardial infarction and acute disorders of cerebral circulation

Simultaneous translation

Chairpersons: **Martsevich S.Yu. (Moscow), Garganeeva A.A. (Tomsk)**

- **Martsevich S.Yu., Kutishenko N.P. (Moscow).** Main principles of secondary prevention of myocardial infarction and stroke: clinical guidelines, standards for regular medical check-ups and clinical practice.
- **Kanakakis I. (Greece).** Optimizing the current care of STEMI. Setting up an efficient STEMI network.
- **Garganeeva A.A., Okrugin S.A., Borel K.N., Kuzheleva E.A. (Tomsk).** 30-year trend of acute myocardial infarction epidemiology. Risk factors of remote negative outcomes.
- **Alasheev A.M., Prazdnichkova E.V. (Ekaterinburg).** Interdisciplinary interaction in treatment of patients with acute disorders of cerebral circulation. Experience of the Sverdlovsk region.
- **Lukyanov M.M., Yakushin S.S., Vorobiev A.N., Yakusevich V.V. (Moscow, Ryazan, Yaroslavl).** Prevention of myocardial infarction and acute disorders of cerebral circulation in outpatient practice.

CONFERENCE HALL 7

11.00–12.30

SYMPOSIUM

Extrasystolic arrhythmia: risk stratification and management in different clinical situations

Chairpersons:

Shaposhnik I.I. (Chelyabinsk), Miller O.N. (Novosibirsk)

- **Matyushin G.V. (Krasnoyarsk).** Classification and risk stratification of extrasystolic arrhythmia.
- **Arkhipov M.V. (Ekaterinburg).** Functional extrasystolic arrhythmia: to treat or not to treat?
- **Shaposhnik I.I. (Chelyabinsk).** Extrasystolic arrhythmia in patients with organic heart disease.
- **Miller O.N. (Novosibirsk).** Extrasystolic arrhythmia in pregnant women and athletes

PLENARY SESSION HALL

12.40–13.20

PLENARY LECTURE

Online broadcasting | Simultaneous translation

Moderator: **Lebedev D.S. (Saint-Petersburg)**

- **Oliveira M. (Portugal).** Autonomic modulation therapy for the management of cardiovascular diseases.

PLENARY SESSION HALL

13.30–15.00

PLENARY SESSION

Epidemiology, prevention, sport medicine

Online broadcasting | Simultaneous translation

Chairpersons:

Oganov R.G. (Moscow), Nedoshivin A.O. (Saint-Petersburg)

- **Ferrari R. (Italy).** ESC registries and the EURObservational Research Programme.
- **Boitsov S.A. (Moscow).** Cardiovascular prevention in Russia: word or action?
- **Mirrakhimov E.M. (Kyrgyzstan).** Cardiac diseases and mountains.

CONFERENCE HALL 1

13.30–15.00

SYMPOSIUM

Combination therapy of hypertension. What to choose and how to treat?

(supported by Takeda)

Online broadcasting

Chairperson: **Karpov Yu.A. (Moscow)**

- **Karpov Yu.A. (Moscow).** Current guidelines on hypertension treatment. Whom and when we can prescribe mono or combination therapy.
- **Nedogoda S.V. (Volgograd).** How to choose the optimal combination of antihypertensive treatment. Thiazide diuretics in combination therapy in historical retrospective.
- **Kobalava Zh.D. (Moscow).** Edarbi Clo – the only combination of diuretic Chlortalidon and a sartan in Russia.

КОНФЕРЕНЦ-ЗАЛ № 1А

13.30–15.00

SYMPOSIUM

Multi-faced comorbidity in patients with chronic coronary artery disease

Chairpersons:

Borovkov N.N. (Nizhny Novgorod), Koryagina N.A. (Perm)

- **Vasilets L.M. (Perm).** Anti-arrhythmic therapy in coronary artery disease. New perspective for «old» problems.
- **Borovkov N.N. (Nizhny Novgorod).** Choosing anti-anginal second-line drug in treatment of stable coronary artery disease.
- **Shulkina S.G. (Perm).** Management of a patient with coronary artery disease and diabetes mellitus.
- **Borovkova N.Yu. (Nizhny Novgorod).** Homeostatis vegetal in patients with coronary artery diasese and signs of chronic renal diasese.
- **Koryagina N.A. (Perm).** Coronary artery diasese in females of working age.

CONFERENCE HALL 2

13.30–15.00

SYMPOSIUM

CHRONIC HEART FAILURE: TAKING INITIATIVE IN THE STRUGGLE FOR OUTCOME

(supported by Pfizer)

Chairperson:

Arutyunov G.P. (Moscow)

- **Arutyunov G.P. (Moscow).** *Mineralocorticoid receptor antagonists at various stages of cardiovascular continuum.*
- **Tkacheva O.N. (Moscow), Barbarash O.L. (Kemerovo).** Straight talk: elderly patients with myocardial infarction complicated by heart failure. Conservative tactics – improving prognosis.

CONFERENCE HALL 3

13.30–15.00

SYMPOSIUM

Long-term (longer than 1 year) dual antiplatelet therapy: possible benefits and risks?

(supported by AstraZeneca)

Chairperson:

Ruda M.Ya. (Moscow)

- **Panchenko E.P. (Moscow).** Does risk of recurrent cardiovascular events remain 1 year after myocardial infarction?
- **Yavelov I.S. (Moscow).** Benefits and risks of dual antiplatelet therapy longer than 1 year after myocardial infarction: overall results of PEGASUS study.
- **Averkov O.V. (Moscow).** Possible approaches to patient selection for a long-term dual antiplatelet therapy.

CONFERENCE HALL 4

13.30–15.00

SYMPOSIUM

Three whales of adherence in AH treatment

(supported by Servier)

Presidium: **Prof. Glezer M.G. (Moscow)**

- **Glezer M.G. (Moscow).** OPTIMUM study results.
- **Kislyak O.A. (Moscow).** Personalized therapy: place of diuretics.
- **Zubkov D. (Moscow).** Legal aspects of doctor-patient interaction.

CONFERENCE HALL 4A

13.30–15.00

SECTION SESSION

Noncoronary diseases, valve pathology, congenital disorders, pediatric cardiology, pulmonary hypertension Part I

Chairpersons: **Demin A.A. (Novosibirsk), Reznik I.I. (Ekaterinburg)**

- **Mullova I.S., Dzhinibalaeva Zh.V., Semagin A.P., Zybin A.A., Tukhbatova A.A., Duplyakov D.V. (Samara).** Clinical case of infectious endocarditis of aortic and pulmonic valves and recanalization of ventricular septal defect.
- **Kislukhin V.V. (Moscow).** Hemodynamics and oxygen delivery in children with univentricular heart after the Norwood operation.
- **Grigoricheva E.A. (Chelyabinsk).** Association between ECG manifestations of cardiac disorders and frequency of phenotype markers of connective tissue dysplasia in different age groups.
- **Legkonogov A.V. (Simferopol).** Acute noncoronary pathology in cardiology practice.
- **Vasiltseva O.Ya., Lavrov A.G., Silivanova I.Kh., Gorlova A.A., Vorozhtsova I.N., Karpov R.S. (Tomsk).** Thromboembolism of pulmonary artery in atrial fibrillation.
- **Demetskaya V.V., Stompel D.R., Chernov I.I., Kozmin D.Yu., Kondratiev D.A., Nechepurenko A.A., Budanova V.A., Kadykova A.V., Tarasov D.G. (Astrakhan).** Experience of infectious endocarditis treatment in the Center for Cardiovascular Surgery.

CONFERENCE HALL 5

13.30–15.00

SYMPOSIUM

Medical assistance to patients with acute vascular conditions (myocardial infarction and stroke) – team approach

Chairpersons:

Alekyan B.G. (Moscow), Shlyakhto E.V. (Saint-Petersburg)

- **Alekyan B.G. (Moscow).** Current state and approaches to treatment of patients with acute myocardial infarction.
- **Protopopov A.V. (Krasnoyarsk).** Current state and approaches to treatment of patients with acute ischemic stroke: similarities and differences compared to acute MI.
- **Shamalov N.A. (Moscow).** A patient with acute ischemic stroke: how to choose optimal treatment according to clinical guidelines and existing evidences?
- **Savello A.V., Kuzmin A.S., Simakov K.V., Guskov A.S. (Saint-Petersburg).** Intravascular interventions during the most acute period of ischemic stroke: team approach.
- **Kandyba D.V. (Saint-Petersburg).** Endovascular thromboextraction in acute ischemic stroke: how to ensure safety and efficacy of the intervention step by step.

CONFERENCE HALL 5A

13.30–15.00

SCIENTIFIC SESSION

Genetic issues of clinical pharmacology in cardiology practice

Chairpersons:

Sychev D.A. (Moscow), Lifshits G.I. (Novosibirsk)

- **Sychev D.A. (Moscow).** Pharmacogenetic and pharmacokinetic approaches in personalized administration of new oral anticoagulants.
- **Kopylov F.Yu., Fadeev V.V., Byakina O.A., Nikitina Yu.M., Aksenova M.G., Syrkin A.L. (Moscow).** Pharmacogenetic aspects of amiodarone-induced thyroid dysfunction.

- **Lifshits G.I. (Novosibirsk), Apartsin K.A. (Irkutsk), Ganyukova V.I. (Kemerovo).** Which antiplatelet drug is optimal for patients of Siberian region? (Genetic profile)
- **Kokh N.V., Lifshits G.I. (Novosibirsk).** Which statin is more effective for patients of Siberian region? (Genes recommend).
- **Repin A.N., Muslimova E.F., Afanasiev S.A. (Tomsk).** Association between polymorphisms of endothelial nitric oxide synthase gene and effectiveness of antiplatelet drugs.
- **Minushkina L.O., Nikitin A.G., Zateischikov D.A. (Moscow).** Genetic predictors of vascular rigidity in patients with hypertension and coronary artery disease.

CONFERENCE HALL 6

13.30–15.00

SYMPOSIUM

Current anticoagulation therapy: from randomized studies and guidelines to clinical practice

(supported by Bayer)

Chairperson: **Belenkov Yu.N. (Moscow)**

- **Lopatin Yu.M. (Volgograd).** A typical patient with atrial fibrillation seeing a cardiologist. What to focus on?
- **Mareev V.Yu. (Moscow).** Atrial fibrillation and chronic heart failure.
- **Gilyarevsky S.R. (Moscow).** New oral anticoagulants. A clinical pharmacologist's perspective.

CONFERENCE HALL 7

13.30–15.00

SYMPOSIUM

Discussion board: adherence. Why do patients not always follow doctor's advice?

(supported by Berlin-Chemie)

Chairpersons: **Chukaeva I.I. (Moscow), Ageev F.T. (Moscow)**

- **Chukaeva I.I., Ageev F.T. (Moscow).** Low adherence as a barrier on the way to cardiovascular disease treatment.
- **Chukaeva I.I. , Ageev F.T. (Moscow).** How to improve adherence?

PLENARY SESSION HALL

15.30–17.00

PLENARY SESSION

Noncoronary myocardial diseases

Online broadcasting

Chairperson: **Boitsov S.A. (Moscow)**

- **Blagova O.V., Nedostup A.V. (Moscow).** Classification of noncoronary myocardial diseases: our point of view on the problem.
- **Zaklyazminskaya E.V. (Moscow).** Genetic methods of diagnosis of cardiomyopathies: expectations and reality.
- **Dzemeshevich S.L., Frolova Yu.V. (Moscow).** Myocardial dysfunction and cardiac surgery.

CONFERENCE HALL 1

15.30–17.00

SYMPOSIUM

New era in atherosclerosis treatment: the impossible is possible

(supported by Amgen)

Chairpersons:

**Ezhov M.V. (Moscow), Voevoda M.I. (Novosibirsk),
Kukharchuk V.V. (Moscow)**

- **Ezhov M.V. (Moscow), Voevoda M.I. (Novosibirsk), Kukharchuk V.V. (Moscow).** Opening remarks. Welcome and introduction.
- **Zakharova E.Yu. (Moscow).** Hyperlipidemia: a patient's story and perspective.
- **Konovalov G.A. (Moscow).** Cardiovascular risk and target LDL levels: what to aim at and what not to be afraid of.
- **Gilyarevsky S.R. (Moscow).** Unmet needs of hyperlipidemia patients: when the standard therapy is not enough?
- **Ezhov M.V. (Moscow).** Evolocumab – innovative treatment for patients with refractory dyslipidemia: the long-hoped solution.
- Discussion.

CONFERENCE HALL 1A

15.30–17.00

MASTER CLASS

One's own doctor: myths and self-deceptions of patients

- **Rotar O.P. (Saint-Petersburg).** One's own doctor: myths and deceptions of patients.
- **Efremova E.V. (Ulyanovsk).** Adherence: who is to blame and what to do?

CONFERENCE HALL 2

15.30–17.00

SYMPOSIUM

Current approaches in diagnosis and treatment of pulmonary hypertension

(supported by Pfizer)

Online broadcasting

Chairpersons:

Ivanov S.N. (Novosibirsk), Gorbachevsky S.V. (Moscow)

- **Ivanov S.N. (Novosibirsk).** Pulmonary hypertension: current standards of diagnosis and treatment.
- **Gorbachevsky S.V. (Moscow).** Combination therapy for pulmonary hypertension.
- **Volkov A.V. (Moscow).** Pulmonary hypertension in patients with connective tissue systemic diseases.

CONFERENCE HALL 3

15.30–17.00

SYMPOSIUM

Time for innovations: what else can we do for a patient?

Chairpersons:

Alekyan B.G. (Moscow), Barbarash O.L. (Kemerovo)

- **Alekyan B.G. (Moscow).** Current trends in endovascular treatment of some cardiovascular diseases.
- **Barbarash O.L. (Kemerovo).** Coronary artery stenting in patients with IHD: a cardiologist's perspective.
- **Ustyugov S.A. (Krasnoyarsk).** Severe aortic stenosis in clinical practice: can we help?
- **Neminuschy N.M. (Moscow).** Good quality of life for patients with implantable cardioverter defibrillator: myth or reality? SmartShock technology in Medtronic devices.
- **Chernyavskaya T.K. (Moscow).** A patient with aortic and peripheral vascular disease: complex approach.
- Discussion.

CONFERENCE HALL 4

15.30–17.00

SCIENTIFIC SESSION

Coronary artery disease and depression: a dilemma for practice

Chairpersons:

Oganov R.G. (Moscow), Pogosova N.V. (Moscow)

- **Oganov R.G. (Moscow).** Psychosocial risk factors of CAD and its impact on prognosis.
- **Pogosova N.V. (Moscow).** Heart, brain, anxiety, depression and outcomes in CAD patients: recent data and a new Russian study KOMETA.
- **Kursakov A.A. (Moscow).** Depressive symptoms in CAD patients: evidence-based approaches to diagnosis and management.
- **Pogosova N.V. (Moscow).** Clinical practicum.

CONFERENCE HALL 4A

15.30–17.00

SECTION SESSION

**Noncoronary diseases, valve pathology, congenital disorders, pediatric cardiology, pulmonary hypertension
Part II**

Chairpersons:

Vasiltseva O.Ya. (Tomsk), Demetskaya V.V. (Astrakhan)

- **Reznik I.I., Iofin A.I., Bykov A.N. (Ekaterinburg).** Myocarditis of transplanted heart.
- **Sarybaev A.Sh., Maripov A.M., Sydykov A.S., Sartmyrzaeva M.A., Cholponbaeva M., Muratali uulu Kubat, Dyushebaev M.I. (Bishkek, Kyrgyzstan).** Frequency of pulmonary hypertension and congenital heart diseases in highlands.
- **Legkonogov A.V., Legkonogova L.G. (Simferopol).** Clinical picture and echocardiography characteristics in left ventricular noncompaction.
- **Berns S.A., Shmidt E.A., Barbarash O.L. (Kemerovo).** Risk factors of pulmonary thromboembolism adverse outcomes in females. .
- **Gromova M.A., Kotova E.O., Moiseev V.S. (Moscow).** Assessment of risk factors of thromboembolic events in patients with infectious endocarditis.

CONFERENCE HALL 5

15.30–17.00

SYMPOSIUM

Current diuretic therapy
(supported by Takeda)

Chairperson: **Arutyunov G.P. (Moscow)**

- **Koziołova N.A. (Perm).** Mistakes in edema syndrome treatment in patients with chronic heart failure.
- **Orlova Ya.A. (Moscow).** Loop diuretics in hypertension treatment.
- **Arutyunov G.P. (Moscow).** Strategy of diuretic therapy in patients with chronic heart failure.

CONFERENCE HALL 5A

15.30–17.00

SCIENTIFIC SESSION

Genetic basis of cardiac diseases

Chairpersons:

Nikulina S.Yu. (Krasnoyarsk), Minushkina L.O. (Moscow)

- **Boeva O.I., Scheglova E.V. (Stavropol).** Genetic risk of development and progression of calcific aortic valve disease.
- **Lifshits G.I. (Novosibirsk), Apartsin K.A., Kireeva V.V. (Irkutsk).** What is the genetic profile of a hypertensive patient in Siberia?
- **Chernova A.A., Lebedeva I.I., Nikulina S.Yu., Matyushin G.V. (Krasnoyarsk).** Genetic determination of Wolff-Parkinson-White syndrome.
- **Nikulina S.Yu., Platonova I.M., Chernova A.A. (Krasnoyarsk).** Genes-predictors of ischemic stroke.
- **Chernova A.A., Nikulina S.Yu., Marilovtseva O.V. (Krasnoyarsk).** Genes associated with idiopathic sick sinus syndrome.
- **Aksyutina N.V., Poplavskaya E.E., Shulman V.A., Nikulina S.Yu. (Krasnoyarsk).** Association of chromosome 4 with idiopathic atrial fibrillation.

CONFERENCE HALL 6

15.30–17.00

SYMPOSIUM

Safe and patient-oriented activities of nurses in cardiology units

Chairperson: **Levina I.A. (Ekaterinburg)**

- **Nazarova I.R. (Ufa).** Routing of ACS patients in Bashkortostan and the Republican Cardiology Center.
- **Veselina L.P. (Tyumen).** Medical and social care of cardiac patients. Experience of the Tyumen Municipal Polyclinic #8.
- **Shepeleva E.A. (Chelyabinsk).** Priority of interests and safety of patients in a cardiosurgical hospital.
- **Aitmukhamedova N.V. (Surgut).** Current approaches to safe using high-tech equipment in cardiosurgical units.

- **Kopshar A.B. (Ekaterinburg).** Medical care of newborns with congenital heart diseases in the third-level medical institutions.
- **Zabalkanskaya N.V., Inozemtseva S.V. (Samara).** The role of a nurse in rehabilitation of patients with cardiovascular diseases.

CONFERENCE HALL 7

15.30–17.00

DEBATES

Biomarkers in acute coronary syndrome

Chairperson: **Ruda M.Ya. (Moscow)**

- **Markov V.A. (Tomsk).** Which myocardial necrosis biomarker in ACS is preferred: fatty acid-binding protein.
- **Zateischikov D.A. (Moscow).** Which myocardial necrosis biomarker in ACS is preferred: cardiac troponins.
- **Shtegman O.A., Petrova M.M. (Krasnoyarsk).** Is pre-hospital detection of myocardial necrosis biomarkers necessary: pros.
- **Averkov O.V. (Moscow).** Is pre-hospital detection of myocardial necrosis biomarkers necessary: contras.

PLENARY SESSION HALL

17.30–19.00


ASSEMBLY OF THE RUSSIAN SOCIETY OF CARDIOLOGY BOARD

Time/Hall	PLENARY SESSION HALL	CONFERENCE HALL 1	CONFERENCE HALL 1A	CONFERENCE HALL 2	CONFERENCE HALL 3
09.00–10.30	PLENARY SESSION	SYMPOSIUM	SECTION SESSION	SYMPOSIUM	SYMPOSIUM
	Chronic heart failure - 2016 Online broadcasting	Acetylsalicylic acid: yesterday, today, tomorrow <i>(supported by Takeda)</i>	Fundamental research Part I	Role of continuous ECG monitoring in emergency cardiology <i>(supported by Meditek)</i>	Obesity: population and clinical challenges in current Russian practice
10.30–11.00	BREAK				
11.00–12.30	PLENARY SESSION	SYMPOSIUM	SECTION SESSION	SYMPOSIUM	ROUND TABLE
	Fundamental re-research in cardiology Online broadcasting	Board of experts: difficult issues of antianginal drugs choice. Ranolazine in clinical practice <i>(supported by Berlin-Chemie/Menarini)</i>	Fundamental research Part II	Acute chest pain: current approach to a difficult diagnosis <i>(supported by GE Healthcare)</i>	Comorbidity and gender aspects
12.40–13.20	PLENARY SESSION HALL	PLENARY LECTURE			
		S. Mehta (USA). Improving STEMI outcomes Online broadcasting Simultaneous translation			
12.30–13.30	BREAK				
13.30–15.00	PLENARY SESSION	SYMPOSIUM	MASTER CLASS	SYMPOSIUM	SYMPOSIUM
	Hybrid technologies in CVD treatment Online broadcasting	CVD epidemiology and risk factors in CIS countries: similarities and ethnic differences	Preventive consulting in cardiology	Uncontrolled and resistant hypertension: new technologies in diagnosis and treatment	Pulmonary embolism — 2016
15.00–15.30	BREAK				

CONFERENCE HALL 4	CONFERENCE HALL 4A	CONFERENCE HALL 5	CONFERENCE HALL 5A	CONFERENCE HALL 6	CONFERENCE HALL 7
SYMPOSIUM The power of four elements in cardiology <i>(supported by Abbott Laboratories)</i>	SECTION SESSION Cardiovascular surgery Part I	SYMPOSIUM Endovascular technologies in treatment of structural cardiac pathology and hypertension <i>(supported by Cardiomedics/Boston Scientific)</i>	SYMPOSIUM Difficulties in diagnosis of acute myocardial infarction	SCIENTIFIC SESSION Obesity as a chronic disease with a high risk of cardiometabolic complications	SYMPOSIUM Myocardites: diagnosis and treatment
SYMPOSIUM Prospects of diagnosis and treatment of atherosclerosis	SECTION SESSION Cardiovascular surgery Part II	ROUND TABLE Unresolved issues in cardiology. Management of patients with implanted devices. New opportunities and «old» problems <i>(supported by Cardiomedics/Boston Scientific)</i>	SYMPOSIUM Rare and difficult diagnoses in cardiology	CLINICAL CASE STUDIES A difficult patient with obesity	SCIENTIFIC SESSION From risk factors to cardiovascular complications. A model of cardiovascular continuum in Russia
DEBATES Evidence-based cardiology and controversial issues in anticoagulant and antithrombotic therapies	SECTION SESSION Epidemiology, prevention and rehabilitation. Sports Medicine Part I	SYMPOSIUM Arterial stiffness in clinical practice	SYMPOSIUM Hot issues in psychocardiology	SCIENTIFIC SESSION Hotline in atherosclerosis and CAD	RUSSIAN-BELORUSSIAN SYMPOSIUM Part I Physician's library: focus on a «difficult patient» with AF

Time/Hall	PLENARY SESSION HALL	CONFERENCE HALL 1	CONFERENCE HALL 1A	CONFERENCE HALL 2	CONFERENCE HALL 3
15.30–17.00	PLENARY LECTURES Shpektor A.V. (Moscow). ACS: what's new? Velchev V. (Bulgaria). Does the primary PCI network capable to serve? Pozdnyakov Yu.M. (Moscow). Stable angina in males and females. Online broadcasting Simultaneous translation	SCIENTIFIC AND PRACTICAL CONFERENCE Professional public accreditation of educational programmes as an element of medical education quality improvement. <i>(Joint meeting of RSC and National Medical Chamber supported by Knowledge Society, Russia)</i>	SYMPOSIUM Cardiorehabilitation and differentiation of medical approaches to achieve a better clinical outcome	SYMPOSIUM Obesity in cardiology practice	SCIENTIFIC SESSION Materials of the Russian ACS Registry RECORD-3
15.30–17.00	CONFERENCE HALL 8	MASTER CLASS Is it easy to quit smoking? Management of a smoking patient in cardiology practice			
17.00–17.30		ПЕРЕРЫВ			
17.30–19.00	SCHOOL FOR CARDIOLOGISTS AND INTERNISTS Current issues of antithrombotic therapy in cardiovascular diseases	SYMPOSIUM Medical prevention and outcomes in patients with atrial fibrillation: clinical guidelines and clinical practice	SECTION SESSION Heart failure/ left ventricular dysfunction	SYMPOSIUM Secondary arterial hypertension: from assumptions to verification of diagnosis and treatment	SYMPOSIUM Acute kidney injury in cardiology practice

CONFERENCE HALL 4	CONFERENCE HALL 4A	CONFERENCE HALL 5	CONFERENCE HALL 5A	CONFERENCE HALL 6	CONFERENCE HALL 7
SYMPOSIUM Heart Failure Journal presents: evidence- based cardiology for physicians	SECTION SESSION Epidemiology, prevention and rehabilitation. Sports Medicine Part II	SYMPOSIUM New methods in echocardiography	SYMPOSIUM Current understanding of molecu- lar-genetic and pathophysio- logic aspects of hyperlipidaemia and atheroscle- rosis	SYMPOSIUM Cardiomyopathies with a high risk of sudden cardiac death	RUSSIAN- BELORUSSIAN SYMPOSIUM Part II Facts and misconceptions in treatment of concomitant diseases of cardiologic patients



LECTURES What's new in the ESC Guidelines for infective endocarditis – 2015? A patient with depression and hypertension: how to optimize pharmacother- apy? Cardiovascu- lar safety of osteoarthritis anti-inflammatory therapy – 2016.	SECTION SESSION Epidemiology, prevention and rehabilitation. Sports medicine. Part III	SYMPOSIUM Echocardiography in acute care	CLINICAL CASE STUDIES Thromboses in cardiology clinic. Diagnostic algorithms and therapeutic strategies	INTERACTIVE CLINICAL CASE STUDIES What is behind the diagnosis of dilated cardiomyopathy?	SYMPOSIUM Heart rate lowering therapy mysteries
---	--	---	---	---	---

PLENARY SESSION HALL

09.00–10.30

PLENARY SESSION

Chronic heart failure – 2016

Online broadcasting

Chairpersons:

Belenkov Yu.N. (Moscow), Lopatin Yu.M. (Volgograd)

- **Mareev V.Yu. (Moscow).** Novelties in prevention and treatment of chronic heart failure.
- **Lopatin Yu.M. (Volgograd).** Management of patients with angina and heart failure: news of 2016.
- **Belenkov Yu.N. (Moscow).** What is necessary to know about secondary admissions of patients with chronic heart failure.
- **Fomin I.V. (Nizhny Novgorod).** Chronic heart failure in real clinical practice in Russia: resolved and unresolved issues.

CONFERENCE HALL 1

09.00–10.30

SYMPOSIUM

Acetylsalicylic acid: yesterday, today, tomorrow

(supported by Takeda)

Chairperson:

Minushkina L.O. (Moscow)

- **Zotova I.V. (Moscow).** Efficiency of ASA in primary and secondary prevention, dosages and dosage forms.
- **Minushkina L.O. (Moscow).** Safety of ASA in prevention of cardiovascular diseases.
- **Lomakin N.V. (Moscow).** Perspectives and unresolved questions of ASA administration.

CONFERENCE HALL 1A

09.00–10.30

SECTION SESSION

Fundamental research. Part I

Chairpersons:

Lifshits G.I. (Novosibirsk), Aksyutina N.V. (Krasnoyarsk)

- **Aksyutina N.V., Shulman V.A., Nikulina S.Yu., Nazarov B.V. (Krasnoyarsk).** Regression model of ischemic stroke in patients with atrial fibrillation depending on prediction genotypes.
- **Todosyichuk V.V., Kuznetsov V.A. (Tyumen).** Ischemic myocardial preconditioning: 30 years of hopes and disappointments.
- **Kosinova A.A., Grinshtein I.Yu., Grinshtein Yu.I., Savchenko A.A., Subbotina T.N.. (Krasnoyarsk).** Association of polymorphisms in platelet receptors gene and P450 cytochrome as a predictor of cardiovascular events after CABG.
- **Lifshits G.I., Kokh N.V., Apartsin K.A. (Novosibirsk).** Association of CYP11B2 and GNB3 genes with the risk of hypertension and atherothrombotic complications.
- **Mikhailichenko E.S., Kardashevskaya L.I. (Ukraine).** Impact of RAAS blockers on AT1R receptor's density in patients with multifocal atherosclerosis.

CONFERENCE HALL 2

09.00–10.30

SYMPOSIUM

Role of continuous ECG monitoring in emergency cardiology

(supported by Meditek)

Chairperson: **Ruda M.Ya. (Moscow)**

- **Yavelov I.S. (Moscow).** Continuous ECG monitoring: what do clinical guidelines say?
- **Oleinikov V.E. (Penza).** Continuous ECG monitoring in acute coronary syndrome. Detection of rethrombosis diagnosis in patients with myocardial infarction.
- **Pevzner A.V. (Moscow).** Continuous ECG monitoring: arrhythmologist's perspective.

CONFERENCE HALL 3

09.00–10.30

SYMPOSIUM

Obesity: population and clinical challenges in current Russian practice

Chairpersons:

Drapkina O.M. (Moscow), Shalnova S.A. (Moscow)

- **Kontsevaya A.V. (Moscow).** Population obesity trends in Russia: causes and consequences.
- **Rotar O.P. (Saint-Petersburg).** Metabolically healthy obesity.
- **Zhernakova Yu.A., Chazova I.E., Oschepkova E.V. (Moscow).** Obesity and metabolic continuum, the focus on the cause.
- **Shaposhnik I.I. (Chelyabinsk).** Obesity and diabetes mellitus.
- **Drapkina O.M. (Moscow).** Steatosis.

CONFERENCE HALL 4

09.00–10.30

SYMPOSIUM

The power of four elements in cardiology (supported by Abbott Laboratories)

Chairperson:

Arutyunov G.P. (Moscow)

- **Nedogoda S.V. (Volgograd).** Fire: how to reduce the heat of high BP effectively?
- **Sergienko I.V. (Moscow).** Earth: Fibrates and their place on Earth.
- **Arutyunov G.P. (Moscow).** Water: why fish don't suffer from cardiovascular diseases and what MI patients cannot live without?
- **Ostroumova O.D. (Moscow).** Air: when your vertigo is not the case of triumph...

CONFERENCE HALL 4A

09.00–10.30

SECTION SESSION

Cardiovascular surgery

Part I

Chairpersons:

Karpenko M.A. (Saint-Petersburg), Buziashvili Yu.I. (Moscow)

- **Abdulgasanov R.A., Bokeria L.A., Alshibaya M.M., Abdulgasanova M.R., Ivanov A.V., Provotorova Yu.R., Gasymov E.G. (Moscow).** Antimicrobial patches BASEX in treatment of postinfarction left ventricular aneurysms.
- **Bokeria L.A., Abdulgasanov R.A., Abdulgasanova M.R., Ivanov A.V., Provotorova Yu.R., Gasymov E.G. (Moscow).** Prosthetic aortic infection: conservative treatment.
- **Shneider Yu.A., Tsoi V.G., Shilenko P.A., Khudenkikh E.E., Cherkes A.N. (Kaliningrad).** Natural bifurcation of internal thoracic arteries for CABG in case of their bilateral use to prolong the effect of myocardial revascularization.
- **Gudkova S.A., Duplyakov D.V., Tukhbatova A.A. (Samara).** Aorto-caval fistula simulating signs of cardiomyopathy.
- **Stepin A.V. (Ekaterinburg).** CABG without interventions on ascending aorta in elderly patients: comparative analysis of immediate post-operative results.
- **Abdulgasanov R.A., Bokeria L.A., Abdulgasanova M.R., Ivanov A.V., Provotorova Yu.R., Gasymov E.G. (Moscow).** Renal arterial stenoses and occlusions in patients with hypertension.

CONFERENCE HALL 5

09.00–10.30

SYMPOSIUM

Endovascular technologies in treatment of structural cardiac pathology and hypertension

(supported by Cardiomedics/Boston Scientific)

Moderators: **Abugov S.A. (Moscow)**,
Shlyakhto E.V. (Saint-Petersburg), **Boitsov S.A. (Moscow)**

- **Abugov S.A. (Moscow)**. Key research of TAVI and patient selection strategy for a procedure.
- **Imaev T.E. (Moscow)**. TAVI in Russia: method implementation, specificities of the procedure and management of patients.
- **Romanov A.B. (Novosibirsk)**. Prevention of stroke in patients with non-valvular atrial fibrillation and high risk of hemorrhagic complications: how to select and where to refer a patient for left atrial appendage occluder implantation?
- **Babunashvili A.M. (Moscow)**. Renal artery denervation in treatment of resistant hypertension.
- Best question competition and award.

CONFERENCE HALL 5A

09.00–10.30

SYMPOSIUM

Difficulties in diagnosis of acute myocardial infarction

Chairpersons: **Boldueva S.A. (Saint-Petersburg)**,
Kukharchik G.A. (Saint-Petersburg)

- **Boldueva S.A. (Saint-Petersburg)**. Acute myocardial infarction with unchanged coronary arteries.
- **Kukharchik G.A. (Saint-Petersburg)**. Difficulties in diagnosis of acute myocardial infarction.
- **Boldueva S.A., Ryzhikova M.V., Titova I.Yu. (Saint-Petersburg)**. Takotsubo syndrome as an acute form of microvascular dysfunction.
- **Kukharchik G.A., Sorokin L.A., Koval I.N., Saraev G.B., Azarov M.S. (Saint-Petersburg)**. Rare case of acute myocardial infarction in a young male with coronary artery ectasia.

CONFERENCE HALL 6

09.00–10.30

SCIENTIFIC SESSION

Obesity as a chronic disease with a high risk of cardiometabolic complications

Chairpersons:

Chumakova G.A. (Barnaul), Kuznetsova T.Yu. (Petrozavodsk), Libis R.A. (Orenburg)

- **Kushnarenko N.N., Govorin A.V. (Chita).** Multi-faced gout: current aspects of correlation between obesity, insulin resistance and cardiovascular disorders.
- **Chugunova Yu.V., Chumakova G.A. (Barnaul).** Obesity as a risk factor of cognitive dysfunction in CABG perioperative period.
- **Kuznetsova T.Yu., Druzhilov M.A. (Petrozavodsk).** Ultrasonic indicators of visceral adipose tissue: from visceral adiposity markers to independent factors of cardiovascular risk.
- **Libis R.A. (Orenburg).** NT-proBNP as a marker of heart damage in patients with metabolic syndrome.
- **Chumakova G.A. (Barnaul), Veselovskaya N.G. (Kemerovo).** General and systemic effects of local fat depots.

CONFERENCE HALL 7

09.00–10.30

SYMPOSIUM

Myocardites: diagnosis and treatment

Chairpersons:

Paleev F.N. (Moscow), Blagova O.V. (Moscow)

- **Alieva I.N., Blagova O.V., Gagarina N.V., Nedostup A.V., Ternovoy S.K. (Moscow).** Contrast MSCT of heart in diagnosis of myocarditis and its prognosis.
- **Reznik I.I., Molyakh S.F., Fedorova O.K. (Ekaterinburg).** Differential diagnosis of HCM and cardiac sarcoidosis.
- **Blagova O.V., Nedostup A.V. (Moscow).** Myocarditis and surgery: who and when to refer for a surgical treatment.
- **Babaev M.A. (Moscow).** Heart failure: cardiac intensivist's perspective.
- **Idov E.M., Reznik I.I. (Ekaterinburg).** Myocarditis of transplanted heart.

PLENARY SESSION HALL

11.00–12.30

PLENARY SESSION

Fundamental research in cardiology

Online broadcasting

Chairpersons:

Voevoda M.I. (Novosibirsk), Tkachuk V.A. (Moscow)

- **Voevoda M.I. (Novosibirsk).** Epidemiology and molecular genetics of cardiovascular diseases in Siberia.
- **Kurochkin I.N. (Moscow).** Prognostic modeling in cardiology.
- **Konstantinov V.O. (Saint-Petersburg).** Family hyperlipidemia: from genetics to treatment.
- **Zateischikov D.A. (Moscow).** Genome-wide revolution in cardiology.

CONFERENCE HALL 1

11.00–12.30

SYMPOSIUM

Board of experts: difficult issues of antianginal drugs choice. Ranolazine in clinical practice (supported by Berlin-Chemie/Menarini)

Chairperson: **Konradi A.O (Saint-Petersburg)**

Moderator: **Arutyunov G.P. (Moscow)**

- **Orlova Ya.A. (Moscow).** Ranolazine in combination therapy of stable angina.
- **Koziołova N.A. (Perm).** Characteristics and analysis of patients taking ranolazine.

EXPERTS DISCUSSION

Moderator: **Arutyunov G.P. (Moscow)**

Board Members:

Konradi A.O. (Saint-Petersburg), Arutyunov G.P. (Moscow), Orlova Ya.A. (Moscow), Vasyuk Yu.A. (Moscow), Koziolova N.A. (Perm), Tarlovskaya E.I. (Nizhny Novgorod), Chesnikova A.I. (Rostov-on-Don), Bubnova M.G. (Moscow), Nedoshivin A.O. (Saint-Petersburg).

CONFERENCE HALL 1A

11.00–12.30

SECTION SESSION

Fundamental research

Part II

Chairpersons:

Shesternya P.A. (Krasnoyarsk), Kostareva A.A. (Saint-Petersburg)

- **Lifshits G.I., Kokh N.V., Voronina E.N. (Novosibirsk).** APOE gene polymorphism as a pharmaco-genetic marker of efficacy and safety of statin therapy in patients with atherothrombosis.
- **Michurova M.S., Kalashnikov V.Yu., Smirnova O.M., Terekhin S.A., Ivanova O.N., Stepanova S.M. (Moscow).** Dynamics of endothelial progenitor cells and vascular endothelial growth factor in patients with type 2 diabetes after endovascular interventions.
- **Gazizova D.Sh., Lischuk V.A. (Moscow).** From differentiation and analysis to synthesis of integrity – an example of dilated cardiomyopathy pathogenesis study.
- **Lukin O.N., Protsenko Yu.L. (Ekaterinburg).** Main *calcium sequestration mechanisms* in length-related regulation of contractile response in rat's cardiomyocyte.

CONFERENCE HALL 2

11.00–12.30

SYMPOSIUM

Acute chest pain: current approach to a difficult diagnosis
(supported by GE Healthcare)

Chairpersons:

Shlyakhto E.V. (Saint-Petersburg), Sinitsyn V.E. (Moscow)

- **Sinitsyn V.E. (Moscow).** Acute chest pain: current approach to diagnosis.
- **Sablairolles J.-L., Timofeeva I.V. (France).** Clinical case discussion (acute coronary syndrome, acute aortic syndrome, PE, abnormal development, CT after cardiac and aortic interventions).

CONFERENCE HALL 3

11.00–12.30

ROUND TABLE

Comorbidity and gender aspects

Chairpersons:

Oganov R.G. (Moscow), Mamedov M.N. (Moscow)

- **Oganov R.G. (Moscow).** Female heart: gender specificities of cardiovascular diseases.
- **Mamedov M.N. (Moscow).** Male health problems: a predictor or an outcome of cardiovascular diseases.
- **Glukhovskaya S.V., Maksimova Zh.V. (Ekaterinburg).** Cardiac health of working age men. Implementation of prevention programme at the regional level.

CONFERENCE HALL 4

11.00–12.30

SYMPOSIUM

Prospects of diagnosis and treatment of atherosclerosis

Chairpersons:

Ezhov M.V. (Moscow), Kukharchuk V.V. (Moscow)

- **Arabidze G.G. (Moscow).** Immunology of atherosclerosis: from bench to bedside.
- **Ezhov M.V. (Moscow).** Aortic stenosis, LDL and Lipoprotein-a.
- **Sergienko I.V. (Moscow).** Family hypercholesterolemia: diagnosis and treatment.
- **Kukharchuk V.V. (Moscow).** Do we need new guidelines on dyslipidemia?

CONFERENCE HALL 4A

11.00–12.30

SECTION SESSION

Cardiovascular surgery

Part II

Chairpersons:

Eregin S.Ya. (Yaroslavl), Shneider Yu.A. (Kaliningrad)

- **Bokeria L.A., Abdulgasanov R.A., Abdulgasanova M.R., Ivanov A.V., Provotorova Yu.R., Gasymov E.G. (Moscow).** Diagnostic methods of purulent-septic complications in angiosurgery.
- **Abdulgasanov R.A., Bokeria L.A., Abdulgasanova M.R., Ivanov A.V., Provotorova Yu.R., Gasymov E.G. (Moscow).** Prevention and treatment of perioperative hemorrhagic complications in angiosurgery.
- **Gabinsky Ya.L., Stepin A.V., Flikova E.V. (Ekaterinburg).** Current opportunities of organ-sparing surgical interventions in patients with severe forms of chronic heart failure.
- **Primaichenko M.V., Bernau Hendrik, Eichler Ingolf, Chares Michael, Stolze Markus, Krakor Ralf (Dortmund, Germany).** Total off-pump coronary revascularization improves outcomes in elderly patients.

- **Bezdeneshnykh N.A., Sumin A.N., Bezdeneshnykh A.V., Ivanov S.V., Barbarash O.L. (Kemerovo).** Impact of pre-diabetes and type 2 diabetes on frequency of remote major cardiovascular events in patients after CABG.
- **Gruzdeva O.V., Fanaskova E.V., Uchasova E.G., Akbasheva O.E., Penskaya T.Yu., Plotnikov G.P., Barbarash O.L. (Kemerovo).** Thrombin generation test in hemostatic potential assessment in CABG.

CONFERENCE HALL 5

11.00–12.30

ROUND TABLE

Unresolved issues in cardiology. Management of patients with implanted devices. New opportunities and «old» problems

(supported by Cardiomedics/Boston Scientific)

Part I: Chronic heart failure. What new can we offer to a doctor and a patient?

Moderators:

Shlyakhto E.V. (Saint-Petersburg), Revishvili A.Sh. (Moscow), Popov S.V. (Tomsk), Lebedev D.S. (Saint-Petersburg)

Participants: Sitnikova M.Yu. (Saint-Petersburg)

- **Sitnikova M.Yu. (Saint-Petersburg).** Current approaches in treatment of heart failure. Possibilities and limitations of treatment methods.
- **Lebedev D.S., Mikailov E.N. (Saint-Petersburg).** Modulation of cardiac contractility in patients with chronic heart failure: key studies, tactics of selection and reference of patients for Optimizer implantation.
- Discussion.

Part II. Complications of endocardial antiarrhythmic systems – availability of surgical methods in Russia

Moderators:

Shlyakhto E.V. (Saint-Petersburg), Revishvili A.Sh. (Moscow), Popov S.V. (Tomsk), Lebedev D.S. (Saint-Petersburg)

Participants:

Krivolapov S.N. (Tomsk), Romanov A.B. (Novosibirsk)

- **Losik D.V. (Novosibirsk).** Infectious and non-infectious complications. How not to overlook a patient with a stimulation system complication. Indications for a surgical intervention.
- **Krivolapov S.N. (Tomsk).** Technologies of endocardial electrodes removal: survey and specificities of the existing methods.
- Discussion.

CONFERENCE HALL 5A

11.00–12.30

SYMPOSIUM

Rare and difficult diagnoses in cardiology

Chairpersons:

Andreev D.A. (Moscow), Syrkin A.L. (Moscow)

- **Poltavskaya M.G. (Moscow).** Rare reasons of a cardiac tamponade.
- **Kopylov F.Yu. (Moscow).** Acute cardiorenal syndrome V type.
- **Novikova N.A. (Moscow).** Rare causes of retrosternal pain.
- **Andreev D.A. (Moscow).** Myocarditis or myocardial infarction.
- **Gilyarov M.Yu. (Moscow).** Clinical, electrocardiographic and angiographic discrepancies in ACS patients.

CONFERENCE HALL 6

11.00–12.30

CLINICAL CASE STUDIES

A difficult patient with obesity

Chairpersons:

Gorbunov V.V. (Chita), Chumakova G.A. (Barnaul)

- **Kuznetsova T.Yu., Druzhilov M.A. (Petrozavodsk).** Atrial fibrillation in a patient with morbid obesity.
- **Gorbunov V.V. (Chita).** Resistant hypertension in a patient with obesity.
- **Chumakova G.A. (Barnaul), Veselovskaya N.G. (Kemerovo).** Coronary artery bypass surgery and obesity.
- **Leonova N.V. (Barnaul).** Obese patients in cardiology practice. Endocrinologist's perspective.

CONFERENCE HALL 7

11.00–12.30

SCIENTIFIC SESSION

From risk factors to cardiovascular complications. A model of cardiovascular continuum in Russia

Chairperson: **Boitsov S.A. (Moscow)**

- **Boitsov S.A. (Moscow).** Mechanisms of altering cardiovascular mortality in Russia.
- **Shalnova S.A., Kontsevaya A.V. (Moscow).** Modeling cardiovascular risk in cardiovascular continuum: the rationale and methodology.
- **Karpov Yu.A. (Moscow).** Prognosis in CAD patients as an important component of treatment strategy and tactics.
- **Ostroumova O.D. (Moscow).** Causes and effects of stroke. Cardiologist's perspective.
- **Ageev F.T. (Moscow).** Significance of heart failure in prognosis of a cardiovascular patient in follow-up care.

PLENARY SESSION HALL

12.40–13.20

PLENARY LECTURE

Online broadcasting | Simultaneous translation

Moderator: **Yakovlev A. N. (Saint-Petersburg)**

- **Mehta S. (USA).** Improving STEMI outcomes.

PLENARY SESSION HALL

13.30–15.00

PLENARY SESSION

Hybrid technologies in CVD treatment

Online broadcasting

Chairpersons:

Akchurin R.S. (Moscow), Alekyan B.G. (Moscow)

- **Akchurin R.S. (Moscow).** Hybrid surgery in aortic valve stenosis treatment in adults.
- **Abugov S.A. (Moscow).** Hybrid interventions in aortic aneurysms treatment.
- **Alekyan B.G. (Moscow).** Hybrid (surgical and endovascular) interventions in coronary artery disease treatment.
- **Drozdov S.A. (Moscow).** Combined surgery and endovascular interventions in peripheral arteries pathology.
- **Alekyan B.G. (Moscow).** Hybrid interventions in some congenital heart disorders treatment.
- Discussion.

CONFERENCE HALL 1

13.30–15.00

SYMPOSIUM

CVD epidemiology and risk factors in CIS countries: similarities and ethnic differences

Chairpersons:

**Alikhanova K.A. (Kazakhstan), Podpalov V.P. (Belarus),
Djumagulova A.S. (Kyrgyzstan)**

- **Kontsevaya A.V., Myrzamatova A.O. (Moscow).** Ethnic aspects and risk factors of CVD in CIS countries: are there more similarities or differences (based on InterEpid study data)?
- **Polupanov A.G., Altymysheva A.T., Khalmatov A.N. (Kyrgyzstan).** Cardiovascular risk factors in Kyrgyzstan and their impact on prognosis (InterEpid study prospective phase data).
- **Alikhanova K.A., Iskakov E.K. (Kazakhstan).** CVD epidemiology and risk factors in the Karaganda region of Kazakhstan.
- **Podpalov V.P. (Belarus), Deev A.D. (Moscow).** Development of circulatory disease incidents: role of comorbid pathology (based on a 5-year prospective study in Belarus).
- **Balanova Yu.A. (Moscow).** Epidemiologic studies in Russia and opportunities of international cooperation.

CONFERENCE HALL 1A

13.30–15.00

MASTER CLASS

Preventive consulting in cardiology

Presenter:

Maximova Zh.V. (Ekaterinburg)

CONFERENCE HALL 2

13.30–15.00

SYMPOSIUM

Uncontrolled and resistant hypertension: new technologies in diagnosis and treatment

Chairpersons:

**Konradi A.O. (Saint Petersburg), Popov S.V. (Tomsk),
Karpov R.S. (Tomsk)**

- **Konradi A.O. (Saint Petersburg).** Pharmacotherapy versus interventional techniques: a cardiologist's perspective.
- **Pekarsky S.E., Baev A.E., Mordovin V.F., Semke G.V., Ripp T.M., Falkovskaya A.Yu., Sitkova E.S., Lichikaki V.A., Kuzmichkina M.A. (Tomsk), Zyubanova I.V. (Moscow).** Interventional therapy of hypertension – current state and prospects of development.
- **Ripp T.M., Mordovin V.F., Semke G.V. (Tomsk), Ryabova T.R. (Moscow), Pekarskiy S.E., Falkovskaya A.Yu., Sitkova E.S., Lichikaki V.A., Popov S.V. (Tomsk).** Organoprotective potential of new technologies in hypertension treatment, hopes of a cardiologist.
- **Zvartau N.E. (Saint-Petersburg), Avdonina N.G. (Saint-Petersburg), Konradi A.O. (Saint-Petersburg).** Current approaches to detection and correction of uncontrolled arterial hypertension.
- **Usov V.Yu., Shelkovnikova T.A., Mordovin V.F., Lukyanenok P.I., Zyubanova I.V., Sitkova E.S., Mochula O.V. (Tomsk).** Tomographic technologies in diagnostic imaging of target organs in arterial hypertension: methodological, diagnostic and prognostic aspects.

CONFERENCE HALL 3

13.30–15.00

SYMPOSIUM

Pulmonary embolism — 2016

Chairpersons: **Yavelov I.S. (Moscow), Panchenko E.P. (Moscow)**

- **Yavelov I.S. (Moscow).** Is current pulmonary embolism diagnosis reliable enough?
- **Panchenko E.P. (Moscow).** Hospital treatment of pulmonary embolism: how to choose a right approach.
- **Komarov A. L. (Moscow).** Long-term treatment after discharge – a key for prevention of recurrent pulmonary embolism.

CONFERENCE HALL № 4

13.30–15.00

DEBATES

Evidence-based cardiology and controversial issues in anticoagulant and antithrombotic therapies

Chairpersons:

Gilarevsky S.P. (Moscow), Pershukov I.V. (Voronezh)

- **Gilarevsky S.P. (Moscow).** Hypotheses, fantasies and proven facts in tactics of oral anticoagulants administration in patients with atrial fibrillation.
- **Pershukov I.V. (Voronezh).** True, wild guesses and tales of antithrombotic therapy in patients with coronary heart disease.

CONFERENCE HALL 4A

13.30–15.00

SECTION SESSION

Epidemiology, prevention and rehabilitation. Sports Medicine Part I

Chairpersons:

Gafarov V.V. (Novosibirsk), Artamonova G.V. (Kemerovo)

- **Gafarov V.V., Gromova E.A., Panov D.O., Gagulin I.V., Gafarova A.V. (Novosibirsk).** Sleep disturbances and stroke risk within 14 years among Russian/Siberian males (MONICA-psychosocial WHO program).
- **Gafarov V.V., Gromova E.A., Panov D.O., Gagulin I.V., Gafarova A.V., Timoschenko O.V. (Novosibirsk).** Gender-specific risk of CVD in people with depression in Russia/Siberia (MONICA-psychosocial WHO program).
- **Artamonova G.V., Barbarash L.S., Maksimov S.A., Tabakaev M.V. (Kemerovo).** Innovative methods of statistical analysis of cardiovascular mortality indicators in the Russian Federation regions.
- **Zakroeva A.G., Andrianov O.V., Solodovnikov A.G., Lesniak O.M. (Ekaterinburg).** Comparative analysis of hypertension and its risk factors prevalence and associations with parameters of mental health in rural and urban populations of the Sverdlovsk region.

- **Ershova A.I., Meshkov A.N., Storozhok M.A., Efanov A.Yu., Indukaeva E.V., Danilchenko Ya.V., Kuzmina O.K., Medvedeva I.V., Barbarash O.L., Shalnova S.A., Boytsov S.A. (Moscow).** Prevalence of familial hypercholesterolemia in the Russian population: ESSAY-RF substudy.
- **Argunova Yu.A., Trubinkova O.A., Kagan E.S., Barbarash O.L. (Kemerovo).** Cerebroprotective effects of physical training in patients after CABG.
- **Muromtseva G.A., Deev A.D., Shalnova S.A., Konstantinov V.V., Kapustin A.V. (Moscow).** Self-assessment of health and all causes and CVD death risk in the Moscow population of 55 years and older.

CONFERENCE HALL 5

13.30–15.00

SYMPOSIUM

Arterial stiffness in clinical practice

Chairpersons:

Vasyuk Y.A. (Moscow), Oleynikov V.E. (Penza)

- **Vasyuk Y.A., Ivanova S.V., Shkolnik E.L., Kotovskaya Y.V. (Moscow), Milyagin V.A. (Smolensk), Oleynikov V.E. (Penza), Orlova Ya.A. (Moscow), Sumin A.N. (Kemerovo).** Russian experts consensus on arterial stiffness.
- **Oleynikov V.E., Salyamova L.I., Khromova A.A., Sergatskaya N.V. (Penza).** Local and regional arterial stiffness on high doses of Atorvastatin in patients with STEMI.
- **Ivanova S.V., Shkolnik E.L., Teltevskeya I.I., Vasyuk Yu.A. (Moscow).** Arterial stiffness in patients with diabetes mellitus.
- **Cherkashin D.V., Makiev R.G., Kirichenko P.Yu. (Saint-Petersburg).** CAVI in clinical practice of medical departments of the Russian Defense Ministry as surrogate atherosclerosis marker and to predict cardiovascular prognosis.

CONFERENCE HALL 5A

13.30–15.00

SYMPOSIUM

Hot issues in psychocardiology

Chairpersons:

Smulevich A.B. (Moscow), Syrkin A.L. (Moscow)

- **Belyalov F.I. (Irkutsk).** Treatment of coronary artery disease with comorbid anxiety and depression.
- **Kopylov F.Yu., Syrkina E.A. (Moscow).** Depression in cardiology practice: a cardiologist's perspective.
- **Volel B.A., Troshina D.V., Grubova M.V. (Moscow).** The impact of mental (personality) disorders on the course of cardiovascular diseases.
- **Repin A.N., Lebedeva E.V., Sergienko T.N. (Tomsk).** Remote results of multidisciplinary rehabilitation programmes in patients with coronary artery disease and depression.
- **Garganeeva N.P. (Tomsk).** Anxiety-depressive disorders in practice of a cardiologist: focus on current guidelines for prevention of cardiovascular diseases.
- **Chitlova V.V. (Moscow).** Psychotropic drugs in cardiology practice.

CONFERENCE HALL 6

13.30–15.00

SCIENTIFIC SESSION

Hotline in atherosclerosis and CAD

Chairpersons:

Bubnova M.G. (Moscow), Ezhov M.V. (Moscow)

- **Bubnova M. G. (Moscow).** Hotline in dyslipidemia
- **Ezhov M.V. (Moscow).** Hotline in atherosclerosis.
- **Shaposhnik I.I. (Chelyabinsk).** Hotline in CAD.

CONFERENCE HALL 7

13.30–15.00

RUSSIAN-BELORUSSIAN SYMPOSIUM

Part I

Physician's library: focus on a «difficult patient» with AF

Chairpersons:

Golitsyn S.P. (Moscow), Mitkovskaya N.P. (Belarus)

- **Chesnikova A.I. (Rostov-on-Don).** Atrial fibrillation and asthma: «mirror» reflection of the problem.
- **Kozioleva N.A. (Perm).** Correcting mistakes in management of patients with atrial fibrillation and thrombophilia.
- **Mitkovskaya N.P. (Belarus).** Algorithms for the antithrombotic therapy selection in patients with atrial fibrillation after organ transplantation.
- **Tarlovskaya E.I. (Nizhny Novgorod).** Proarrhythmic effects of antiarrhythmic drugs: prevalence and true risks.

PLENARY SESSION HALL

15.30–17.00

PLENARY LECTURES

Chairpersons:

Vasilyeva E.Yu. (Moscow), Dovgalevsky P.Ya. (Saratov)

Online broadcasting | Simultaneous translation

- **Shpektor A.V. (Moscow).** ACS: what's new?
- **Velchev V. (Bulgaria).** Does the primary PCI network capable to serve?
- **Pozdnyakov Yu.M. (Moscow).** Stable angina in males and females.

CONFERENCE HALL 1

15.30–17.00

SCIENTIFIC AND PRACTICAL CONFERENCE

Professional public accreditation of educational programmes as an element of medical education quality improvement

(Joint meeting of RSC and National Medical Chamber supported by Knowledge Society, Russia)

Chairpersons:

**Shlyakhto E.V. (Saint-Petersburg), Kontsevaya A.V. (Moscow),
Parmon E.V. (Saint-Petersburg)**

- **Ushanov Yu.V. (Moscow).** Professional standards in the system of Russian education.
- **Kontsevaya A.V. (Moscow).** Current trends in training of new generation cardiologists.
- **Sirotkina O.V. (Saint- Petersburg).** RSC experience in organization of regional platforms for accreditation of education programmes in cardiology.
- **Ischuk T.N. (Saint- Petersburg).** Creating the institution of independent experts for professional public accreditation of educational programmes.
- Discussion.

CONFERENCE HALL 1A

15.30–17.00

SYMPOSIUM

Cardiorehabilitation and differentiation of medical approaches to achieve a better clinical outcome

Chairpersons:

Aronov D.M. (Moscow), Bubnova M.G. (Moscow)

- **Demchenko E.A. (Saint-Petersburg).** Current paradoxes of cardiorehabilitation.
- **Aronov D.M. (Moscow).** Clinical effects of cardiorehabilitation in patients with acute myocardial infarction and comorbidities.

- **Perepech N.B. (Saint-Petersburg).** Principles of personalized rehabilitation programmes at the second stage of cardiorehabilitation.
- **Bubnova M.G., Aronov D.M., Makhinova M.M., Novikova N.K., Davtyan K.V. (Moscow).** Therapeutic effects of physical rehabilitation in patients after radiofrequency ablation due to paroxysmal atrial fibrillation: preliminary results.

CONFERENCE HALL 2

15.30–17.00

SYMPOSIUM

Obesity in cardiology practice

Chairpersons:

Baranova E.I. (Saint-Petersburg), Nedogoda S.V. (Volgograd)

- **Konradi A.O. (Saint-Petersburg).** Challenge of obesity in cardiology practice.
- **Baranova E.I. (Saint-Petersburg).** Antihypertensive treatment in obesity.
- **Nedogoda S.V. (Volgograd).** Carbohydrate and lipid metabolic disorders treatment in obesity.
- **Lopatin Yu.M. (Volgograd).** Treating coronary artery disease and heart failure in obesity.
- **Drapkina O.M. (Moscow).** Hepatoprotection in obesity.
- **Statsenko M.E. (Volgograd).** Nephroprotection in obesity.

CONFERENCE HALL 3

15.30–17.00

SCIENTIFIC SESSION

Materials of the Russian ACS Registry RECORD-3

Chairpersons:

Barbarash O.L. (Kemerovo), Erlikh A.D. (Moscow), Gratsiansky N. (Moscow)

- **Barbarash O.L. (Kemerovo).** Non-STEMI patients treatment in the Russian hospitals.
- **Kosmacheva E.D., Raff S.A., Kruchinova S.V. (Krasnodar).** ACS management in the Krasnodar region.

- **Syromyatnikova L.I. (Perm).** The problem of ACS diagnostics accuracy and hemodynamically insignificant stenosis of coronary arteries.
- **Kashtalap V.V. (Kemerovo).** Gender and age aspects of STEMI patients management.
- **Duplyakov D.V. (Samara).** Specificities of treatment and outcomes in patients with ACS and ECG-proved left bundle branch block.
- **Erlikh A.D. (Moscow).** 6 months after ACS: outcomes and adherence to treatment.

CONFERENCE HALL 4

15.30–17.00

SYMPOSIUM

Heart Failure Journal presents: evidence- based cardiology for physicians

Chairpersons:

Arutyunov G.P. (Moscow), Belenkov Yu.N. (Moscow)

- **Arutyunov G.P. (Moscow).** Publications in the field of heart failure: analysis of global trends and key tendencies of the «Heart Failure» journal.
- **Mareev V.Yu. (Moscow).** How to evaluate and apply RCT results in clinical practice.
- **Gilyarevsky S.R. (Moscow).** Systematic review and meta-analysis in the current structure of evidence-based information: opportunities, limitations and methodology.
- **Begrambekova Yu.L. (Moscow).** Studies of non-pharmacological methods: planning, organization and results presentation.

CONFERENCE HALL 4A

15.30–17.00

SECTION SESSION

Epidemiology, prevention and rehabilitation.

Sports Medicine

Part II

Chairpersons:

Kontsevaya A.V. (Moscow), Garganeeva A.A. (Tomsk)

- **Maksimov S.A., Artamonova G.V. (Kemerovo).** Socio-economic aspects of CAD population risk (ESSE-RF study in the Kemerovo region).
- **Mulerova T.A., Maksimov V.N., Ogarkov M.Yu. (Novokuznetsk).** Nation-specific specificities of MTHFR gene polymorphism in lipid metabolism disorders.
- **Belov V.N., Shilkina E.Z., Belova E.A., Lubovina E.A., Zaitsev T.A. (Voronezh).** Rehabilitation effectiveness in CHF patients with reduced LV ejection fraction.
- **Pecherina T.B., Kashtalov V.V., Barbarash O.L. (Kemerovo).** Cytokine status in patients with systolic dysfunction in the acute period of STEMI.
- **Chumakova O.S., Isaeva M.Yu., Drobyazko O.A., Motrich O.G., Tipteva T.A., Zateyschikov D.A. (Moscow).** Pathological ECG changes in adult professional athletes and their further examination.

CONFERENCE HALL 5

15.30–17.00

SYMPOSIUM

New methods in echocardiography

Chairpersons:

Krinochkin D.V. (Tyumen region), Ivanova S.V. (Moscow)

- **Krinochkin D.V. (Tyumen region).** Echocardiography to select patients and predict response to CRT.
- **Surkova E.A. (Samara).** Current approaches to right chambers quantification.
- **Ivanova S.V., Shkolnik E.L., Teltevsckaya I.I., Vasyuk Yu.A. (Moscow).** Association of arterial stiffness and myocardial deformation in patients with cerebral circulation disorders.
- **Tereshina O.V. (Samara).** Contrast echocardiography.

CONFERENCE HALL 5A

15.30–17.00

SYMPOSIUM

Current understanding of molecular-genetic and pathophysiologic aspects of hyperlipidaemia and atherosclerosis

Chairpersons:

Ragino Y. (Novosibirsk), Voevoda M. (Novosibirsk)

- **Ragino Y.I. (Novosibirsk).** PCSK9, biochemical and molecular genetic studies, association with a poor prognosis
- **Maksimov V.N. (Novosibirsk).** Telomere length and atherosclerosis: a population-based study.
- **Kashtanova E.V. (Novosibirsk).** Pathogenetically significant markers of coronary atherosclerosis. Laboratory diagnosis of the disease.
- **Shakhtshneider E.V. (Novosibirsk).** Cascade genetic screening of familial hypercholesterolemia: Russian experience.
- **Sergienko I.V. (Moscow).** Genetic diagnostic of familial hypercholesterolemia. Clinical case.
- **Lozhkina N.G. (Novosibirsk).** Genetic markers of ACS adverse outcome.

CONFERENCE HALL 6

15.30–17.00

SYMPOSIUM

Cardiomyopathies with a high risk of sudden cardiac death

Chairpersons:

Krylov N.S. (Moscow), Idov E.M. (Ekaterinburg)

- **Idov E.M., Kashtanov M.G., Reznik I.I. (Ekaterinburg).** Septal ablation in hypertrophic cardiomyopathy.
- **Krylova N.S., Poteskin N.G., Kovalevskaya E.A., Demkina A.E., Khashieva F.M. (Moscow).** Sudden death in hypertrophic cardiomyopathy: search for new risk factors.
- **Zaklyazminskaya E.V. (Moscow).** Contribution of genetic data into the risk stratification of sudden death in cardiomyopathies.

- **Parmon E.V., Kurilenko T.A., Gordeeva M.S., Zemskov I.A. (Saint- Petersburg).** Role of ECG markers in sudden cardiac death risk evaluation in patients with cardiomyopathies.
- **Sedov A.V., Tsaregorodtsev D.A., Sulimov V.A. (Moscow).** Non-invasive markers of sudden cardiac death high risk: do we use them for patients with dilated cardiomyopathy?

CONFERENCE HALL 7

15.30–17.00

RUSSIAN-BELORUSSIAN SYMPOSIUM

Part II

Facts and misconceptions in treatment of concomitant diseases of cardiologic patients

Chairpersons:

Mitkovskaya N.P. (Belarus), Rebrov A.P. (Saratov)

- **Mitkovskaya N.P. (Belarus).** Cerebroprotectors in AH patients after stroke: any evidence of effect on prognosis and life quality?
- **Kozioleva N.A. (Perm).** Insulin therapy in diabetes mellitus type 2 and ACS: benefits and risks ratio.
- **Tarlovskaya E.I. (Nizhny Novgorod).** Aspirin: is there any benefit in primary prevention in case of extracardiac localization of atherosclerosis?
- **Rebrov A.P. (Saratov).** Non-steroidal anti-inflammatory drugs: what is their cardiovascular safety level?

CONFERENCE HALL 8

15.30–17.00

MASTER CLASS

Is it easy to quit smoking?

Management of a smoking patient in cardiology practice

Presenter:

Andrianova O.V. (Ekaterinburg)

PLENARY SESSION HALL

17.30–19.00

SCHOOL FOR CARDIOLOGISTS AND INTERNISTS

Current issues of antithrombotic therapy in cardiovascular diseases

Chairpersons:

**Panchenko E.P. (Moscow), Dobrovolsky A.B. (Moscow),
Yavelov I.S. (Moscow)**

- **Dobrovolsky A. (Moscow).** Main coagulologic tests for thrombosis diagnostics and control of antithrombotic therapy.
- **Panchenko E.P. (Moscow).** Anticoagulants in patients with atrial fibrillation. From clinical trials to clinical practice.
- **Yavelov I.S. (Moscow).** New options in acute and long-term antithrombotic treatment in patients with deep vein thrombosis and pulmonary embolism.

CONFERENCE HALL 1

17.30–19.00

SYMPOSIUM

Medical prevention and outcomes in patients with atrial fibrillation: clinical guidelines and clinical practice.

Chairpersons:

Martsevich S.Yu. (Moscow), Bunin Yu.A. (Moscow)

- **Martsevich S.Yu., Kutishenko N.P., Zagrebelsky A.V. (Moscow).** Medical prevention of cardiovascular complications in patients with atrial fibrillation. Main approaches to treatment quality assessment.
- **Bunin Yu.A. (Moscow).** Controversial issues in antiarrhythmic therapy in patients with atrial fibrillation.
- **Geraskina L.A. (Moscow).** Medical treatment and prevention in patients with acute stroke and atrial fibrillation.
- **Lukyanov M.M. (Moscow), Yakushin S.S. (Ryazan), Yakusevich V.V. (Yaroslavl), Gomova T.A. (Tula region), Mikhlin V.P. (Kursk).** Patients with atrial fibrillation and concomitant cardiovascular diseases in clinical practice: medical treatment, outcomes, stroke prevention on registries data.

CONFERENCE HALL 1A

17.30–19.00

SECTION SESSION

Heart failure/left ventricular dysfunction

Chairpersons:

Koziołova N.A. (Perm), Shlyk S.V. (Rostov-on-Don)

- **Berezin A.E., Kremzer A.A., Berezina T.A., Martovitskaya Yu.V., Gromenko E.A. (Ukraine).** Quantity of endothelial progenitor cells and apoptotic endothelial microparticles ratio in patients with chronic heart failure.
- **Pochinka I.G., Jurkova K.N., Dvornikova M.I., Baranova A.A., Botova S.N., Razumovsky A.V., Strongin L.G. (Nizhny Novgorod).** Type 2 diabetes mellitus and prognosis in acute decompensated heart failure.
- **Liskova Yu.V., Salikova S.P., Tverdokhlib N.V., Rozhkov V.O., Avchenko G.M., Erkhov A.Yu., Popov A.B. (Orenburg, Saint-Petersburg).** Translational research in early diagnosis and prognosis of chronic heart failure.
- **Benevolenskaya S.S., Trukshina M.A., Lyasnikova E.A., Sitnikova M.Yu. (Saint-Petersburg).** Effectiveness of cardiac resynchronization therapy in patients with permanent atrial fibrillation.
- **Kryukov N.N., Gubareva I.V., Gubarev E.Yu. (Samara).** Plasma brain natriuretic peptide levels in men with hypertension and chronic heart failure with preserved left ventricular ejection fraction.
- **Kirillova V.V. (Kazan).** Early diagnosis of venous pulmonary hypertension.
- **Gruzdeva O.V., Dyleva Yu.A., Uchasova E.G., Akbasheva O.E., Fedorova N.V., Karetnikova V.N., Kashtalap V.V., Barbarash O.L. (Kemerovo).** Assessment of stimulating growth factor (ST2) and NT-f fragment natriuretic peptide concentration to evaluate left ventricle remodeling option.
- **Vlasov A.A., Grinevich V.B., Salikova S.P., Osipov G.A., Avdonin V.S. (Saint-Petersburg, Moscow).** Rifaximin effect on microbial markers concentration in rats blood in experimental heart failure.

CONFERENCE HALL 2

17.30–19.00

SYMPOSIUM

Secondary arterial hypertension: from assumptions to verification of diagnosis and treatment

Chairpersons:

Nebieridze D.V. (Moscow), Yakushin S.S. (Ryazan)

- **Nebieridze D.V. (Moscow).** Hot issues in AH diagnosis within current guidelines: focus on secondary forms.
- **Yakushin S.S. (Ryazan).** Renovascular hypertension: current aspects of diagnosis and treatment.
- **Vasyuk Yu.A. (Moscow).** Association between obesity and hypertension: how to diagnose and treat?
- **Kopylov F.Yu., Palman A.D. (Moscow).** Obstructive sleep apnea: a cause, a symptom or a consequence of hypertension?
- **Filippov E.V. (Ryazan).** Management of patients with pheochromocytoma: roles of an internist and a cardiologist.

CONFERENCE HALL 3

17.30–19.00

SYMPOSIUM

Acute kidney injury in cardiology practice

Chairpersons:

Smirnov A.V. (Saint-Petersburg),

Dobronravov V.A. (Saint-Petersburg), Shutov A.M. (Ulyanovsk)

- **Smirnov A.V. (Saint-Petersburg).** Cardio-renal relations and cardiovascular risk
- **Dobronravov V.A. (Saint-Petersburg).** Current understanding of acute kidney injury.
- **Shutov A. (Ulyanovsk).** Acute kidney injury in cardiology practice. Is it only radiocontrast nephropathy?

CONFERENCE HALL 4

17.30–19.00

LECTURES

- **Demin A.A. (Novosibirsk).** What's new in the ESC Guidelines for infective endocarditis – 2015?
- **Skibitskiy V.V. (Krasnodar).** A patient with depression and hypertension: how to optimize pharmacotherapy?
- **Demin A.A. (Novosibirsk).** Cardiovascular safety of osteoarthritis anti-inflammatory therapy – 2016.

CONFERENCE HALL 4A

17.30–19.00

SECTION SESSION

Epidemiology, prevention and rehabilitation.

Sports medicine.

Part III

Chairpersons:

Gluhovskaya S.V. (Ekaterinburg), Syromyatnikova L.I. (Perm)

- **Pecherina T.B. Kashtalov V.V., Gruzdev O.V., Barbarash O.L. (Kemerovo).** Clinical significance of matrix metalloproteinases in patients with myocardial infarction in combination with peripheral artery atherosclerosis.
- **Sarybaev A. (Kyrgyzstan).** Highland pulmonary hypertension – 2016.
- **Mehdiyeva K.R., Zinovieva Yu.A., Blyakhman F.A. (Ekaterinburg).** Anomalous chords of the left ventricle may increase the risk of sudden death in young athletes.
- **Komkov D.S., Boytsov S.A., Toporkova V.V. (Moscow).** Organizational models of remote medical technologies application.
- **Erina A.M., Rotar O.P., Konradi A.O., Shalnova S.A., Balanova Yu.A., Deev A.D., Zhernakova Yu.V., Oshchepkova E.V., Karpov Yu.A., Chazova I.E., Shlyakhto E.V. (Saint-Petersburg, Moscow).** Association of pre-hypertension with cardiovascular risk factors. Based on ESSE-RF study.

CONFERENCE HALL 5

17.30–19.00

SYMPOSIUM

Echocardiography in acute care

Chairpersons:

Tereshina O.V. (Samara), Yaroslavskaya E.I. (Tyumen)

- **Tereshina O.V. (Samara).** Echocardiography algorithm for patients in critical condition.
- **Yaroslavskaya E.I. (Tyumen).** Unusual echocardiography syndromes in CAD.
- **Oleynikov V.E., Romanovskaya E.M., Galimskaya V.A., Salyamova L.I. (Penza).** LV deformation imaging in patients with STEMI

CONFERENCE HALL 5A

17.30–19.00

CLINICAL CASE STUDIES

Thromboses in cardiology clinic. Diagnostic algorithms and therapeutic strategies.

Chairperson:

Zadionchenko V.S. (Moscow)

- **Adasheva T.V. (Moscow).** Clinical case 1. A patient with recurrent thromboembolism of small branches of the pulmonary artery
- **Nesterenko O.I. (Moscow).** Clinical case 2. A patient with recurrent arterial and venous thrombosis
- **Adasheva T.V. (Moscow).** Screening for thrombophilia in cardiology clinic – who, when and how.

CONFERENCE HALL 6

17.30–19.00

INTERACTIVE CLINICAL CASE STUDIES

What is behind the diagnosis of dilated cardiomyopathy?

Chairpersons:

Nedostup A.V. (Moscow), Frolova Yu.V. (Moscow)

- **Kulikova V.A., Lutokhina Yu.A., Blagova O.V., Nedostup A.V. (Moscow).** Inflammatory nature of dilated cardiomyopathy syndrome.
- **Aliev I.N., Zaklyazminskaya E.V., Blagova O.V. (Moscow).** Genetic nature of dilated cardiomyopathy syndrome.
- **Blagova O.V., Sherstneva L.V., Gulyaev S.V. (Moscow).** DCM syndrome as a part of systemic disease.

CONFERENCE HALL 7

17.30–19.00

SYMPOSIUM

Heart rate lowering therapy mysteries

Chairpersons:

Tarlovskaya E.I. (Nizhny Novgorod), Fomin I.V. (Nizhny Novgorod)

- **Tarlovskaya E.I. (Nizhny Novgorod).** Heart rate-lowering therapy: physician's perspective. Focus on beta-blockers.
- **Fomin I.V. (Nizhny Novgorod).** Heart rate-lowering therapy: physician's perspective. Focus on Ivabradin.
- **Mazalov K.V. (Moscow).** A «difficult» patient: clinical case.

Time/Hall	PLENARY SESSION HALL	CONFERENCE HALL 1	CONFERENCE HALL 1A	CONFERENCE HALL 2	CONFERENCE HALL 3	CONFERENCE HALL 4
09.00–10.30	PLENARY SESSION Controversial and unsolved issues in hypertension treatment Online broadcasting	SYMPOSIUM What to do if?.. Problems at the junction of two specialities	SECTION SESSION Emergency cardiology Part I	SYMPOSIUM Athlete's heart: theoretical and practical aspects	SCHOOL on diabetes and cardiovascular disease Part I	SYMPOSIUM To the 60th anniversary of presentation by P.E. Lukomsky and E.M.Tareev on origin and course of myocardial infarction
10.30–11.00	BREAK					
11.00–12.30	PLENARY SESSION Coronary heart disease, lipids and atheroscle- rosis Online broadcasting Simultaneous translation	SYMPOSIUM Prevention of cardiovascular diseases: experience of Russian regions	SECTION SESSION Emergency cardiology Part II	EXPERTS' MEETING Inflammatory heart diseases	SCHOOL on diabetes and cardiovascular disease Part II	SYMPOSIUM Restrictive and unclassified cardiomyopa- thies in clinical practice
12.30–13.00	BREAK					
13.00–15.00	PLENARY SESSION HALL	PLENARY SESSION Cardiology 2016 – a view into the future Online broadcasting Simultaneous translation				

CONFERENCE HALL 4A	CONFERENCE HALL 5	CONFERENCE HALL 5A	CONFERENCE HALL 6	CONFERENCE HALL 7	CONFERENCE HALL 8
SECTION SESSIONS Imaging in cardiology, computer technologies	SYMPOSIUM Non-invasive CAD diagnosis: session of Echocardiography WG	SYMPOSIUM Complicated issues of cardiovascular diseases in elderly patients	RUSSIAN-SERBIAN SYMPOSIUM Innovations in interventional cardiology Simultaneous translation	SCHOOL Hot issues in atrial fibrillation treatment Part I	WORKING GROUP Young Cardiologists - from bench to bedside
SYMPOSIUM Obstructive sleep apnea: new diagnostic approaches, known complications and long-term effects	Cardio-jeopardy interactive quiz on cardiovascular imaging	SYMPOSIUM Accelerated ageing in chronic obstructive pulmonary disease and cardiovascular disorders. Is there the Makropulos secret?	SCIENTIFIC SESSION Microcirculation in cardiology	SCHOOL Hot issues in atrial fibrillation treatment Part II	SECTION SESSION Arrhythmology, stimulation and resynchronization Part II

PLENARY SESSION HALL

09.00–10.30

PLENARY SESSION

Controversial and unsolved issues in hypertension treatment

Online broadcasting

Chairpersons:

Karpov R.S. (Tomsk), Borovkov N.N. (Nizhny Novgorod)

- **Chumakov G.A. (Barnaul).** Metabolic syndrome: to be or not to be?
- **Konradi A.O. (Saint-Petersburg).** Shall we change the target blood pressure level?
- **Nedogoda S.V. (Volgograd).** Is it necessary to treat borderline hypertension?
- **Baranova E.I. (Saint-Petersburg).** Treatment of hypertension in metabolic syndrome – not only drugs ...

CONFERENCE HALL 1

09.00–10.30

SYMPOSIUM

What to do if?.. Problems at the junction of two specialities

Chairpersons:

Stryuk R.I. (Moscow), Yakushin S.S.(Ryazan)

- **Shostak N.A. (Moscow), Klimenko A.A. (Moscow).** Chronic thromboembolic pulmonary hypertension as an interdisciplinary problem. Cardiologist's perspective.
- **Tyurin V.P. (Moscow).** Infective endocarditis: the imposition of valves, non-infectious and neoplastic etiologies
- **Stryuk R.I. (Moscow).** Arrhythmias in pregnancy: treatment principles taking based on risk-benefit category.
- **Smirnova E.A. (Ryazan).** Management of patients with polycythaemia vera and acute coronary syndrome.
- **Filippov E.V. (Ryazan).** Chronic obstructive pulmonary disease and atrial fibrillation: how to break the vicious circle.

CONFERENCE HALL 1A

09.00–10.30

SECTION SESSION

Emergency cardiology

Part I

Chairpersons:

Yakovlev A.N. (Saint-Petersburg), Skibitsky V.V. (Krasnodar)

- **Tavluева E.V., Makarov S.A., Barbarash O.L. (Kemerovo).** Results of Emergency Call Service program at the Kuzbass Regional Vascular Center in 2015.
- **Dyplyakov D.V., Pavlova T.V., Mullova I.S., Kurakina E.A., Khokhlunov S.M. (Samara).** Differences in the clinical presentation and management of patients with confirmed and unconfirmed pulmonary embolism.
- **Skorodumova E.A., Kostenko V.A., Sitnikova M.Yu., Pivovarova L.P., Malyshev M.E., Ariskina O.B., Osipova I.V., Rysev A.V., Lyakhovets E.G., Fedorov A.N., Siverina A.V. (Saint-Petersburg).** Kidneys injury in acute coronary syndrome due to systemic inflammatory response activation – a bridge to myocardial remodeling and development of decompensated CHF.
- **Borovkova N.Yu., Spassky A.A., Ilyina A.S., Borovkov N.N. (Nizhny Novgorod, Moscow).** Acute kidney injury in STEMI based on Regional Vascular Center data.
- **Pochinka I.G., Botova S.N., Dvornikova M.I., Strongin L.G., Razumovsky A.V. (Nizhny Novgorod).** Thrombolytic therapy for pulmonary embolism in clinical practice.
- **Lipchenko A.A., Dmitriev V.K., Arkhipov M.V., Kozlov S.V. (Ekaterinburg).** Assessment of coronary blood flow in patients with non-STEMI and atrial fibrillation.
- **Gabinsky Ya.L., Shimkevich A.M., Leontieva N.A. (Ekaterinburg).** Efficacy and safety of reperfusion therapy for STEMI in elderly and middle-aged patients.
- **Vyshlov E.V., Avetisyan V.Yu., Krylov A.L., Garganeeva A.A., Markov V.A. (Tomsk).** Results of routine delayed PCI after successful thrombolysis in stabilized elderly patients with myocardial infarction.

CONFERENCE HALL 2

09.00–10.30

SYMPOSIUM

Athlete's heart: theoretical and practical aspects

Chairpersons: **Smolensky A.V. (Moscow)**,
Mikhailova A.V. (Moscow), **Shlyk N.I. (Udmurtia region)**

- **Smolensky A.V. (Moscow)**. Risk factors of athlete's heart electrical remodeling.
- **Mikhailova A.V. (Moscow)**. Heart remodeling in athletes with cardiovascular overexertion.
- **Makarov L.M., Fedina N.N. (Moscow)**. Heart rate variability in young elite athletes.
- **Shlyk N.I. (Udmurtia region)**. Heart rate variability analysis in training and competitive activities of skiing athletes.
- **Bondarev S.A. (Saint-Petersburg)**. Cloud technologies of ECG registration in the diagnosis of cardiac arrhythmias in athletes.

CONFERENCE HALL 3

09.00–10.30

SCHOOL ON DIABETES AND CARDIOVASCULAR DISEASE

Part I

Chairpersons: **Mamedov M.N. (Moscow)**,
Bubnova M.G. (Moscow), **Koshelskaya O.A. (Tomsk)**

- **Mamedov M.N. (Moscow)**. Diabetes mellitus – a new pandemic increasing risk of cardiovascular complications: meta-analysis of international studies.
- **Bubnova M.G. (Moscow)**. Diabetes mellitus and ischemic heart disease: atherothrombotic and metabolic specificities of food and exercise impact..
- **Koshelskaya O.A. (Tomsk)**. Statin therapy in patients with diabetes and metabolic disorders: are all problems solved?
- **Arabidze G.G. (Moscow)**. Effective therapy in patients with hypertension and type 2 diabetes at the current stage from the standpoint of evidence-based medicine.
- **Averin Y.E. (Moscow)**. Beyond the limits of guidelines: recent lessons in management of diabetes patients.

CONFERENCE HALL 4

09.00–10.30

SYMPOSIUM

To the 60th anniversary of presentation by P.E. Lukomsky and E.M. Tareev on origin and course of myocardial infarction

Chairpersons:

**Oganov R.G. (Moscow), Gratsiansky N.A. (Moscow),
Gordeev I.G. (Moscow)**

- **Oganov R.G. (Moscow).** Introduction
- **Shalnova S.A. (Moscow).** Epidemiology of myocardial infarction – Russia, 2016
- **Duplyakov D.V. (Samara).** Challenges of management organisation for patients with myocardial infarction in a large Russian region.
- **Gordeev I.G. (Moscow), Lebedeva A.Yu. (Moscow).** Challenges of management organisation for patients with myocardial infarction in a large municipal multispecialty hospital.
- **Erlikh A.D. (Moscow).** Management of patients with myocardial infarction in Russian hospitals. Data of RECORD registries.
- **Gratsiansky N.A. (Moscow).** Conclusion. Current problems detection and future development.

CONFERENCE HALL 4A

09.00–10.30

SECTION SESSIONS

Imaging in cardiology, computer technologies

Chairpersons:

Lishmanov Yu.B. (Tomsk), Ryzhkova D.V. (Saint-Petersburg)

- **Ripp T.M., Mordovin V.F., Semke G.V., Usov V.Yu., Ripp E.G., Popov S.V., Karpov R.S. (Tomsk).** New technologies of arterial reactivity assessment and classification in patients with hypertension.
- **Ardashev V.N., Melkumova E.Yu., Tarabarina N.B. (Moscow).** Heart and brain: cardiocerebral pathology in patients with ischemic stroke based on MRI and ECG Holter monitoring.

- **Gabinsky Ya.L., Stepin A.V., Mamontov D.A., Leschinskaya O.V. (Ekaterinburg).** CT for bypass patency assessment in early postoperative period.
- **Usov V.Yu., Bobrikova E.E., Bakhmetieva T.A., Lukyanenok P.I., Pushnikova E.Yu., Goltsov S.G., Aptekar V.D., Shelkovnikova T.A., Arkhangelsky V.A. (Tomsk, Moscow).** Paramagnetic contrast enhancement MRI of coronary artery atherosclerotic lesions.
- **Legkonogov A.V., Legkonogova L.G. (Simferopol).** Newly diagnosed congenital heart disease in adults and elderly patients: late diagnosis or echocardiographic findings?
- **Mazyrina M.V., Aretinsky V.B., Budkar L.N., Karpova E.A. (Ekaterinburg).** Results of CABG patients rehabilitation at a specialized medical rehabilitation stage (based on treadmill test).

CONFERENCE HALL 5

09.00–10.30

SYMPOSIUM

Non-invasive CAD diagnosis

(session of Echocardiography WG)

Chairpersons:

Matskeplishvili S.T. (Moscow), Surkova E. A. (Samara)

- **Duplyakov D.V. (Samara).** Diagnosis of stable CAD in Russia.
- **Matskeplishvili S.T. (Moscow).** Stress-echocardiography for CAD diagnosis.
- **Surkova E.A. (Samara).** Grant programmes for young cardiologists and cardiovascular imaging specialists.
- **Matskeplishvili S.T. (Moscow), Moroz-Vodolazhskaya N.N. (Belarus).** Interactive educational EACVI project on non-invasive diagnosis of CAD – EDUCAD.

CONFERENCE HALL 5A

09.00–10.30

SYMPOSIUM

Complicated issues of cardiovascular diseases in elderly patients

Chairpersons:

Tkacheva O.N. (Moscow), Kotovskaya Yu.V. (Moscow)

- **Akasheva D.U. (Moscow).** Anticoagulants in elderly patients: an expert opinion.
- **Kotovskaya Yu.V. (Moscow).** Treatment of hypertension in vulnerable elderly patients: an expert opinion.

CONFERENCE HALL 6

09.00–10.30

RUSSIAN-SERBIAN SYMPOSIUM

Innovations in interventional cardiology

Simultaneous translation

Chairpersons:

Kanjuh V. (Serbia), Shlyakhto E. (Saint-Petersburg)

- **Nedeljkovic M., Kanjuh V. (Serbia).** Future directions in TAVI, widening the indications
- **Imaev T. (Moscow).** TAVI after cardiac surgery.
- **Kanjuh V., Nedeljković M., Kanjuh S., Nedeljković J. (Serbia).** Holistic approach to the vulnerable patient with coronary athero- thrombosis.
- **Shugushuev Z. (Moscow).** Endovascular treatment of ACS patients with left main coronary artery lesion.

CONFERENCE HALL 7

09.00–10.30

SCHOOL

Hot issues in atrial fibrillation treatment

Part I

Chairpersons:

Saiganov S.A. (Saint-Petersburg), Ardashev A.V. (Moscow)

- **Ardashev A.V. (Moscow).** Current problems in atrial fibrillation treatment. Modern medical and interventional strategies.
- **Saiganov S.A. (Saint-Petersburg).** Atrial fibrillation in patients with myocardial infarction.
- **Zotova I.V. (Moscow).** Implementation of current guidelines into clinical practice. Clinical protocol of AF patients management.

CONFERENCE HALL 8

09.00–10.30

WORKING GROUP YOUNG CARDIOLOGISTS – FROM BENCH TO BEDSIDE

Chairpersons:

**Chernova A.A. (Krasnoyarsk), Efremova E.V. (Ulyanovsk),
Garkina S.V. (Saint- Petersburg).**

- **Shepel R.N. (Moscow).** Global trends in obesity epidemiology.
- **Ankudinov A.A. (Irkutsk).** Chronic heart failure and joint disease: assessment of comorbid status.
- **Kercheva M.A. (Tomsk).** Tomsk regional branch of Young Cardiologists Working Group. Research areas, projects and ideas for development.
- **Lyakhovets E. G. (Saint-Petersburg).** Red cell distribution width as a potential new marker of heart failure acute decompensation.
- **Efremova E.V. (Ulyanovsk).** The Ulyanovsk regional branch of RSC. The problem of comorbidity in a cardiologist's practice.
- **Semenova E.V., Chindareva O.I., Loginova E.N., Drokina O.V. (Omsk).** The Omsk Young Cardiologists: Connective tissue dysplasia: clinical presentation, mechanisms of development, morpho-functional and molecular genetic, diagnostic and prognostic criteria, technologies of treatment and prevention.

- **Benimetskaya K.S., Kozik V.A., Batluk. T.I. (Novosibirsk).**
The Novosibirsk Young Cardiologists: pending problems in lipidology.
- **Belan I.A., Barbuhatti K.O., Porkhanov V.A. (Krasnodar).**
Young Cardiologists of the Krasnodar region. Surgical myocardial revascularization. Practical issues and clinical experience.
- **Chugunova Yu.V. (Barnaul).** Young cardiologists of the Altai region – achievements and prospects.

PLENARY SESSION HALL

11.00–12.30

PLENARY SESSION

Coronary heart disease, lipids and atherosclerosis

Online broadcasting | Simultaneous translation

Chairpersons:

**Oganov R.O. (Moscow), Kukharchuk V.V. (Moscow),
Karpov Yu.A. (Moscow)**

- **Karpov Yu.A. (Moscow).** What changes are necessary in the new Russian guidelines for diagnosis and treatment of stable CAD.
- **Gilard M. (France).** Management of double antiplatelet therapy.
- **Ezhov M.V. (Moscow).** Guidelines 2016 on prevention of cardiovascular complications (ESC/EAS) and non-statin lipid-lowering therapy (AHA/ACC): what to use?
- **Laanmets P. (Estonia).** Rationale of CTO revascularization. Personal Experience – CTO programme in North-Estonia Medical Centre. Discussion.

CONFERENCE HALL 1

11.00–12.30

SYMPOSIUM

Prevention of cardiovascular diseases: experience of Russian regions

Chairpersons:

Shalnova S.A. (Moscow), Yakushin S.S. (Ryazan)

- **Drozdova L.Yu. (Moscow), Kalinina A.M. (Moscow).** Prevention of cardiovascular diseases in primary health care: state of the art.
- **Yakushin S.S. (Ryazan), Filippov E.V. (Ryazan).** Targeted prevention programme in the Ryazan region: mistakes and achievements.
- **Duplyakov D.V., Khokhlunov S.M., Kislukhin T.V. (Samara).** Act Fast! Save a Life! – prevention programme in the Samara region (within Stent for Life).
- **Trubacheva I.A., Serebryakova V.N., Kaveshnikov V.S., Karpov R.S. (Tomsk).** Prevention of cardiovascular diseases in the Tomsk region: what has been done.
- **Glukhovskaya S.V., Alasheev A.M. (Ekaterinburg).** Regional project in the Sverdlovsk region «Stop the Stroke!» Prevention and justified expectations.

CONFERENCE HALL 1A

11.00–12.30

SECTION SESSION

Emergency cardiology Part II

Chairpersons:

Tavlyeva E.V. (Kemerovo), Erlikh A.D. (Moscow)

- **Tkachenko K.G., Erlich A.D. (Moscow).** Treatment and long-term outcomes of ACS associated with AF in patients hospitalized in the «non-invasive» hospital.
- **Kozlov S.V., Dmitriev V.K., Lipchenko A.A., Fokina E., Drozd A. (Ekaterinburg).** Clinical case of a generalized catheter-induced aortic dissection during rescue PCI for failed pre-hospital thrombolytic therapy in a STEMI patient.

- **Kozhokar K.G., Urvantseva I.A., Nikolaev K.Yu. (Surgut).** Correlation of non-conventional risk factors with the severity of ACS in patients living in the North.
- **Islamova S.V., Babushkina G.V. (Ufa).** A 6 months follow-up study of statin effect on the degree of carotid stenosis in patients with ACS.
- **Repin A.N. (Tomsk).** Experience of organization and introduction of modern ACS treatment technologies in the Tomsk region.
- **Muromkina A.V., Belova O.A., Kachkina O.A., Nazarova O.A. (Ivanovo).** Analysis of emergency care tactics in atrial fibrillation.
- **Fedorova N.V., Kashtalap V.V., Barbarash O.L. (Kemerovo).** Assessment of a year-long prognosis with galectin-3 in STEMI patients.
- **Nikolaeva T.O., Anikin V.V., Izvarina O.A. (Tver).** Myocardial infarction: mortality causes.

CONFERENCE HALL 2

11.00–12.30

EXPERTS' MEETING

Inflammatory heart diseases

Chairpersons:

Demin A.A. (Novosibirsk), Reznik I.I. (Ekaterinburg), Tyurin V.P. (Moscow)

- **Demin A.A. (Novosibirsk).** Inflammatory heart disease: changing guidelines.
- **Reznik I.I. (Ekaterinburg).** Infective endocarditis and surgery.
- **Tyurin V.P. (Moscow).** Inflammatory heart diseases in daily practice.
- **Kogmasheva V.V. (Ekaterinburg).** Diagnosis of pericarditis in view of European Guidelines 2015.

CONFERENCE HALL 3

11.00–12.30

SCHOOL ON DIABETES AND CARDIOVASCULAR DISEASES

Part II

Chairpersons:

Aronov D.M. (Moscow), Mamedov M.N. (Moscow)

- **Abdalkina E.N. (Samara).** The therapy of patients with diabetes mellitus 2 type and cardiovascular diseases: how to make the right choice.
- **Falkovskaya A.Yu. (Tomsk).** Cerebroprotective efficacy and safety of medical and endovascular treatment in patients with type 2 diabetes.
- **Mardanov B.U. (Moscow).** Diabetes mellitus and chronic heart failure: from guidelines to clinical practice.
- **Aronov D.M. (Moscow).** Aspects of cardiorehabilitation in diabetic patients after acute myocardial infarction.

CONFERENCE HALL 4

11.00–12.30

SYMPOSIUM

Restrictive and unclassified cardiomyopathies in clinical practice

Chairpersons:

Drapkina O.M. (Moscow), Koretsky S.N. (Moscow)

- **Drapkina O.M. (Moscow).** Medical detective. Cardiac amyloidosis in clinical practice.
- **Myasnikov R.P., Mazygula E.P., Boitsov S.A. (Moscow).** Controversies in diagnosis of cardiomyopathes.
- **Koretsky S.N. (Moscow).** Multimodal imaging of restrictive and unclassified cardiomyopathies. Diastolic dysfunction in myocardial injury.

CONFERENCE HALL 4A

11.00–12.30

SYMPOSIUM

Obstructive sleep apnea: new diagnostic approaches, known complications and long-term effects

Chairpersons:

**Kalinkin A.L. (Moscow), Agaltsov M.V. (Moscow),
Sviryaev Y.V. (Saint Petersburg)**

- **Kalinkin A.L. (Moscow).** New screening method of obstructive sleep apnea diagnosis.
- **Bochkarev M.V. (Saint Petersburg), Tomskikh A. S. (Saint Petersburg), Yakushenko E.S., Korostovtseva L.S., Sviryaev Yu.V., Tikhonenko M.V. (Saint Petersburg).** Actigraphy for sleep assessment in out-patient monitoring of physiological parameters.
- **Agaltsov M.V. (Moscow).** Arrhythmogenesis specificities in patients with sleep-disordered breathing.
- **Sviryaev Yu.V., Semenov A.P., Bochkarev M.V., Korostovtseva L.S. (Saint-Petersburg).** Prevalence of sleep-disordered breathing in patients with conductive heart disturbances: retrospective analysis.
- **Renko I.E. (Penza).** Poorer prognosis for patients with obstructive sleep apnea after pacemaker implantation.

CONFERENCE HALL 5

11.00–12.30

CARDIO-JEOPARDY INTERACTIVE QUIZ ON CARDIOVASCULAR IMAGING

Moderator:

Matskeplishvili S.T. (Moscow).

CONFERENCE HALL 5A

11.00–12.30

SYMPOSIUM

Accelerated ageing in chronic obstructive pulmonary disease and cardiovascular disorders. Is there the Makropulos secret?

Chairperson:

Zadionchenko V.S. (Moscow)

- **Zadionchenko V.S. (Moscow).** Theories of ageing. Chronic obstructive pulmonary disease and cardiovascular disorders as a universal model of accelerated ageing.
- **Li V.V. (Moscow).** Systemic inflammation as a key element of vascular ageing.
- **Adasheva T. (Moscow).** Is there the Makropulos secret?
Current anti-inflammatory strategies for chronic obstructive pulmonary disease and cardiovascular disorders.

CONFERENCE HALL 6

11.00–12.30

SCIENTIFIC SESSION

Microcirculation in cardiology

Chairpersons:

Soboleva G.N. (Moscow), Ryzhkova D.V. (Saint-Petersburg)

- **Soboleva G. (Moscow).** Microcirculation vascular tone regulation: mechanisms and significance in clinical cardiology.
- **Ryzhkova D.V. (Saint-Petersburg).** PET in an assessment of myocardial microcirculation in patients with cardiovascular diseases.
- **Fedorovich A.A., Boiko V.V. (Moscow).** Laser Doppler floumetry in a microcirculation assessment in coronary artery disease and arterial hypertension.
- **Karpova I.E., Soboleva G.N., Karpov Yu.A. (Moscow).** Effects of antianginal agents on microcirculation vascular tone in patients with microvascular angina.

CONFERENCE HALL 7

11.00–12.30

SCHOOL

Hot issues in atrial fibrillation treatment

Part II

Chairpersons:

Saiganov S.A. (Saint-Petersburg), Ardashev A.V. (Moscow)

- **Ardashev A.A. (Moscow).** Combined approaches in management of patients with AF in complicated clinical situations: end-stage HF, chronic AF, cordarone-induced hyperthyroidism, Frederick syndrome. Clinical cases.
- **Zotova I.V. (Moscow).** A patient with atrial fibrillation and ACS.
- **Knigin A.V. (Moscow).** When is endovascular closure of left atrial appendage in patients with AF preferable to medical prevention of thromboembolic complications?

CONFERENCE HALL 8

11.00–12.30

SECTION SESSION

Arrhythmology, stimulation and resynchronization

Part II

Chairpersons:

Shaposhnik I.I. (Chelyabinsk), Zakirova A.N. (Ufa)

- **Galyautdinov G.S., Lonkin M.A. (Kazan).** Gender differences in assessing quality of life and cognitive function in patients with atrial fibrillation.
- **Adzhigitov A.Yu., Chichkova M.A., Frolkova A.B., Kadiev G.M., Orlov F.V. (Astrakhan).** Predicted stability of hemodynamics in patients with CAD and implanted pacemaker in critical condition of ischemic stroke.
- **Kuznetsov V.A., Todosiychuk V.V., Kutrunov V.N., Dyachkov S.M. (Tyumen).** Predicting risk of ventricular high grade arrhythmias in patients referred to coronary angiography with neural circuitry.
- **Legkonogov A.V., Sokolovskaya E.A. (Simferopol).** Heart rate variability, dispersion of ECG Q-T interval and ventricular arrhythmias in different types of myocardial remodeling.

- **Novikova T.N., Kiseleva M.V., Chupik M.A. (Saint-Petersburg).** Anticoagulant therapy with non-valvular atrial fibrillation in clinical practice.
- **Opolonsky D.V., Maksimov N.I., Luzhevskaya K.S., Bekhtereva S.V., Opolonskaya P.E. (Izhevsk).** Variability of R-R interval of electrocardiogram as a predictor of ischemic stroke in patients with atrial fibrillation.
- **Dolginina S.I., Soldatkina I.P., Khokhlunov S.M., Rubanenko A.O., Scherbakova L.A. (Samara).** Optimization of selection of patients with atrial fibrillation for interventional treatment.

PLENARY SESSION HALL

13.30–15.00

PLENARY SESSION

Cardiology 2016 – a view into the future

Online broadcasting | Simultaneous translation

Chairpersons:

Shlyakhto E. V. (Saint-Petersburg), Luscher T. (Switzerland)

- **Luscher T. (Switzerland).** Highlights of cardiology 2016.
- **Berkinbaev S.F., Dzhunusbekova G.A., Musagalieva A.T., Tundybaeva M.K., Daniyarova L.B. (Kazakhstan).** Epidemiological monitoring of cardiovascular diseases, risk factors and comorbid pathologies.
- **Nedogoda S.V. (Volgograd).** Results of 2015 in arterial hypertension: new paradigms or reasons for discussion.
- **Aronov D. M., Barbarash O.L., Bubnova M.G. (Moscow, Kemerovo).** Presentation of Russian clinical guidelines on CABG for CAD patients: rehabilitation and secondary prevention.
- **Vasyuk Yu.A., Shupenina E.Yu. (Moscow).** Open questions and new opportunities in diagnosis of HF with preserved left ventricular ejection.



CONGRESS GENERAL PARTNERS



CONGRESS PARTNERS



GENERAL MEDIA PARTNER



ИНТЕРНЕТ СЕССИЯ

ВСЕРОССИЙСКАЯ ОБРАЗОВАТЕЛЬНАЯ ПРОГРАММА ДЛЯ ВРАЧЕЙ

MEDIA PARTNERS

Доктор.Ру
МЕДИЦИНСКИЙ ЖУРНАЛ

КАРДИОЛОГИЯ



МЕДИА
СФЕРА



MEDIAMEDICA

 МЕДФОРУМ

журнал
Поликлиника
научно-практический журнал для специалистов
в области общей практики


РЕМЕДИУМ
ГРУППА КОМПАНИЙ



РФК Рациональная
Фармакотерапия
в Кардиологии

EXHIBITORS



Филиал Томского НИМЦ
Тюменский
кардиологический
научный центр



ЧЕЛЯБИНСКАЯ ОБЛАСТЬ



BPlab®

Grindex





ПРЕДОТВРАЩАЕТ БОЛЬШЕ
СЕРДЕЧНО-СОСУДИСТЫХ СМЕРТЕЙ
У ПАЦИЕНТОВ С ИМ, ЧЕМ КЛОПИДОГРЕЛ¹

AstraZeneca 



Прадакса® – лучшая защита от инсульта, которой Вы можете доверять*1-6

Прадакса® – единственный НОАК,
профиль безопасности которого
подтвержден в независимом
исследовании FDA (>134 000
пациентов)²

Прадакса® 150 мг – единственный
НОАК, превзошедший варфарин
в снижении риска ишемического
инсульта¹

*снижение риска ишемического инсульта у пациентов с фибрилляцией предсердий
НОАК – новый оральные антикоагулянты

FDA – Food and Drug Administration – управление по контролю за продуктами и лекарствами
Министерства здравоохранения США

«У меня много планов. Инсульт в них не входит»

Литература:

1. Connolly SJ et al. N Engl J Med 2009;361:1139-1151; Connolly SJ et al. N Engl J Med 2010;363:1875-1876. 2. Graham DJ et al. Circulation 2014; doi: 10.1161/CIRCULATIONAHA.114.012061. 3. Seeger JD et al. Presented at AHA 2014; Villines TC et al. Presented at AHA 2014. 4. Larsen TB et al. Am J Med 2014;127-329-336. doi: 10.1016/j.amjmed.2013.12.005. 6. Eizekovitz M. et al. Presentation # 1068at AHA Scientific sessions; 16-20 Nov 2013; Dallas; available at <http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mid=3281&key=dddc5c9e-416b-4e7b-ba5f-336b6a928665&key=c281570-0c15-40b3-a538-e0b2e8f810>

Краткая инструкция по применению лекарственного препарата для медицинского применения Прадакса® (Pradaxa®)

Регистрационный номер: ЛСР-007065/09 (для дозировок 75 мг и 110 мг); ЛП-000872 (для дозировки 150 мг). МНН: дабигатрана этексилат. Лекарственная форма: капсулы. Состав: одна капсула содержит 86,48 мг, 126,83 мг или 172,95 мг дабигатрана этексилата мезилата, что соответствует 75 мг, 110 мг или 150 мг дабигатрана этексилата. Показания: профилактика венозных тромбозов и инсульта, системных тромбозов и снижение сердечно-сосудистой смертности у пациентов с фибрилляцией предсердий; лечение острого тромбоза глубоких вен (ПГВ) и/или тромбозов легочной артерии (ПЛА) и профилактика смертельных исходов, вызываемых этими заболеваниями; профилактика рецидивирующего тромбоза глубоких вен (ПГВ) и/или тромбозов легочной артерии (ПЛА) и смертельных исходов, вызываемых этими заболеваниями. Противопоказания: известная гиперчувствительность к дабигатрану, дабигатрана этексилату или к любому из вспомогательных веществ; тяжелая степень почечной недостаточности (КК менее 30 мл/мин); активное клинически значимое кровотечение, геморрагический диатез, спонтанное или фармакологически индуцированное нарушение гемостаза; поражение органов в результате клинически значимого кровотечения, включая геморрагический инсульт в течение 6 месяцев до начала терапии; существенный риск развития большого кровотечения из имеющегося или недавнего изъязвления ЖКТ, наличие злокачественных образований с высоким риском кровотечения, недавнее повреждение головного или спинного мозга, недавняя операция на головном или спинном мозге или ортотомическая операция, недавнее внутричерепное кровоизлияние, наличие или подозрение на варикозно-расширенные вены пищевода, врожденные артериовенозные дефекты, сосудистые аневризмы или большие внутриполостные или внутриорганные сосудистые нарушения; одновременное назначение любых других антикоагулянтов, в том числе

нефракционированного гепарина, низкомолекулярных гепаринов (НМГ) (эноксапарин, далтепарин и др.), производных гепарина (фондапаринукс и др.), пероральных антикоагулянтов (варфарин, ривароксабан, апиксабан и др.), за исключением случаев перехода лечения с или на препарат ПРАДАКСА или в случае применения нефракционированного гепарина в дозах, необходимых для поддержания центрального венозного или артериального катетера; одновременное назначение кетоконазола для системного применения, циклоспорина, итраконазола, таколимуза и дронадрона; нарушения функции печени и заболевания печени, которые могут повлиять на выживаемость; наличие протезированного клапана сердца; возраст до 18 лет (клинические данные отсутствуют). Способ применения и дозы: капсулы следует принимать внутрь 1 или 2 раза в день (в зависимости от показаний) независимо от времени приема пищи, запивая стаканом воды для облегчения прохождения препарата в желудок. Не следует вскрывать капсулы. Особые указания при изъятии капсул из блистера: оторвите один индивидуальный блистер от блистер-упаковки по линии perforации; выньте капсулу из блистера, отставив фольгу; не выдавливайте капсулы через фольгу. Побочное действие: побочные эффекты, выявленные при применении препарата с целью профилактики ИТБЗ после ортопедических операций; для профилактики инсульта и системных тромбозов у пациентов с фибрилляцией предсердий; для лечения острого тромбоза глубоких вен (ПГВ) и/или тромбозов легочной артерии (ПЛА) и профилактики смертельных исходов, вызываемых этими заболеваниями; для профилактики рецидивирующего тромбоза глубоких вен (ПГВ) и/или тромбозов легочной артерии (ПЛА) и смертельных исходов, вызываемых этими заболеваниями. Частот (от 1/100 до 1/10 случаев): анемия, носовое кровотечение, желудочно-кишечные кровотечения, ректальные кровотечения, боль в животе, диарея, диспепсия, тошнота, нарушение функции печени, кожный

геморрагический синдром, ургентные/геморрагические кровотечения, гематурия. Перечень всех побочных эффектов представлен в инструкции по медицинскому применению. Особые указания: риск развития кровотечения. Применение препарата ПРАДАКСА, так же как и других антикоагулянтов, рекомендуется с осторожностью при состояниях, характеризующихся повышенным риском кровотечения. Во время терапии препаратом ПРАДАКСА возможно развитие кровотечений различной локализации. Снижение концентрации гемоглобина и/или гематокрита в крови, сопровождающееся снижением АД, является основанием для поиска источника кровотечения. Лечение препаратом ПРАДАКСА не требует контроля антикоагулянтной активности. Тест для определения МНО применяться не должен, поскольку есть данные о ложном завышении уровня МНО. Для выявления чрезмерной антикоагулянтной активности дабигатрана следует использовать тесты для определения тромбинового или экранного времени свертывания. В случае, когда эти тесты недоступны, следует использовать тест для определения АЧТВ. В исследовании RELY у пациентов с фибрилляцией предсердий превышение уровня АЧТВ в 2-3 раза выше границы нормы перед приемом очередной дозы препарата было ассоциировано с повышенным риском кровотечения. Условия хранения: в сухом месте, при температуре не выше 25 °С. Хранить в недоступном для детей месте. Срок годности: 3 года. Полная информация представлена в инструкции по медицинскому применению.

150 мг 2 раза в день

Прадакса®
дабигатрана этексилат

Защита от инсульта, подтвержденная практикой®



Доверие препаратам KRKA –
это доверие передовым технологиям
и высокому Европейскому качеству⁽¹⁾

КО-ДАЛЬНЕВА®

амлодипин, индапамид, периндоприл
таблетки

5 мг/0,625 мг/2 мг 5 мг/1,25 мг/4 мг
5 мг/2,5 мг/8 мг 10 мг/2,5 мг/8 мг

Синергия тройной силы



ДАЛЬНЕВА®

амлодипин и периндоприл
таблетки

5 мг/4 мг 10 мг/4 мг
5 мг/8 мг 10 мг/8 мг

Синергия двойной силы



Дальнева®

Показания к применению: артериальная гипертензия и/или ишемическая болезнь сердца: стабильная стенокардия напряжения у пациентов, которым требуется терапия периндоприлом и амлодипином. **Способ применения и дозы:** внутрь, по одной таблетке 1 раз в день, предпочтительно утром перед приемом пищи. Доза препарата Дальнева® подбирается после ранее проведенного титрования доз отдельных компонентов препарата: периндоприла и амлодипина у пациентов с артериальной гипертензией и стабильной стенокардией. Максимальная суточная доза: амлодипин 10 мг + периндоприл 8 мг. **Условия отпуска из аптек:** по рецепту. **Форма выпуска:** таблетки 5 мг + 4 мг, 10 мг + 4 мг, 5 мг + 8 мг, 10 мг + 8 мг по 30 таблеток.

Ко-Дальнева®

Показания к применению: артериальная гипертензия (при необходимости одновременной терапии амлодипином, индапамидом и периндоприлом в дозах, применяемых в монотерапии отдельных компонентов).

Способ применения и дозы: внутрь, по одной таблетке 1 раз в день, предпочтительно утром перед приемом пищи. Доза препарата Ко-Дальнева® подбирается после ранее проведенного титрования доз отдельных активных компонентов препарата. Максимальная суточная доза препарата Ко-Дальнева® составляет 10 мг амлодипина + 2,5 мг индапамида + 8 мг периндоприла. **Условия отпуска из аптек:** по рецепту. **Форма выпуска:** таблетки 5 мг + 0,625 мг + 2 мг, 5 мг + 1,25 мг + 4 мг, 5 мг + 2,5 мг + 8 мг, 10 мг + 2,5 мг + 8 мг по 30 таблеток.

1. Собственные данные компании KRKA, Ново Место, Словения, 2016 г.

Информация предназначена для медицинских
и фармацевтических работников.

Заказчик размещения рекламы ООО «КРКА ФАРМА»
РФ, 125212, г. Москва, Головинское шоссе, д. 5, корп. 1.
Тел.: (495) 981 1095, факс (495) 981 1091
E-mail: info@krka.ru, www.krka.ru



Наши инновации и опыт –
залог эффективных
и безопасных препаратов
высочайшего качества.

ГОРДОСТЬ ВРАЧА — СПАСЕННЫЕ ЖИЗНИ



**ТАБЛЕТКА
РАЗ В ДЕНЬ
ГОД**

Плавикс® / Коплавикс®

♥ **Универсальный антиагрегант при любой стратегии лечения ОКС^{1,2}**
♥ **Двойная защита от повторного сердечно-сосудистого события²**

¹ CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with Acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345: 494–502.

² Sabatine M, et al. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. N Engl J Med. 2005; 352: 1179–1189.

Плавикс®. МЕЖДУНАРОДНОЕ НЕПАТЕНТОВАННОЕ НАЗВАНИЕ. Клопидогрел. **ДЕЙСТВУЮЩЕЕ ВЕЩЕСТВО.** Клопидогрел гидрохлорид в форме II. **ФАРМАКОТЕРАПЕВТИЧЕСКАЯ ГРУППА:** антиагрегантное средство. Код АТХ: B01AC06. **ЛЕКАРСТВЕННАЯ ФОРМА.** Таблетки, покрытые пленочной оболочкой. В 1 таблетке содержится действующее вещество: клопидогрел гидрохлорид в форме II — 90/875 мг (в пересчете на клопидогрел — 75,0 мг) и вспомогательные вещества. **ФАРМАКОДИНАМИЧЕСКИЕ СВОЙСТВА.** Клопидогрел представляет собой пролекарство, одним из активных метаболитов которого является ингибитор агрегации тромбоцитов. Активный метаболит клопидогрела селективно ингибирует связывание ADP с P2Y₁₂-рецепторами тромбоцитов и последующую ADP-опосредованную активацию комплекса GPIIb/IIIa, приводя к подавлению агрегации тромбоцитов. **ПОКАЗАНИЯ К ПРИМЕНЕНИЮ.** Предотвращение атеротромботических и тромбоэмболических осложнений при фибрилляции предсердий. **ПРОТИВОПОКАЗАНИЯ.** Повышенная чувствительность к клопидогрелу или любому из вспомогательных веществ препарата; тяжелая печеночная недостаточность; острое кровотечение, например кровотечение из желудочно-кишечного тракта или внутримозговое кровоизлияние; редкая наследственная непереносимость галактозы, дефицит лактазы и глюкозо-галактозная мальабсорбция; беременность и период грудного вскармливания; детский возраст до 18 лет. **БЕЗОПАСНОСТЬ.** Не рекомендуется прием клопидогрела во время беременности, за исключением тех случаев, когда, по мнению врача, его применение настоятельно необходимо. **ПЕРИОД КОМБИНИРОВАННОГО ПРИМЕНЕНИЯ.** Печеночная недостаточность, тяжелая почечная недостаточность, острое кровотечение, брадикардия, диарея. Для ознакомления с побочными эффектами, возникающими нечасто, редко и очень редко, ознакомьтесь с официальной инструкцией по медицинскому применению лекарственного препарата. **СПОСОБ ПРИМЕНЕНИЯ И ДОЗЫ.** Клопидогрел следует принимать внутрь, независимо от приема пищи. Инфаркт миокарда, ишемический инсульт и дислоцированная окклюзионная болезнь периферических артерий: препарат принимается по 75 мг 1 раз в сутки. Острый коронарный синдром без подъема сегмента ST: лечение клопидогрелом должно быть начато с однократного приема нагрузочной дозы, составляющей 300 мг, а затем продолжено приемом дозы 75 мг 1 раз в сутки (в сочетании с ацетилсалициловой кислотой в дозах 75–325 мг в сутки). Острый коронарный синдром с подъемом сегмента ST: клопидогрел следует принимать однократно в сутки в дозе 75 мг с первоначальным однократным приемом нагрузочной дозы клопидогрела 300 мг в комбинации с ацетилсалициловой кислотой в сочетании с тромболитиками или без сочетания с тромболитиками. У пациентов старше 75 лет лечение клопидогрелом должно начинаться без приема его нагрузочной дозы. **ПОБОЧНОЕ ДЕЙСТВИЕ.** Кровотечения и кровоизлияния; нарушения со стороны крови; диспепсия, абдоминальные боли, диарея. Для ознакомления с побочными эффектами, возникающими нечасто, редко и очень редко, ознакомьтесь с официальной инструкцией по медицинскому применению лекарственного препарата. **ПЕРЕДОЗИРОВАНИЕ.** При появлении кровотечения требуется проведение соответствующих лечебных мероприятий. Антитид клопидогрела не установлен. Если необходима быстрая коррекция удлиненного времени кровотечения, то рекомендуется проведение переливания тромбоцитарной массы. **ФОРМА ВЫПУСКА.** Таблетки, покрытые пленочной оболочкой, 75 мг. По 7, 10 или 14 таблеток в блистер из ПВХ/ПВХ и фольги алюминиевой или ПВХ/ПВХ и фольги алюминиевой. По 2, 2 или 3 блистера по 10 или 14 таблеток по 1, 2, 3 или 10 блистеров по 10 таблеток вместе с инструкцией по применению в картонную пачку. **УСЛОВИЯ ХРАНЕНИЯ.** Хранить при температуре не выше 30 °С. Хранить в недоступном для детей месте. **СРОК ГОДНОСТИ.** 3 года. **УСЛОВИЯ ОТПУСКА.** Отпускается по рецепту. **РЕГИСТРАЦИОННЫЙ НОМЕР.** П N 0155-02/01. Дата регистрации 15.03.2003. Дата последних изменений 15.05.2015. С подробной информацией о препарате можно ознакомиться в официальной инструкции по медицинскому применению лекарственного препарата.

Коплавикс®. МЕЖДУНАРОДНОЕ НЕПАТЕНТОВАННОЕ НАЗВАНИЕ. Ацетилсалициловая кислота + клопидогрел. **ДЕЙСТВУЮЩЕЕ ВЕЩЕСТВО.** Клопидогрел гидрохлорид в форме II, ацетилсалициловая кислота. **ФАРМАКОТЕРАПЕВТИЧЕСКАЯ ГРУППА:** антиагрегантное средство. Код АТХ: B01AC06. **ЛЕКАРСТВЕННАЯ ФОРМА.** Таблетки, покрытые пленочной оболочкой. **ФАРМАКОДИНАМИЧЕСКИЕ СВОЙСТВА.** Клопидогрел представляет собой пролекарство, одним из активных метаболитов которого является ингибитор агрегации тромбоцитов. Его активный метаболит неабсолютно связывается с тромбоцитарными ADP-рецепторами (рецепторами аденозиндифосфата) и селективно ингибирует связывание ADP с ADP-рецепторами тромбоцитов и последующую активацию комплекса GPIIb/IIIa под действием ADP, благодаря чему подавляется ADP-индуцируемая агрегация тромбоцитов. Ацетилсалициловая кислота (АСК) подавляет агрегацию тромбоцитов за счет необратимого ингибирования простациклиногенеза и в результате этого уменьшения образования тромбоксана A₂. **ПОКАЗАНИЯ К ПРИМЕНЕНИЮ.** Показан для применения у пациентов, которые уже получают одновременно клопидогрел и ацетилсалициловую кислоту. Предотвращение атеротромботических и тромбоэмболических осложнений при фибрилляции предсердий. **ПРОТИВОПОКАЗАНИЯ.** Повышенная чувствительность к любому из компонентов веществ препарата; тяжелая печеночная недостаточность, тяжелая почечная недостаточность, острое кровотечение, брадикардия, диарея, индукция приемам саллицилатов и других нестероидных противовоспалительных препаратов (НПВП), синдром бронхальной астмы, ринита и рецидивирующего полипоза носа и околоносовых пазух, гиперчувствительность к НПВП, астматическое, редкие наследственные состояния: непереносимость галактозы, непереносимость лактозы вследствие дефицита лактазы, синдром мальабсорбции глюкозы-галактозы, беременность и период грудного вскармливания; детский возраст до 18 лет. **БЕЗОПАСНОСТЬ.** В качестве меры предосторожности препарат Коплавикс® не следует принимать в течение первых двух триместров беременности, за исключением случаев, когда клиническое состояние женщины требует лечения клопидогрелом в комбинации с АСК. В связи с наличием в составе препарата АСК он противопоказан в 3-м триместре беременности. **ПЕРИОД КОМБИНИРОВАННОГО ПРИМЕНЕНИЯ.** Грудное вскармливание в случае лечения препаратом Коплавикс® следует прекратить. **СПОСОБ ПРИМЕНЕНИЯ И ДОЗЫ.** Препарат Коплавикс® следует принимать 1 раз в сутки вне зависимости от приема пищи. Острый коронарный синдром (ОКС): прием препарата Коплавикс® начинают после однократной нагрузочной дозы клопидогрела в комбинации с АСК в виде отдельных препаратов, а именно: клопидогрел в дозе 300 мг и АСК в дозах 75–325 мг в сутки. Фибрилляция предсердий: препарат Коплавикс® следует принимать 1 раз в сутки после начала лечения клопидогрелом 75 мг и АСК 100 мг в виде отдельных препаратов. **ПОБОЧНОЕ ДЕЙСТВИЕ.** Кровотечения и кровоизлияния; желудочно-кишечные кровотечения, диспепсия, абдоминальные боли, диарея. Для ознакомления с побочными эффектами, возникающими нечасто, редко и очень редко, ознакомьтесь с официальной инструкцией по медицинскому применению лекарственного препарата. **ПЕРЕДОЗИРОВАНИЕ.** При появлении кровотечения требуется проведение соответствующего лечения. Антитид клопидогрела не установлен. Если необходима быстрая коррекция удлиненного времени кровотечения, то рекомендуется переливание тромбоцитарной массы. При выявлении симптомов тяжелой передозировки АСК требуется госпитализация. При умеренной интоксикации можно попытаться искусственно вызвать рвоту, в случае неудачи промыть желудок. **ФОРМА ВЫПУСКА.** По 7 таблеток в ПВХ/ПВХ/Алюминиевый блистер. По 2, 2 или 4 блистера вместе с инструкцией по применению в картонную пачку. По 10 таблеток в ПВХ/ПВХ/Алюминиевый блистер. По 10 блистерам вместе с инструкцией по применению в картонную пачку. **УСЛОВИЯ ХРАНЕНИЯ.** Хранить при температуре не выше 25 °С. Хранить в недоступном для детей месте. **СРОК ГОДНОСТИ.** 2 года. **УСЛОВИЯ ОТПУСКА.** Отпускается по рецепту. **РЕГИСТРАЦИОННЫЙ НОМЕР.** ЛП-001615. Дата регистрации 15.12.2014. Дата последних изменений 25.02.2016. С подробной информацией о препарате можно ознакомиться в официальной инструкции по медицинскому применению лекарственного препарата.

Представительство АО «Санofi-авентис групп» (Франция).

125009, Москва, ул. Тверская, 22. Тел.: (495) 721-14-00, факс: (495) 721-14-11, www.sanofi.ru

Материал предназначен для медицинских (фармацевтических) работников.

С ПОДРОБНОЙ ИНФОРМАЦИЕЙ О ПРЕПАРАТЕ МОЖНО ОЗНАКОМИТЬСЯ В ИНСТРУКЦИИ ПО МЕДИЦИНСКОМУ ПРИМЕНЕНИЮ.

Реклама.



1 ТАБЛЕТКА В ДЕНЬ

Тел.: +7 495 937 0700; факс: +7 495 937 0701

[illegible]



МОЩНЫЙ СОЮЗ

ДЛЯ СНИЖЕНИЯ АД
В ТЕЧЕНИЕ 24 ЧАСОВ^{1, 2}

**АЗИЛСАРТАН
ПРЕВОСХОДИТ
ДРУГИЕ САРТАНЫ*
В АНТИГИПЕРТЕНЗИВНОМ
ЭФФЕКТЕ^{3, 4}**

**ХЛОРТАЛИДОН
ИМЕЕТ ОБШИРНУЮ
ДОКАЗАТЕЛЬНУЮ
БАЗУ⁵⁻⁹**

**ПО СНИЖЕНИЮ
РИСКА ССО**
У ПАЦИЕНТОВ С АГ**



Эдарби® Кло
азилсартана медоксомил + хлорталидон

МОЩНЫЙ СОЮЗ

Реклама

Сокращённая информация по применению

Торговое название: Эдарби® Кло. **МНН или группировочное название:** азилсартана медоксомил + хлорталидон. **Лекарственная форма:** таблетки, покрытые плёночной оболочкой 40 мг + 12,5 мг; 40 мг + 25 мг. **Показания к применению:** эссенциальная гипертензия (пациентам, которым показана комбинированная терапия). **Противопоказания:** повышенная чувствительность к активным веществам и другим компонентам препарата. Рефрактерная гипотензия. Анурия. Беременность и период грудного вскармливания. Одновременный приём алискирена и алискиренсодержащих препаратов у пациентов с сахарным диабетом или умеренным или тяжёлым нарушениями функции почек. Тяжёлые формы сахарного диабета. Возраст до 18 лет. Нарушения функции печени тяжёлой степени. Печеночная недостаточность тяжёлой степени. **Способ применения и дозы:** препарат Эдарби® Кло принимают внутрь один раз в сутки независимо от времени приёма пищи. Рекомендованная начальная доза препарата Эдарби® Кло составляет 40 мг азилсартана медоксомила + 12,5 мг хлорталидона 1 раз в сутки. При необходимости дополнительного снижения АД дозу препарата Эдарби® Кло можно увеличить до максимальной 40 мг азилсартана медоксомила + 25 мг хлорталидона 1 раз в сутки. **Основные побочные эффекты:** очень часто: повышение концентрации креатинина, гиперлипидемия, гипотензия, часто: повышенная утомляемость, головокружение, постуральное головокружение, выраженное снижение АД, периферические отеки, крапивница, гипонатриемия, гиперурикемия, повышение концентрации мочевины, повышение активности креатинфосфокиназы, тошнота, потеря аппетита, желудочно-кишечные расстройства, диарея, снижение потенции. **Полный перечень побочных эффектов содержится в инструкции по медицинскому применению.** **С осторожностью:** тяжёлая хроническая сердечная недостаточность; нарушение функции почек; нарушение функции печени лёгкой и умеренной степени; двусторонний стеноз почечных артерий и стеноз артерии единственной функционирующей почки; ишемическая кардиомиопатия; ишемические цереброваскулярные заболевания; состояние после трансплантации почки; состояние, сопровождающееся снижением объема циркулирующей крови, а также у пациентов, соблюдающих диету с ограничением поваренной соли; порочный гипертальдостеронизм; гиперурикемия и подагра; бронхиальная астма; системная красная волчанка; стеноз аортального и митрального клапанов; гипертрофическая обструктивная кардиомиопатия; возраст старше 75 лет; гипоталазмизм. Если у вас есть из почечных заболеваний, перед приёмом препарата Эдарби® Кло обязательно проконсультируйтесь с врачом. **Полная информация по препарату содержится в инструкции по медицинскому применению.**



* Валсартан, олометартан. ** ССО – сердечно-сосудистые осложнения. **1.** Инструкция по применению препарата. **2.** Cushman W.C., et al. Hypertension, 2012; 60: 310–318. **3.** Sica D., et al. J. Clin. Hypertens, 2011; 13: 467–472. **4.** White W.B., et al. Hypertension, 2011; 57: 413–420. **5.** Hypertension Detection and Follow-up Program Cooperative Group. JAMA, 1979; 242: 2562–2571. **6.** Multiple Risk Factor Intervention Trial Research Group. Circulation, 1990; 82: 1616–1628. **7.** Dorsch M.P., et al. Hypertension, 2011; 57: 689–694. **8.** SHEP Cooperative Research Group. JAMA, 1991; 265: 3255–3264. **9.** ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. JAMA, 2002; 288: 2981–2997.



РЕПАТА: ПЕРВЫЙ ОДОБРЕННЫЙ В РФ ИНГИБИТОР PCSK9, ОБЕСПЕЧИВАЮЩИЙ СТАБИЛЬНОЕ И ИНТЕНСИВНОЕ СНИЖЕНИЕ ХС-ЛПНП^{1,2}

ХС-ЛПНП – холестерин липопротеинов низкой плотности; PCSK9 – пропротеинконвертаза субтилизина/кислотного типа 9

* Данные, полученные в рандомизированном, двойном слепом, плацебо- и эзетимиб-контролируемом, многоцентровом международном исследовании (LAPACE-2) с участием 1856 пациентов с первичной гиперхолестеринемией или смешанной дислипидемией. В среднем между 10 и 12 неделями 86-95% пациентов, получавших Репата и статины, достигли уровня ХС-ЛПНП < 70 мг/дл (< 1,8 ммоль/л). Среди пациентов, принимающих только статины, 2-39% пациентов достигли уровня ХС-ЛПНП < 70 мг/дл (< 1,8 ммоль/л). Среди пациентов, получавших статистатины в эзетимиб, 17-62% пациентов достигли уровня ХС-ЛПНП < 70 мг/дл (< 1,8 ммоль/л).

Репата (эволюкумаб). Раствор для подкожного введения 140 мг/мл

Краткая инструкция по применению

ПОКАЖАЛАСЯ, ОЗНАКОМЬТЕСЬ СПОКОЙНО ИНСТРУКЦИЕЙ ПО ПРИМЕНЕНИЮ ПЕРЕД НАЗНАЧЕНИЕМ ПРЕПАРАТА

Регистрационный номер: РП-003574

ФАРМАКОЛОГИЧЕСКИЕ СВОЙСТВА: Эволюкумаб является полностью человеческим моноклональным иммуноглобулином G2 (IgG2), ингибирующим пропротеинконвертазу субтилизина/кислотного типа (PCSK9). Было показано, что подавление первичной гиперлипидемии и смешанной дислипидемии эволюкумаб снижает концентрацию несвязанной PCSK9, ХС-ЛПНП, общего холестерина (ОХ), аполипопротеина В (АпоВ), холестерина липопротеинов низкой плотности (ХС-ЛПНП), холестерина липопротеинов очень низкой плотности (ХС-ЛПНП), триглицеридов и липопротеинов (ЛПНП), повышает концентрацию холестерина липопротеинов высокой плотности (ХС-ЛПВП) и аполипопротеина А1 (АпоА1), улучшая соотношение ОХ/ХС-ЛПВП, АпоВ/аполипопротеина А1 (АпоА1). **ПОКАЗАНИЯ К ПРИМЕНЕНИЮ:** Репата назначается взрослым с первичной гиперлипидемией (гетерозиготной семейной и несемейной) и со смешанной дислипидемией (Репата типа Ia, Ib, II, IV по классификации Фредриксона) в качестве дополнения к диете для снижения ХС-ЛПНП, общего холестерина, АпоВ, ХС-ЛПНП, общего холестерина (ХС-ЛПНП, АпоВ/АпоА1, ХС-ЛПНП, триглицеридов, ЛПНП) и для повышения ХС-ЛПВП и АпоА1 в сочетании со статинами или в сочетании со статинами и другой гиполипидемической терапией (например, эзетимибом, или в монотерапии, или в сочетании с другой гиполипидемической терапией) пациентов, у которых применение статина считается непереносимым, клинически точная терапия. Репата показана для применения у взрослых пациентов и подростков в возрасте 12 лет и старше с гомозиготной семейной гиперхолестеринемией (тип Ia по классификации Фредриксона) для снижения концентраций ХС-ЛПНП, ОХ, АпоВ, и ХС-ЛПНП в сочетании с другой гиполипидемической терапией (например, статинами, аферезом ЛПНП). **ПРОТИВОПОКАЗАНИЯ:** Повышенная чувствительность к любому из компонентов препарата, беременность и период грудного вскармливания, возраст до 18 лет при первичной гиперлипидемии (гетерозиготной семейной и несемейной) и при смешанной дислипидемии, возраст до 12 лет при гомозиготной семейной гиперхолестеринемии. **СОСТОЯТЕЛЬНОСТЬ:** Исходящие клинические данные у пациентов с серьезными хроническими заболеваниями на сегодняшний день не ограничивают применение препарата Репата таким пациентам, однако основываясь на индивидуальной оценке потенциальной пользы применения препарата у таких пациентов и возможного риска (см. также раздел «ОСТОРОЖНОСТЬ»), тепловая непереносимость недостаточности (класс I по классификации Чайлд-Пью), повышенные активности креатинфосфокиназы (более чем в 3 раза по сравнению с верхней границей нормы), неконтролируемые нарушения функции щитовидной железы (повышение тиреотропного гормона (ТТГ) > 1,5 выше нормы и ниже нормы), нестабильные стенокардии, тяжелые артериальные гипертензии, пароксизмальная желудочковая тахикардия, ишемиче прекардиаль (встречаются вентрикулярные отеки, наджелудочковая тахикардия, неконтролируемая медикаментозно), неконтролируемая артериальная гипертензия (систолическое артериальное давление > 180 мм ртутного столба или диастолическое артериальное давление > 110 мм ртутного столба в покое), сердечная недостаточность (класс II по функциональной классификации NYHA или фракция выброса левого желудочка менее 30%), сахарный диабет 1 типа. **ПРИМЕНЕНИЕ В ПЕРИОД БЕРЕМЕННОСТИ И ГРУДНОГО ВОСКЛИВАНИЯ:** По результатам исследований эволюкумаб, включающих беременных, не проводилось, поэтому применение препарата Репата при беременности не рекомендуется. Неизвестно, выделяется ли эволюкумаб в грудное молоко. Решение об отмене препарата или прекращении грудного вскармливания должно приниматься на основании оценки потенциальной пользы продолжения терапии для матери или возможного риска нежелательного влияния на новорожденного. **ПОДРОБНЫЕ ИНСТРУКЦИИ ПО СПОСОБУ ПРИМЕНЕНИЯ И ДОЗАМ ПРИВЕДЕНЫ В ПОЛНОЙ ИНСТРУКЦИИ ПО МЕДИЦИНСКОМУ ПРИМЕНЕНИЮ. ПОКАЖАЛАСЯ, ПЕРЕД НАЧАЛОМ ПРИМЕНЕНИЯ ОЗНАКОМЬТЕСЬ С ПОЛНОЙ ИНФОРМАЦИЕЙ ПО ПРЕПАРАТУ.** Перед началом терапии пациентам должны перейти к соответствующей гиполипидемической диете и соблюдать эту диету во время всего периода терапии препаратом Репата. **Взрослым с первичной гиперлипидемией и смешанной дислипидемией:** рекомендуемая доза препарата Репата – одна подкожная инъекция 140 мг каждые 2 недели или 420 мг ежемесячно. Обе дозы являются клинически эквивалентными. Взрослым и детям старше 12 лет с гомозиготной семейной гиперхолестеринемией: рекомендуемая доза препарата Репата составляет 420 мг 2 раза в две недели или 1 раз в месяц подкожно. Информация по применению у отдельных групп пациентов и инструкции по введению препарата приведены в полной версии инструкции. При применении препарата Репата **НЕЖЕЛАТЕЛЬНЫЕ РЕАКЦИИ:** О развитии следующих нежелательных реакций сообщайте в А и III фазы клинических исследований у пациентов с первичной гиперхолестеринемией и смешанной дислипидемией и гомозиготной семейной гиперхолестеринемией: **Инфекции и инвазии:** грипп, назофарингит, инфекции верхних дыхательных путей; **со стороны системы пищеварения:** тошнота; **со стороны кожи и**

подкожных тканей: кожная сыпь, крапивница; **со стороны мышечно-скелетной системы и соединительной ткани:** боли в спине, артралгия; **общие нарушения и реакции в месте введения препарата:** реакция в месте введения (боль, покраснение, гематома). Профиль безопасности в популяции Ito-CTC, аналогичен таковому у пациентов с первичной гиперлипидемией и смешанной дислипидемией. **ПЕРЕДОЗИРОВАНИЕ:** Не сообщалось о случаях передозировки препарата. Эффекты при передозировке неизвестны. Не существует специфического антидота при передозировке препарата. В случае передозировки – лечение симптоматическое, поддерживающее терапия при необходимости. **ВЗАИМОДЕЙСТВИЕ С ДРУГИМИ ЛЕКАРСТВЕННЫМИ СРЕДСТВАМИ:** Фармакокинетическое взаимодействие между статинами и эволюкумабом оценивали в программе клинических исследований. Отмечалось приблизительно 20%-ное увеличение клиренса эволюкумаба при однократном применении со статинами. Увеличенный клиренс обусловлен опосредованным статинами повышением концентрации PCSK9, что тем не менее не влияло на фармакодинамический эффект эволюкумаба в отношении липидов. Не требуется коррекция доз статина при однократном назначении с препаратом Репата. **ОСОБЫЕ УКАЗАНИЯ:** Перед началом терапии препаратом Репата следует оценить возможные вторичные причины гиперлипидемии или смешанной дислипидемии (например, сахарный диабет, гипотиреоз, нефротический синдром) и предпринять меры для адекватного контроля ассоциированных заболеваний (см. также раздел «ОСТОРОЖНОСТЬ»). У пациентов с сердечной недостаточностью средней степени не отмечалось снижения экспозиции эволюкумаба, что потенциально может привести к снижению эффекта в отношении ХС-ЛПНП. Пациенты с активностью креатинфосфокиназы выше чем в 3 раза по сравнению с верхней границей нормы не включались в клинические исследования. Однако, в клинических исследованиях не обнаружено снижения безопасности при применении эволюкумаба со стороны почек или повышения активности креатинфосфокиназы. Пациенты с неконтролируемыми нарушениями функции щитовидной железы (ТТГ > 1,5 выше и ниже нормы) не включались в клинические исследования до достижения адекватного контроля над заболеванием. Во время клинических исследований нежелательные явления гипотиреоза или гипертиреоза сообщались с приблизительно одинаковой частотой на всех этапах лечения – менее 0,3%. Пациенты с нестабильной стенокардией не включались в клинические исследования. Долгосрочные данные по безопасности применения эволюкумаба из открытой фазы исследований показали, что риски основных сердечно-сосудистых событий (гипертония) по поводу нестабильной стенокардии и сердечной недостаточности не увеличивались. Сопоставление рисков 0,5 (95% ДИ 0,29, 0,86). Пациенты с тяжелыми нарушениями сердечного ритма не включались в клинические исследования. Отдельная оценка нежелательных реакций со стороны сердца показала, что частота вновь возникающих отклонений на электрокардиограммах была сравнима между группами эволюкумаба и контрольными группами в исследованиях и сообщении о нежелательных явлениях со стороны сердца между группами. Скорые результаты получены при отдаленном анализе нежелательных реакций, потенциально ассоциируемых с увеличением репродукции. Проведенный анализ не выявил каких-либо влияний эволюкумаба на интервал QT/QTc. Пациенты с неконтролируемой артериальной гипертензией (систолическое артериальное давление > 180 мм ртутного столба или диастолическое артериальное давление > 110 мм ртутного столба в покое) не включались в клинические исследования. Анализ данных конечной и промежуточной оценки систолического и диастолического артериального давления не выявил каких-либо существенных различий в группах эволюкумаба или контрольных групп в клинических исследованиях. Пациенты с хронической сердечной недостаточностью (II и IV функциональные классы по классификации NYHA) не включались в клинические исследования. Во время клинических исследований о нежелательных явлениях сердечной недостаточности или хронической сердечной недостаточности сообщалось с приблизительно одинаковой частотой на всех этапах лечения – менее 0,3%. Долгосрочные данные по безопасности применения эволюкумаба из открытой фазы исследований показали, что риски основных сердечно-сосудистых событий и сопоставлений по поводу нестабильной стенокардии и сердечной недостаточности не увеличивались. Сопоставление рисков 0,5 (95% ДИ 0,29, 0,86). Пациенты с сахарным диабетом 1 типа или ремиссионным сахарным диабетом 2 типа (HbA1c > 8,5%) не включались в клинические исследования. Отдельная оценка нежелательных реакций показала, что изменения показателей гликемического гемоглобина в покое между группами были сравнимыми во всех группах исследований. Не обнаружено клинически значимых отличий при анализе безопасности в подгруппе пациентов с сахарным диабетом 2 типа. **Применение в составе комбинированной терапии:** При однократном назначении препарата Репата с другими гиполипидемическими препаратами (апретамид, эзетимиб, статины) следует учитывать противопоказания и особые указания, приведенные в одобренных инструкциях по применению данных препаратов. **Влияние на способность к вождению автомобиля и работе с механизмами:** не проводилось исследований влияния на способность к управлению автотранспортными средствами и работе с механизмами, требующими повышенного концентрации внимания. Коллапс для и/или предварительного заполнения шприца и предварительного заполнения шприца: ухитрившись отпирательный резистор, полученный из латекса. Сообщите Вашему врачу, если у Вас аллергия на латекс. **УСЛОВИЯ ХРАНЕНИЯ:** хранить при температуре 2-8 °C. Не замораживать. Хранить в оригинальной упаковке для защиты от света. Не использовать. Хранить в недоступном для детей месте. **СРОК ГОДНОСТИ:** 7 года.

1. Robinson JG, et al. JAMA. 2014;311:870-82. 2. Repatha®. EPAR - Public assessment report (www.ema.europa.eu). 3. Stone NJ, et al. J Am Coll Cardiol. 2014;63:25 Pt(B): 2889-934.

RUP-145-16-0616-03378

AMGEN®
Cardiovascular

ООО «Амджен»
Россия, 123317, Москва,
Пресненская наб., д. 8, стр. 1, 7-й эт.
Тел.: +7 (495) 745-0478, факс: +7 (499) 995-1695

Репата
(эволюкумаб)



Ксарелто®: доверие, основанное на рандомизированных исследованиях и реальной клинической практике¹⁻³

- ◆ Опыт практического применения Ксарелто® по 7 показаниям более чем у 18 миллионов пациентов^{4,5}
- ◆ Ксарелто® – наиболее часто назначаемый новый пероральный антикоагулянт в мире⁶

Ксарелто®
РИВАРОКСАБАН

КСАРЕЛТО®

Международное непатентованное название: ривароксабан.
Лекарственная форма: таблетки покрытые пленочной оболочкой. 1 таблетка покрытая пленочной оболочкой содержит 2,5/10/15/20 мг ривароксабана микроинкапсулированного.

ПОКАЗАНИЯ К ПРИМЕНЕНИЮ:

- профилактика смерти вследствие сердечно-сосудистых причин и инфаркта миокарда у пациентов после острого коронарного синдрома (ОКС), протекавшего с повышением кардиоспецифических биомаркеров, в комбинационной терапии с ацетилсалициловой кислотой или с ацетилсалициловой кислотой и тенололидом или «аспирин-дегрен» или тиклидидом (для таблеток 2,5 мг);
- профилактика венозной тромбоэмболии (ВТЭ) у пациентов, подвергающихся большой ортопедическим оперативным вмешательствам на нижних конечностях (для таблеток 10 мг);
- для профилактики инсульта и системной тромбоэмболии у пациентов с фибрилляцией предсердий некалланого происхождения (для таблеток 15/20 мг);
- лечение тромбоза глубоких вен и тромбоэмболии легочной артерии и профилактика рецидивов ТЭВ и ТЭЛА (для таблеток 15/20 мг).

ПРОТИВОПОКАЗАНИЯ

Повышенная чувствительность к ривароксабану или любому вспомогательному веществу таблеток, клинически значимые активные кровотечения (например, внутреннее кровоизлияние, желудочно-кишечное кровотечение), заболевания печени, протекающие с коагулопатией, ведущей к клинически значимому риску кровотечения, беременность и период лактации (период грудного вскармливания), детский возраст до 18 лет, у пациентов с тяжелой почечной недостаточностью (клиренс креатинина <15 мл/мин), сопутствующая терапия какин-либо другим антикоагулянтами, например, непрямыми口服ными гепаринами, низкомолекулярными гепаринами (эноксапарин, далтепарин и др.), производными гепарина (фондараинукс и др.), пероральными антикоагулянтами (варфарин, апиксабан, дабигатран и др.), кроме случаев, когда пациент переводится с терапии или на терапию препаратом Ксарелто®, или же когда НВГ назначается в низких дозах для поддержания проходимости центрального венозного или артериального катетера, наследственная непереносимость лактозы или галактозы (например, врожденный дефицит лактазы или глюкозалактозная мальабсорбция) и/или снижением в составе лактозы. Дополнительно для таблеток 2,5 мг: широкое течение и нарушение функции печени класса В в С по классификации Чайлд-Пью. Дополнительно для таблеток 10/15/20 мг: повреждение или состояние, связанное с повышенным риском большого кровотечения (например, имеющийся или недавно перенесенная желудочно-кишечная язва, наличие

злокачественных опухолей с высоким риском кровотечения, недавние травмы головного или спинного мозга, операции на головном, спинном мозге или глазах, внутреннее кровоизлияние, дислоцированный или предполагаемый варикоз вен пищевода, артериовенозные мальформации, аневризмы сосудов или патология сосудов головного или спинного мозга).

СОСТОЯНОСТИ:

- при лечении пациентов с повышенным риском кровотечения (в том числе при врожденной или приобретенной склонности к кровотечениям, неконтролируемой тяжелой артериальной гипертензией, язвенной болезни желудка и 12-перстной кишки в стадии обострения, недавно перенесенной острой язве желудка и 12-перстной кишки, сосудистой ретинопатии, недавно перенесенном внутримозговом или внутримозговом кровоизлиянии, при наличии известных аномалий сосудов спинного или головного мозга, после недавно перенесенной операции на головном, спинном мозге или глазах, при наличии бронхоэктазов или легочном кровотечении в анамнезе);
- при лечении пациентов с почечной недостаточностью средней степени тяжести (клиренс креатинина 49-50 мл/мин), получающих одновременно препараты, повышающие концентрацию ривароксабана в плазме крови;
- при лечении пациентов с тяжелой почечной недостаточностью (клиренс креатинина 15-29 мл/мин) следует соблюдать осторожность, поскольку концентрация ривароксабана в плазме крови у таких пациентов может значительно повышаться (в среднем в 1,6 раза) и вследствие этого такие пациенты подвержены повышенному риску как кровотечения, так и тромбообразования;
- у пациентов, получающих лекарственные препараты, влияющие на гемостаз (например, НПВП, антиагреганты или другие антитромботические средства);
- у пациентов, получающих системное лечение противотромботическими препаратами азоловой группы (например, кетоконазол, итраконазол, вориконазол и позаконазол) или ингибиторами протазы ВИЧ (например, ритонавиром). Эти лекарственные препараты могут значительно повысить концентрацию ривароксабана в плазме крови (в среднем в 2,6 раза), что увеличивает риск развития кровотечения. Азоловый противотромботический препарат фуконазол оказывает менее выраженное влияние на экспозицию ривароксабана и может применяться с ним одновременно.
- Дополнительно для таблеток 2,5/15/20 мг: Пациенты с тяжелой почечной недостаточностью или повышенным риском кровотечения и пациенты, получающие сопутствующее системное лечение противотромботическими препаратами азоловой группы или ингибиторами протазы ВИЧ, после начала лечения должны находиться под пристальным контролем для своевременного обнаружения осложнений в форме кровотечения. Дополнительно для таблеток 10 мг: У пациентов с риском обострения язвенной болезни желудка и 12-перстной кишки может быть оправдано назначение профилактического противоязвенного лечения.

ПОБОЧНОЕ ДЕЙСТВИЕ

Учитывая механизм действия, применение Ксарелто® может сопровождаться повышением риска кровотечения или явного кровотечения из любых органов и тканей, которое может приводить к системному кровоизлиянию. Риск развития кровотечений может увеличиваться у пациентов с неконтролируемой артериальной гипертензией и/или при совместном применении с препаратами, влияющими на гемостаз. Тромбоэмболии исключаются могут проявляться слабостью, бледностью, головокружением, головной болью, одышкой, а также увеличением конечности в объеме или шоком, которое невозможно объяснить другими причинами. В некоторых случаях вследствие анемии развивались симптомы ишемии миокарда, такие как боль в груди и стенокардия. Наиболее частыми НЛР у пациентов, принимавших препарат, являлись кровотечения. Также часто отмечались анемия (включая соответствующее лабораторные параметры), кровоизлияние в глаз (включая кровоизлияние в конъюнктиву), кровоизлияние десен, желудочно-кишечное кровотечение (включая ректальное кровотечение), боль в области желудочно-кишечного тракта, диспепсия, тошнота, запор, диарея, рвота, лихорадка, периферические отеки, снижение общей мышечной силы и тонуса (включая слабость и астению), кровотечения после медицинской манипуляции (включая послеоперационную анемию и кровотечения из ран), избыточная гематома при ушибе, боли в конечностях, головокружение, головная боль, кровотечения из ургентного тракта (всплеск температуры и менструации), повышение активности печеночных трансаминаз, повреждение почек (включая повышение уровня креатинина, повышение уровня мочевины), носовое кровотечение, кровоизлияние, зуд (включая нечастые случаи генерализованного зуда), сыпь, экзема, кожные и подкожные кровоизлияния, выраженное снижение артериального давления, гематома.

Регистрационный номер: для таблеток 2,5 мг: ЛП-002318. Актуальная версия инструкции от 04.08.2015; для таблеток 10 мг: ЛП-000820/09. Актуальная версия инструкции от 04.08.2015; для таблеток 15/20 мг: ЛП-001457. Актуальная версия инструкции от 11.12.2015.

Производитель: Байер Фарма АГ, Германия. Отпускается по рецепту врача. Подробная информация содержится в инструкции по применению.

Литература: 1. Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus Warfarin in non-valvular atrial fibrillation. N Engl J Med. 2011; 365(10): 833-41. 2. Camm J., Ammend D., Haas S. et al. XANTUS Atrial Wave. Prospective observational study of patients treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation. Eur Heart J. 2015; doi:10.1093/eurheartj/ehv466. 3. Tamayo S., Peacock P., Patel M. et al. Characterizing major bleeding in patients with non-valvular atrial fibrillation: a pharmacovigilance study of 27,467 patients taking Rivaroxaban. Clin Cardiol. 2015; 38(2): 53-6. 4. Xarelto® (rivaroxaban). Summary of Product Characteristics as approved by the European Commission. 5. Calculation based on IMS Health MIDAS Database. Monthly Sales June 2015. 6. IMS MIDAS Database. Monthly Sales December 2015. LRU1MKTG06.00.2016.0883

ТОРАСЕМИД
Диувер

Таблетки 5 мг и 10 мг
№20 и №60

ЕЩЁ МНОГОЕ ПРЕДСТОИТ УСПЕТЬ!



- Способствует замедлению развития фиброза миокарда¹
- Возвращает контроль артериального давления²



1. Lopez B. JACC 2004;43; 11: 2028-2035

2. Coca A. American Journal of Hypertension 15, 113A-114A (April 2002) P231

Информация предназначена для специалистов. Перед применением необходимо ознакомиться с полной инструкцией по медицинскому применению.



*20 лет в России.
Улучшая здоровье людей,
мы делаем их счастливыми*

За дополнительной информацией обращаться:
Общество с ограниченной ответственностью «Тева»
Россия, 115054, Москва, ул. Валовая, д. 35
Тел. +7.495.6442234 | Факс +7.495.6442235 | www.teva.ru
DIUV-RU-00014-DOK-28082017

МИЛДРОНАТ®

Мельдоний

Европейское качество и успешный опыт
которому доверяют¹⁻⁶:

произведен ведущей фармацевтической
компанией Балтии⁵

более 25 лет успешной клинической практики в
России¹⁻⁶

включен в Перечень жизненно необходимых
и важнейших лекарственных препаратов для
медицинского применения⁶

Для сердца, мозга и сосудов!



Информация для специалистов здравоохранения

Краткая инструкция по медицинскому применению лекарственного препарата Милдронат®.

Перед назначением препарата, пожалуйста, ознакомьтесь с полным текстом инструкции по медицинскому применению препарата Милдронат®. **Регистрационное удостоверение:** ЛС-001115 от 12.05.2011; П N016028/02 от 23.10.2014. **Торговое наименование:** МИЛДРОНАТ® МН: мельдоний. **Лекарственная форма/состав:** капсулы. 1 капсула содержит активное вещество: мельдоний дигидрат – 250/500 мг; раствор для внутримышечного, внутривенного и парентерального введения, 100 мг/мл. **Фармакотерапевтическая группа:** метаболические средства. **Фармакодинамика:** мельдоний – синтетический аналог гамма-бутиробетана. В условиях ишемии мельдоний восстанавливает равновесие между процессами доставки кислорода и его потребления в клетках, предупреждает нарушение транспорта аденозинтрифосфата (АТФ); одновременно с этим активирует гликолиз, который протекает без дополнительного потребления кислорода. В результате снижения концентрации карнитина усиленно синтезируется гамма-бутиробетан, обладающий вазодилатирующими свойствами. Механизм действия определяет многообразие его фармакологических эффектов: повышение работоспособности, уменьшение симптомов психического и физического перенапряжения, активация тканевого и гуморального иммунитета, кардиопротекторное действие. При острых и хронических ишемических нарушениях мозгового кровообращения улучшает циркуляцию крови в очаге ишемии, способствует перераспределению крови в пользу ишемизированного участка. Эффективен в случае васкулярной и дистрофической патологии сосудов глазного дна. **Показания к применению:** в комплексной терапии ишемической болезни сердца (стенокардия, инфаркт миокарда), хронической сердечной недостаточности и дистрофической кардиомиопатии, а также в комплексной терапии острых и хронических нарушений кровообращения мозга (после инсульта, цереброваскулярной недостаточности). Сниженная работоспособность, умственные и физические перегрузки (в том числе у спортсменов). Синдром абстиненции при хроническом алкоголизме (в комбинации с специфической терапией). **Дополнительно (для раствора):** гемифальтм и кровоизлияния в сетчатку различной этиологии, тромбоз центральной вены сетчатки и ее ветвей, ретинопатии различной этиологии (диабетическая, гипертоническая). **Противопоказания:** Повышенная чувствительность к действующему веществу и другим компонентам препарата, повышение внутричерепного давления (при нарушении венозного оттока, внутричерепных опухолях), возраст до 18 лет (эффективность и безопасность не установлены), беременность, период кормления грудью. **С осторожностью:** при заболеваниях печени и/или почек. **Полностью способ применения и дозы представлены в полной инструкции по применению препарата Милдронат®.** **Побочное действие:** редко – аллергические реакции (покраснение и зуд кожи, кожная сыпь, крапивница, ангионевротический отек), а также – диспепсические явления, тахикардия, снижение или повышение артериального давления, повышенная возбудимость. Очень редко – эозинофилия, общая слабость. **Передозировка:** симптомы: снижение артериального давления, сопровождающееся головной болью, тахикардией, головокружением и общей слабостью. Лечение: симптоматическое. **Взаимодействие с другими лекарственными препаратами:** усиливает действие коронародилатирующих средств, некоторых гипотензивных средств, сердечных гликозидов. Можно сочетать с пролонгированными формами нитратов, другими антиангинальными средствами, антикоагулянтами, антиагреггантами, антигипертензивными средствами, диуретиками, бронхолитиками. Ввиду возможного развития тахикардии и артериальной гипотензии, следует соблюдать осторожность при комбинации с нитроглицерином (для подъязычного применения) и гипотензивными средствами (особенно альфа-адреноблокаторами и короткодействующими формами нифедипина). **Особые указания:** пациентам с хроническими заболеваниями печени и почек следует соблюдать осторожность при длительном применении препарата. Нет достаточных данных о применении препарата МИЛДРОНАТ® у детей до 18 лет. **Беременность и период лактации:** безопасность применения препарата во время беременности не установлена. Чтобы избежать возможного неблагоприятного воздействия на плод, во время беременности применение препарата МИЛДРОНАТ® не рекомендуется. Неизвестно, выделяется ли мельдоний в грудное молоко. Если лечение препаратом МИЛДРОНАТ® для матери необходимо, то кормление ребенка грудью прекращают. **Срок годности:** 4 года. **Условия отпуска:** по рецепту. Для получения дополнительной информации, пожалуйста обращайтесь в ООО «Гриндекс Рус»: 117556, Москва, Барашковского шоссе, д.74, к.3, 5 эт. Тел: +7 (495) 7716505. **Литература:** 1. Инструкция по применению лекарственного препарата Милдронат® (капс., раствор). ЛС-001115 от 12.05.2011/ П N016028/02 от 23.10.2014. 2. Милдронат® в кардиологии. ОБЗОР ИССЛЕДОВАНИЙ В.Я. Дзерже, И.Я. Калинин, Рига 2013. 3. Милдронат в неврологии. ОБЗОР исследований, Логина, Калинин, Рига 2012. 4. И.В. Дамулин, Е.В. Кононенко, Л.М. Антоненко, Н.Н. Коберская, Постинсультные двигательные и когнитивные нарушения: некоторые патогенетические и терапевтические аспекты, <http://www.mednovosti.by/journal.aspx?article=7715>. Grindex's Internal Data 6. Перечень жизненно необходимых и важнейших лекарственных препаратов для медицинского применения на 2016 год <http://government.ru/media/files/MzyV0Mmm2FoDAP7AWAAVL1Lpjo1Shb.pdf>



Добро
посетовать на
mildronat.ru

Grindex

Здоровье. Традиции. Качество.

